Interactions Between Insulin and Adenylyl Cyclase Signalling by Livingstone, Callum
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
Interactions between insulin and adenylyl cyclase signalling
A thesis submitted to the 
FACULTY OF MEDICINE 
for
the degree of 
DOCTOR OF PHILOSOPHY
by
Callum Livingstone
Department of Biochemistry 
University of Glasgow 
October 1993
ProQuest Number: 10992202
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10992202
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
C\^  50
Summary
Hepatocytes immortalised by transfection with S V40 viral DNA have been well 
studied with respect to marker protein expression and the effects of immortalisation on 
cell phenotype. Here, a study was undertaken of adenylyl cyclase signalling in one 
such cell line P9, in order to consider its suitability as a model system for studying this 
system and insulin action.
Cells were found to contain glucose-6-phosphatase activity. Plasma membranes 
possessed adenylyl cyclase activity, comparable to rat hepatocytes with dose- and 
receptor-dependent stimulation by PGEi and receptor-independent stimulation by 
forskolin, sodium fluoride, GTP and GppNHp. There was no stimulation by glucagon 
challenge alone. However, glucagon did enhance the ability of forskolin to stimulate 
adenylyl cyclase activity and elevate P9 cell intracellular cAMP. Gs-a forms and Gi-a 
subtypes expressed in the cells were the same as those in hepatocytes but all 
G-proteins, with the exception of the 42kDa form of Gs-a, were present at higher 
levels in P9 cell than in rat hepatocyte plasma membranes. There was little evidence of 
Gi function in the cells. Unlike the situation in rat hepatocytes, there was no uptake of 
labelled phosphate into P9 cell Gi-2a in response to agonist challenge, suggesting 
either that Gi-2a subunit was already phosphorylated in P9 cells or that there are 
differences in kinase and phosphatase activities in P9 cells as compared to rat 
hepatocytes.
Exposure of the cells to a high concentration of insulin (0.5|iM for 16 hours) 
failed to produce any morphological change or to restore glucagon responsiveness, but 
did have a small mitogenic effect and enhanced both receptor-dependent and 
-independent adenylyl cyclase stimulation in plasma membranes derived from 
insulin-treated cells.
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At a concentration of InM, insulin impaired the ability of PGEi to elevate 
intracellular cAMP in P9 cells, over the same time period. There was no impairment of 
the response to forskolin and the inhibition was not blocked by IBMX, cycloheximide 
or pertussis toxin pre-treatment, suggesting it to be a functional effect, at the level of the 
membrane, independent of protein synthesis or Gi activation and exerted through the 
high affinity insulin receptor at a site proximal to the catalytic subunit of adenylyl 
cyclase.
An examination of the time course for the effect revealed that insulin acutely 
enhanced the ability of PGEi to elevate intracellular cAMP, which later proceded to 
inhibition of the response. This potentiation of the response was dose-dependent for 
insulin and not observed in plasma membranes from insulin-exposed cells or when 
plasma membranes were directly exposed to insulin. It is concluded that adenylyl 
cyclase signalling in the P9 cell line, unlike marker protein expression is considerably 
divergent from that of native rat hepatocytes. However, the cell line may still be useful 
at low passage for studying aspects of cyclase signalling, insulin action and the 
activities of other second messenger systems.
G-protein levels and adenylyl cyclase activity were examined in mononuclear 
leucocyte plasma membranes from type 2 diabetic subjects and corresponding age- and 
sex-matched control subjects. No significant differences in G-protein levels were noted 
between plasma membranes from the two groups. Likewise there was no significant 
difference in the GTP- or forskolin-stimulated adenylyl cyclase activities. There was a 
reduction in PGEi-stimulated adenylyl cyclase in the male diabetic group compared to 
their controls, but without any difference between the groups in fold stimulation over 
basal cyclase activity. Given the sex-specific nature of this difference it seems unlikely 
that it is linked to the reduction in immune functioning characteristic of the diabetic 
state.
iii
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Chapter i 
Introduction
1.1 The molecular basis of insulin signalling
The anabolic hormone insulin is a 5.7kDa protein of 52 amino acids, secreted 
from pancreatic beta cells in response to the fed state. Insulin acts upon its target cells to 
stimulate glucose, protein and lipid metabolism as well as nucleic acid synthesis, by 
altering the activity of various enzymes and transport processes. Considerable effort 
has been made in trying to understand the molecular basis of insulin action, as this is 
necessary for understanding the pathogenesis of diabetes, where there is either an 
absolute deficiency of insulin (type 1) or relative deficiency (type 2). Knowledge of the 
molecular basis of insulin action is also important for understanding a number of 
insulin resistant states such as obesity, uraemia, glucocorticoid and growth hormone 
excess and severe insulin resistance resulting from insulin receptor defects.
1.1.1 Signal generation bv insulin
Insulin is thought to exert its effects on target cells by binding to a trans-plasma 
membrane receptor and activation of a receptor-associated tyrosine kinase (Kasuga et 
al., 1982a) (Fig. 1.1). The cDNA for the insulin receptor precursor has been cloned 
from humans (Ullrich et al., 1985) and Drosophila (Petruzzelli et al., 1986) allowing 
the amino acid sequences to be identified. The sequences are very similar, showing that 
the receptor structure has been well conserved in evolution. The receptor is present in 
almost all mammalian tissues but varies considerably in its level of expression between 
tissues. In liver, a major target tissue for insulin, there are some 50-100 000 copies per 
cell (Kahn, 1976). The hormone binds in a specific and saturable manner, with a Kd in 
the pM to low nM range. This corresponds to the concentration of insulin required for 
half maximal tyrosine kinase activation (Kasuga et al., 1982a). There is a strong 
correlation between binding affinity of insulin for its receptor and its biological action
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(Anderson et a l 1977). As no competitive antagonists of insulin have yet been 
discovered, probably all the structural requirements for binding include all the features 
required for biological action.
The insulin receptor has been purified from various tissue sources and is an 
approximately 450kDa heterotetrameric glycoprotein consisting of two a  subunits (Mr 
= 135kDa) and two 6 subunits (Mr = 95kDa) linked by five disulphide bonds in a 
B-a-a-B structure (Massague et al., 1981). The a  subunit is entirely extracellular and 
contains the insulin binding site as determined both by cross linking of labelled insulin 
to the receptor (Massague et al., 1981) and photoaffinity insulin analogues (Yip et al., 
1978). The B subunits traverse the plasma membrane and have an ATP binding domain 
in their cytosolic portion responsible for the tyrosine kinase activity (Kasuga et al., 
1982a). Complementary DNA cloning of the receptor has shown that the intracellular 
domain of the B subunit is homologous to other tyrosine kinases including receptors for 
epidermal growth factor, platelet-derived growth factor and IGF-1, as well as various 
oncogene products (Ebina etal., 1985, White and Kahn, 1986).
1.1.2 The insulin receptor tvrosine kinase
Insulin binding activates both multisite tyrosine phosphorylation of the receptor 
and phosphorylation of intracellular protein substrates. Autophosphorylation of the 
receptor occurs by an intramolecular cascade, resulting in phosphorylation of at least 
seven tyrosine residues in the B subunit (Sale and Smith, 1989) which then 
phosphorylates endogenous substrates. This activity was found to be maximal within 
one minute of insulin binding (Pang et al., 1985) and to remain for as long as the 
receptor remained phosphorylated, even after insulin dissociation, suggesting that it 
was important for signal transduction (Yu and Czech, 1984). Dephosphorylation of the 
receptor by phosphatases caused a reduction in tyrosine kinase activity, showing that
2
loss of phosphate from tyrosine residues probably terminates the response to insulin 
(King and Sale, 1990).
A number of endogenous substrates for the tyrosine kinase have been found 
which may mediate intracellular responses. The first substrate was detected by White et 
al. (1985) who immunoprecipitated a 185kDa protein from insulin-stimulated Fao 
hepatoma cells. This substrate, termed IRS-1 (formerly ppl85) and similar high 
molecular weight proteins have been observed in all cells studied (White et al., 1987, 
Gibbs et al., 1986). Their phosphorylation is stimulated by insulin and IGF-1 but not 
by other receptor tyrosine kinases.
As a result of studies on a range of receptor tyrosine kinases, it appears that 
they select their targets by recognising a conserved protein sequence of about 100 
amino acids called a SH2 (src homology) domain, found in a range of different 
signalling proteins (Koch etal., 1991). This specific binding may be a means by which 
receptor tyrosine kinases can recruit SH2-containing proteins to the plasma membrane, 
allowing them to act as substrates for phosphorylation (Pawson and Gish, 1992). The 
substrate IRS-1 contains multiple potential tyrosine phosphorylation sites that are 
located within SH2 binding elements (Sun et al., 1991). Tyrosine phosphorylated 
IRS-1 has been shown to bind to the enzyme phosphatidyl inositol-3-kinase 
(PI3-kinase), the enzyme which converts PI-4,5-bisphosphate to 
PI-3,4,5-trisphosphate (Lavan et al., 1992). In addition progress has been made by the 
demonstration that PI3-kinase itself is a substrate for the receptor tyrosine kinase, 
consistent with a role for phosphatidyl inositol-3-phosphate in insulin action 
(Yonezawa et al., 1990), though it remains unclear what this role is.
It is possible that alteration in the functioning of kinase substrates may play a 
role in the pathogenesis of insulin resistance and diabetes. Scott Thies et al. (1990)
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showed in a study that the phosphorylation of the IRS-1 was reduced in adipocytes 
from type 2 diabetic subjects, though it is not possible to say whether the finding was
° f rdue to a defect in the substrate itself. Alteration in the leve^a tyrosine kinase substrate 
has been noted in association with insulin resistance in at least one model system. In 
3T3 LI cells, a fibroblast cell line which will differentiate into adipocytes in response to 
a variety of agents, glucose transport can be down-regulated by prolonged insulin 
exposure (Kozka et al., 1991). This down-regulation is associated with a decrease in 
the level of IRS-1 (Rice et al, 1992). It seems likely then that tyrosine phosphorylation 
of IRS-1 by the insulin receptor may be important for the stimulation of glucose 
transport. However, there is as yet no conclusive evidence that any of the endogenous 
tyrosine kinase substrates are mediators of insulin action.
The most convincing evidence that the activity of the receptor tyrosine kinase is 
important for insulin's action on cells has come from mutagenesis experiments. When 
lysine 1030, a residue thought to be involved in the ATP binding site was changed to 
various other amino acids, the mutant receptors bound insulin normally but were 
inactive both as kinases and in stimulating cellular metabolism (Ebina et al., 1987). 
Antibodies to the intracellular domain of the receptor (Morgan and Roth, 1987) and to 
phosphotyrosine (Takayama et al., 1988a) inhibited the tyrosine kinase and insulin's 
effects. The tyrosine residues in positions 1162-1163 have proven to be important sites 
of phosphorylation and are well conserved amongst tyrosine kinases (Stadtmauer and 
Rosen, 1986). Ellis et al. (1986) demonstrated by mutagenesis that these residues play 
a role in deoxy-glucose transport. Interestingly however, mutating these residues did 
not impair the mitogenic effect of low concentrations of insulin, suggesting that the 
metabolic and mitogenic pathways of insulin signalling may diverge early, at the level 
of the receptor (Debant et al., 1990). Receptors mutated at tyrosine 960 did not 
phosphorylate IRS-1, nor were they able to transmit insulin's action (White et al,
1988) suggesting that this residue is critical for insulin signalling.
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1.1.3 Serine and threonine phosphorylation in response to
insulin
The insulin receptor is also subject to serine and threonine phosphorylation 
(Kasuga et al., 1982b). This is much slower than tyrosine phosphorylation, requiring 
about ten minutes to reach maximal levels (Pang etal., 1985). It can be stimulated by 
phorbol esters (Takayama et al., 1984) and cAMP analogues (Roth and Beaudoin, 
1987), showing that the two protein kinases, protein kinase C (PK-C) and 
cAMP-dependent protein kinase (PK-A) may elicit this phosphorylation. These authors 
demonstrated that, in contrast to tyrosine phosphorylation, serine phosphorylation 
inactivates the kinase. This has led to the suggestion that serine phosphorylation of the 
receptor may be the end point of a negative feedback loop, allowing insulin to regulate 
its own action (Haring et al., 1986) and may also be involved in the action of some 
hormones which antagonise insulin by activation of PK-C or PK-A (Van Obberghen et 
al., 1990). Serine phosphorylation of the receptor may therefore in part represent 
crosstalk from other signalling systems.
A pathological increase in serine phosphorylation might explain the reversible 
decrease in receptor tyrosine kinase activity which has been observed in diabetes 
(Becker and Roth, 1990). Indeed elevation of PK-C activity has been suggested to 
mediate desensitisation of the insulin receptor observed in starved rats and the insulin 
resistance in obese subjects (Pfeiffer and Schatz, 1992). Elevation of diacylglycerol 
levels (the endogenous PK-C activator) by generation via cellular glucose metabolism 
during hyperglycemia may explain this increase in kinase activity (Greene et al., 1987).
Although it is unclear how phosphorylation of the insulin receptor leads to 
action of the hormone on metabolism, most evidence favours some form of 
phosphorylation cascade, as has been described for the PK-A system (Taylor, 1989).
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The phosphorylation cascade hypothesis is complicated by insulin's ability to influence 
both positively and negatively the phosphorylation state of several key metabolic 
enzymes. Those dephosphorylated include glycogen synthase (Sheorain et al., 1982), 
hormone-sensitive lipase (Stralffos et al., 1984) and pyruvate dehydrogenase (Hughes 
et al., 1980). Those phosphorylated include ATP citrate lyase (Alexander et al., 1979), 
acetyl CoA carboxylase (Brownsey and Denton, 1982), phosphofructokinase (Sale and 
Denton, 1985) and S6 kinase (Cobb and Rosen, 1983). In order to substantiate the 
protein kinase cascade hypothesis it has been considered important to identify the serine 
kinases involved in these phosphorylations and the mechanisms by which they are 
activated in response to insulin. At least seven serine/threonine kinases are known to be 
involved in insulin signalling (Sale and Smith, 1989). Their activation is stable to cell 
extraction in the presence of phosphatase inhibitors suggesting that they themselves are 
activated by phosphorylation. None of the serine kinases have however been shown to 
be directly activated by the receptor tyrosine kinase. Presumably more intermediary 
kinases await disovery.
The model in its present state also has difficulty in accounting for the large 
number of different actions of insulin with different time scales, apparently initiated by 
a single phosphorylation event. It is possible that some of insulin's actions may be 
independent of phosphorylation. Other mechanisms of insulin action are discussed 
below in section 1.1.6.
1.1.4 Control of cell responsiveness to insulin
Regulation of a particular cell's response to insulin can occur at the level of 
insulin receptor number, tyrosine kinase activity, dephosphorylation of the receptor 
and post receptor events. There is evidence for all occurring in vitro and influencing 
insulin's action in disease states.
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Regulation of the number of cell surface receptors is a means by which the 
organism can determine specificity in the response of target cells to hormone and adapt 
to changes in its circumstances. Internalisation of the receptor follows ligand binding, 
serving to terminate the signal at the cell surface and allowing control of receptor 
number by degradation and recycling. In cells so far studied, the insulin receptor has a 
half life of 8-12 hours (Hedo et al., 1983, Deutsch et al., 1983) and the 
phosphorylation state of the receptor has been implicated in its internalisation and 
recycling (Knutson, 1991). Insulin receptors recycled back to the plasma membrane are 
devoid of phosphotyrosine, suggesting that they must be dephosphorylated before 
recycling and implicating a phosphatase enzyme as a regulatory component (Backer et 
al., 1989). Insulin exposure causes a down-regulation of cell surface insulin receptors 
and whether this occurs by means of increased receptor inactivation or decreased 
synthesis depends on the cell type (Knutson, 1991). Exposure of rat hepatoma cells 
(Crettaz and Kahn, 1976) or cultured rat hepatocytes (Melin et al., 1990) to high insulin 
concentrations was found to result in a loss of cell surface insulin receptors leading to a 
state of insulin resistance with respect to insulin's metabolic action.
Level of insulin receptor expression also depend on cell type, state of 
differentiation, other hormones eg. glucocorticoids and the cell's metabolic status. 
Receptor levels are lower in growing 3T3 LI pre-adipocytes but approach a maximum 
as cells reach a stationary phase (Karlsson et al., 1979). In contrast, receptor levels are 
high in HL-60 cells (a human promyelocytic cell line) and decrease during 
chemically-induced differentiation. Presumably there are tissue specific and 
developmental factors which regulate expression of the gene.
Altered insulin sensitivity can occur in pathological states. The lowered 
sensitivity of target tissues in the hyperinsulinaemia of obesity and type 2 diabefcs 
mellitus can be accompanied by a decrease in receptor number (Czech, 1985). Ii
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addition, the insulin receptor tyrosine kinase activity has been reported to be impaired in 
starvation (Karasik et a l, 1990), insulin resistance (Takayama et a l, 1988b), obesity 
(Le Marchand-Brustel et al., 1985) and in cases of severe insulin resistance resulting 
from receptor mutations (Becker and Roth, 1990). The diabetic alteration in tyrosine 
kinase activity correlates well with altered sensitivity to glucose transport and 
antilipolysis by insulin (Takayama et al, 1988b) though it is not known whether the 
defect is intrinsic to or secondary to the diabetic condition. Presumably it does not 
result from a mutation as it is reversible with insulin treatment. In rodent models of 
insulin deficient (type 1) diabetes, a decrease in tyrosine kinase activity has been 
observed, despite an increase in receptor number (Okamoto et al, 1986). Conversely, 
tyrosine kinase activity is increased in insulin hyperresponsive adipocytes from young 
obese Zucker rats (Debant et a l, 1987). An increase in phosphotyrosine phosphatase 
activity has been observed in adipocytes and liver from diabetic animals, where it has 
been proposed to contribute to insulin resistance (Begum et a l, 1991). Consequently, 
the receptor tyrosine kinase remains a possible site for future therapeutic intervention in 
diabetes, since enhancing signal generation by insulin might enhance sensitivity of 
target tissues to the hormone.
1.1.5 Regulation of growth and gene expression bv insulin
As well as acutely regulating metabolic flux, insulin over longer time periods 
and at higher concentrations than those present in vivo, is known to influence protein 
synthesis and cell growth (O'Brien and Granner, 1991). Some of these effects may be 
explained by insulin's low affinity action at the IGF-1 receptor (Florini et al, 1991)
(and see below, section 1.2) whilst in a few cell types only insulin can increase DNA 
synthesis at physiological concentrations by acting through its own receptor (Koontz 
andlwahashi, 1981, Taub et al., 1987).
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There are at least 50 genes known to be regulated in response to insulin, the 
best studied being those encoding enzymes involved in regulation of hepatic glucose 
metabolism viz. phosphoenolpyruvate carboxykinase (PEPCK), whose synthesis is 
repressed by insulin and glucokinase, whose expression is enhanced. The mechanisms 
and physiological significance of insulin's regulation of genes are not fully understood, 
but it is clear that insulin can influence gene expression positively and negatively at the 
level of transcription, RNA processing and degradation and translation (Granner, 
1987). In many cases the action of insulin on gene expression is permissive rather than 
overriding, in that its effect is only observed in the presence of other hormones or 
substrates. This tonic role of insulin means that significant changes in gene expression 
are only observed in abnormal circumstances, for example in diabetes or starvation. 
The rapidity of insulin's action on gene expression varies considerably between genes, 
probably a reflection of its different modes of action. Extensive work is underway to 
identify insulin response sequences in genes.
Insulin’s action on gene expression, like its actions on energy metabolism are 
cell specific. For example, insulin stimulates DNA synthesis (McGowan et al., 1981) 
and increases the amount of mRNA for albumin in primary cultured rat hepatocytes 
(Lloyd et al., 1987) but does not do so in the cultured rat hepatoma (H4-H-E) cell line 
(Straus and Takemoto, 1987). Differential effects of insulin on transcription in the two 
cell types are responsible here. For some genes, the effect of insulin varies within 
clones of the same cell line (Stanley, 1988). Thus, cell type and state of differentiation 
are both important in determining insulin responsiveness. In addition, insulin itself can 
influence the state of differentiation of some cell types. It has been shown to promote 
differentiation in 3T3 LI fibroblasts (Watkins et al., 1987), chick embryo muscle cells 
(Schmid et al., 1983) and rat muscle satellite cells (Allen and Boxhom, 1989).
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1.1.6 Other mechanisms of insulin action
Various mechanisms have been proposed by which insulin may exert its effects 
on cells in addition to tyrosine kinase activation. There is considerable evidence that 
some of insulin's actions may involve established second messenger systems. The 
involvement of adenylyl cyclase in insulin signalling is discussed in section 1.5.
Mediators have been isolated from insulin-exposed cells which, after extraction, 
can mimic some of insulin's actions in vitro (Mato, 1989). Mediators have been 
generated from plasma membranes in response to insulin, indicating that all the 
components for their generation are located in the plasma membrane and evidence has 
been presented for their regulation of kinases, phosphatases and direct action on 
pyruvate dehydrogenase. Romero et al. (1988) proposed that a 
phospho-oligosaccharide second messenger could be generated extracellularly by an 
insulin-specific PLC, the substrate for the phospholipase being glycosyl phosphatidyl 
inositol (GPI), released from a GPI-anchored membrane protein by concomitant 
protease activation. Antibodies which recognise these GPI-derived mediators can 
specifically inhibit intracellular actions of insulin (Lamer et al., 1990), suggesting that 
they may play a role in insulin’s action. The insulin mediator hypothesis has also been 
extended to explain insulin's effect on intracellular cAMP levels. Saltiel and 
Cuatrecasas (1986) isolated a mediator from liver following insulin treatment which 
could inhibit plasma membrane adenylyl cyclase activity. A cAMP-lowering mediator 
isolated from adipocyte plasma membranes mimicked insulin's action in lowering 
cAMP and in stimulating lipogenesis and antilipolysis (Zhang et al., 1983). Problems 
with this hypothesis are that the mediators are generated extracellularly, requiring an 
explanation for their uptake into the cell. Moreover, it is unclear how insulin activates 
the protease required for mediator generation and how mediators bring about their
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intracellular effects on metabolism. At best, the mediator hypothesis can account for 
only some of insulin's actions.
A reduction in plasma membrane fluidity, shown using extrinsic probes follows 
the binding of insulin to its receptor, and occurs at physiological concentrations of the 
hormone (Farias, 1987). This action of insulin may have a role in regulating the 
activities of membrane bound enzymes or components of second messenger systems.
In several cell lines and in human fibroblasts it has been shown that increasing 
membrane fluidity by supplementation with polyunsaturated fatty acids is associated 
with an increase in insulin receptor number, decreased insulin binding affinity and 
increased insulin sensitivity (Ginsberg et al., 1990). In studies on insulin resistance in 
cultured hepatoma cells, Bruneau et al. (1987) noted that alteration of the membrane 
lipid composition of hepatoma cells by 25-hydroxycholesterol treatment made the cells 
insulin resistant with respect to insulin's action on glycogen synthesis. Ginsberg et al. 
(1990) proposed that a less fluid membrane may favour receptor aggregation into 
clusters, whereas at high fluidity the clusters dissociate exposing more hormone 
binding sites. Interestingly, these fluidity effects are not observed with the IGF-1 
receptor (Ginsberg et al, 1990). This may be a result of the relatively low homology of 
the transmembrane regions of the insulin and IGF-1 receptors (Ullrich et al., 1986), the 
region presumably most subject to the influence of membrane lipids. However, as 
many other agents are capable of altering membrane fluidity, this effect of insulin is of 
questionable importance in specific actions of the hormone.
As membrane lipid fluidity and hence insulin sensitivity is open to modification 
by dietary means, considerable interest has developed in this facet of insulin's action 
with regard to management of diabetes, particularly as type 2 diabetes is commonly 
associated with hyperlipidaemia. Pathological alteration in lipid fluidity in diabetic states 
has been shown to respond to dietary and insulin treatment. Neufeld et al., (1986),
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working with mononuclear leucocytes from obese type 2 diabetic subjects, showed that 
a reduced receptor number was dependent on an increased cholesterol /phospholipid 
ratio which affected lipid fluidity. An increase in receptor number followed a period of 
caloric restriction in these subjects. Similar findings have been reported in platelets 
from type 1 and type 2 diabetic subjects (Winocour et al., 1990). In addition, 
erythrocyte membrane microviscosity is known to be higher in type 1 diabetes 
(Bryszewska et al., 1986). These findings have been reported to be reduced on insulin 
treatment
Another relatively non-specific means by which insulin has been proposed to 
influence hepatic enzyme activity is its ability to regulate potassium balance and cell 
volume (Vom Dahl et al., 1991). In addition, most of the established intracellular 
second messengers have been suggested to mediate certain of insulin's actions in 
specific cell types viz. calcium ions, diacylglycerol, cGMP and cAMP (Martin, 1987), 
but no one second messenger has emerged as being responsible for all insulin's effects. 
The role of cAMP in insulin signalling is further discussed in section 1.5.
1.2 Insulin-like g rm tli factors
Insulin-like growth factors (IGFs) (or somatomedins) are pro-insulin-like 
hormones found in the circulation whose primary source is thought to be liver 
(Froesch and Zapf, 1985). They have a variety of anabolic actions including glucose 
uptake, amino acid uptake and incorporation into protein, DNA synthesis and cell 
proliferation (Baxter, 1988). IGF-1 is the main mediator for the growth promoting 
effects of growth hormone. Elevated levels of plasma IGF-1 are thought to play a role 
in the pathogenesis of proliferative diabetic retinopathy (Dills et al., 1991).
12
Fig. LI Insulin and insulin-like growth factor receptors
The insulin and IGF-1 receptors possess similar structural features with 
two extracellular, ligand-binding a  subunits and two intracellular 6 subunits with 
tyrosine kinase activity. The white boxes represent the tyrosine kinase region and 
the black boxes cysteine rich, homologous regions. The IGF-2 receptor is a 
monomer, largely extracellular and with 15 repeats of 150 amino acid residues in 
the extracellular portion. It bears no structural homology to the other two 
receptors. (Adapted from Roth et al., 1990).
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The activities of IGFs are well documented in cell lines as well as native cells. 
IGF-1 is a 7.6kDa protein of 70 amino acid residues and IGF-2, a 7.5kDa protein of 67 
amino acids (Florini et a l , 1991). The IGF-1 receptor resembles that for insulin in 
general structure, molecular weight (350kDa) and in possessing tyrosine kinase activity 
(Rechler and Nissley, 1985) (Fig. 1.1). It has specificity in the order IGF-1 > IGF-2 > 
insulin. At high (|iM) concentrations then, insulin is thought to stimulate cell growth 
and differentiation of cells by binding with low affinity to the IGF-1 receptor (Florini et 
al.y 1991). In this way insulin can stimulate DNA synthesis in hepatocytes, which 
contain both insulin and IGF-1 receptors.
The IGF-2 receptor is a 250kDa monomer with no known intrinsic activity 
(Roth, 1988). It does not bind insulin, is not linked by disulphide bonds to other 
subunits and its physiological role is unclear. One possibility is that it plays a role in 
IGF-2 metabolism.
1.3 Adenvlvl cvclase signalling
The second messenger cAMP was discovered during studies of hormone effects 
on liver tissue (Rail et al., 1967). The workers reported production of a heat stable 
adenine ribonucleotide which was able to activate glycogen phosphorylase in the 
supernatant fraction. This was the first example of a liver enzyme altered in activity by 
cAMP. The enzyme producing cAMP, adenylyl cyclase, is a plasma membrane-bound 
enzyme which catalyses the conversion of ATP to cAMP and PPi (Fig. 1.2). Adenylyl 
cyclase activity was found in all tissues studied except for dog erythrocytes and the 
highest activity was found in brain (Sutherland et al.> 1962).
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Fig,.1,2 The reaction catalysed bv adenvlvl cvclase
Adenylyl cyclase catalyses the conversion of ATP to cAMP and PPi.
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1.3.1 The role o f cAM P in metabolism
Cyclic AMP exerts its action on cells by activating cAMP-dependent protein 
kinase (PK-A) and thence a protein kinase cascade in which there is amplification of the 
response before enzyme activity is altered. The action of cAMP is terminated by its 
hydrolysis to 5'AMP by cAMP phosphodiesterase activity (Beavo, 1990). Since the 
discovery that it could stimulate liver glycogen phosphorylase, cAMP has been found 
to be a major regulator of liver and adipose tissue metabolism. It is a ubiquitous 
intracellular messenger and has a variety of different functions in different cells.
In liver, cAMP exerts its influence at two levels. Firstly, it acutely regulates the 
activity of the key enzymes involved in glycolysis, gluconeogenesis and fatty acid 
metabolism. Secondly, it regulates gene transcription. Glucagon, the main 
gluconeogenic hormone elevates cAMP in liver thereby activating PK-A and leading to 
the phosphorylation and activation of phosphorylase kinase and inhibition of the 
glycolytic enzyme pyruvate kinase (Johnson and Veneziale, 1980). This coordinate 
regulation is also evident at the level of gene expression where cAMP abolishes the 
induction of pyruvate kinase (Munnich et al., 1984) and impairs glucokinase 
expression (Pilkis, 1970). Cyclic AMP is the major stimulus for the increased synthesis 
and impaired degradation of mRNA for the gluconeogenic enzyme 
phosphoenolpyruvate carboxykinase (PEPCK) (Hod et al., 1986). The other important 
enzyme regulated in response to cAMP levels is 6-phosphofructo-2-kinase /  
fructose-2,6-bisphosphatase. PK-A phosphorylates and inhibits the kinase and 
activates the bisphosphatase (El-Maghrabi et al., 1982), thereby impairing glycolytic 
flux and enhancing gluconeogenic flux.
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Insulin opposes the action of glucagon and catecholamines on these processes. 
By restraining the level of cAMP it opposes PK-A-mediated phosphorylation and gene 
transcription and has cAMP-independent effects on gene expression which favour the 
anabolic pathways. It enhances pyruvate kinase levels and restores glucokinase levels 
which have been lowered by diabetes mellitus (Spence, 1983). In addition to its effects 
on carbohydrate metabolism, insulin has long been known to oppose the lipolytic action 
of cAMP both in liver and adipose tissue (Illiano and Cuatrecasas, 1972). This 
mechanism of this restraint is further discussed in section 1.5.1.
1.3.2 Regulation of adenvlvl cvclase activity
A possible role for GTP in the regulation of adenylyl cyclase was suggested 14 
years after the discovery of cAMP (Rodbell et al., 1971). The group found that GTP 
regulated binding of glucagon to hepatocyte membranes and that GTP was necessary 
for effective stimulation of adenylyl cyclase by the hormone. They went on to discover 
that GTP could be used both in stimulation and inhibition of the enzyme, which were 
suggested to be separate processes (Yamamura et al., 1977). Their introduction of the 
non-hydrolysable GTP analogue, GppNHp (see appendix) and the discovery of 
catecholamine-induced GTP hydrolysis by Cassel and Selinger (1976) led to the 
proposal of the GTPase cycle (Fig. 1.3). The molecular basis of the GTP binding 
components did not emerge until the introduction of bacterial toxins. The stimulatory 
component Gs was shown to be the site of action of cholera toxin which 
ADP-ribosylated and persistently activated the protein (Johnson etal., 1978). The 
inhibitory component Gi was shown to be the site of action of pertussis toxin, another 
ADP ribosyltransferase (Katada and Ui, 1982). These two toxin substrates were 
subsequently purified. In 1986, Feder et al. demonstrated that adenylyl cyclase could 
be activated by hormone after reconstitution of the purified receptor, G-protein and 
catalytic moiety into phospholipid vesicles, showing that these three components
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were the minimum necessary to form a signal transduction unit (Fig. 1.4).
G-proteins consist of a  (39-52kDa), 6 (35-36kDa) and y (7-10kDa) subunits. 
The a  subunit appears to subserve the most important functions associated with the 
protein. Activation of adenylyl cyclase by stimulatory agonists is thought to proceed by 
the following mechanism (Gilman, 1987). Binding of agonist to the plasma membrane 
receptor results in a conformational change and activation of the receptor which 
increases its affinity for GDP-bound Gs. On colliding with Gs, the receptor catalyses 
exchange of GTP for GDP, thus promoting activation of Gs-a and its dissociation into 
constituent cts-GTP and By components. The a  subunit is then able to interact with and 
activate the effector adenylyl cyclase. Amplification of the response occurs at both the 
receptor-Gs interaction and the Gs-AC interaction. Termination of the response occurs 
due to the intrinsic GTPase activity of the a  subunit which hydrolyses GTP to GDP, 
restoring the a  subunit to its GDP bound, inactive form and permitting reassociation of 
the trimer. Fluoride, when complexed with aluminium is thought to activate adenylyl 
cyclase by binding to the GDP-bound form of Gs-a where it mimics the y phosphate of 
GTP, preventing restoration to the inactive form. Distinct domains on G-protein a  
subunits subserve the functions of GTP binding, receptor and effector interaction. The 
C terminus is considered the site of receptor interaction and N terminus the site of By 
interaction (Kaziro et al., 1991).
Agonist-induced inhibition of adenylyl cyclase is thought to occur in two 
different ways (Gilman, 1987). Firstly, activated Gi-a may interact directly with AC in 
a similar manner to Gs-a but possibly binding at a different site, so as to inhibit its 
activity. Alternatively, a dissociation mechanism has been proposed (Katada et al., 
1984) whereby By subunits released from activated Gi shift the equilibrium for Gs 
dissociation in favour of the inactive trimer. Probably both these mechanisms are 
functional in cells but their contributions to receptor-mediated inhibition will depend
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Fig, 1,3 The G-protein GTPase cvcle
(a) G-protein in the basal state is holomeric and has GTP bound to the a  
subunit.
(b) Activated receptor (R*) catalyses exchange of GDP for GTP; a  
subunit dissociates from the By component.
(c) GTP-bound a  subunit interacts with the effector.
(d) Intrinsic GTPase activity of the a  subunit hydrolyses GTP and the 
trimer reassociates.
(Adapted from Spiegel, 1992)
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Fig. 1.4 Hormonal regulation of adenvlvl cvclase
Stimulatory hormones (Hs) bind to receptors which have a positive effect 
on adenylyl cyclase (AC) activity through Gs. Inhibitory hormones (Hi), on 
activating their receptors, exert a negative influence on adenylyl cyclase through 
Gi. Both stimulatory and inhibitory G-protein-linked receptors are thought to 
consist of a hydrophobic, transmembrane domain of seven a  helices, as well as 
intracellular and extracellular domains. (Adapted from Levitski, 1988).
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Figure 1.4
on the relative concentrations of Gi and Gs (Birnbaumer et al., 1985). Certain types of 
adenylyl cyclase are also thought to be directly regulated by By dimers (Tang and 
Gilman, 1992). Clearly, the extent of inhibition by this mechanism will depend on the 
By and adenylyl cyclase subtypes present in the vicinity. Possibilities for control of 
G-protein function in addition to those mentioned above are becoming apparent. The 
retinal protein phosducin inhibited the activity of several G-proteins, including Gs-a 
mediated adenylyl cyclase activity. In turn, phosducin was inhibited by PK-A, 
suggesting that it may be part of a complicated regulatory network (Bauer et al., 1992).
The signalling functions of G-proteins appear to require that they remain in 
close proximity to the plasma membrane. Although in some systems there is evidence 
for G-proteins leaving the membrane on activation (McArdle et al., 1988) and their 
location at subcellular sites (Bokoch et al., 1988) there is no evidence for G-proteins 
performing signalling functions at sites other than at the plasma membrane.
Cholera toxin from Vibrio cholerae, in the presence of NAD+, ADP-ribosylates
GTP-bound Gs-a, reducing its intrinsic GTPase activity and rendering the protein
permanently active (Northup etal., 1980). Its site of action is an arginine residue
present in all variants of Gs-a (residue 201/202 in the long forms and 187/188 in the
short forms). This persistent activation results in elevated intracellular cAMP levels,
responsible for the symptoms of cholera. Pertussis toxin from Bordetella pertussis, the
causative organism of whooping cough, ADP-ribosylates and inactivates the
GDP-bound (trimeric) form of Gi-a, preventing its dissociation and abolishing both
receptor-mediated and tonic inhibition of adenylyl cyclase. The site of action of the
toxin is a cysteine residue located four residues from the C terminus. The a  subunits of
at least six G-proteins can be modified by pertussis toxin-catalysed ADP-ribosylation
•»
(Freissmuth et al., 1989). Pertussis toxin has proven a particularly useful tool in 
identifying Gi-mediated events and substrates involved in signal transduction.
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Pertussis toxin treatment of cells, by removing inhibitory Gi input into the activity of 
the catalytic subunit, can enhance responses to stimulatory hormones (Heyworth et al., 
1984). Hormonal activity not mediated by G-proteins is not influenced by pertussis 
toxin treatment
1.3.3 G-protein subtypes
It has become apparent that G-protein a  subunits are members of an extensive 
GTP binding protein family which have structural features in common (Bourne et al., 
1991) and some 16 a  subunits have now been cloned (Bimbaumer, 1992). In 
mammalian cells there are at least nine genes coding for these a  subunits, some of 
which give rise to more than one polypeptide by alternative splicing mechanisms 
(Kaziro et al., 1991). Many of the polypeptides have been well characterised but for 
others very little information is available at present on their tissue distribution and 
receptor-effector coupling.
Gs is expressed ubiquitously in mammalian cells. Its presence is essential for 
stimulatory regulation of adenylyl cyclase by hormones. GTP at pM levels is required 
for efficient coupling. Gs-a is encoded by a single gene, but differential splicing can 
produce up to four different polypeptides (Bray et al.y 1986) which have a tissue 
specific distribution (Mumby et al., 1986). On finding that two forms of Gs-a could 
reconstitute fluoride and guanine nucleotide regulatory activity in the Gs-lacking mutant 
S49 eye- cells with equal efficacy, Graziano et al. (1987) proposed that there is no 
functional difference between the different forms, though evidence has also been 
presented that the shorter form may have a greater ability to activate adenylyl cyclase 
(Walseth et al., 1989). It seems likely that differences will be uncovered in their 
receptor coupling abilities, as in the case of Gi-a forms.
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Complementary DNA cloning of Gi-a has revealed three different Gi-a cDNAs 
viz. Gi-la, Gi-2a and Gi-3a (Kaziro et al., 1991) all of which are encoded by distinct 
genes. All three polypeptides have been purified from tissue sources and their 
distribution characterised. They show 85% amino acid sequence identity. Gi-2a 
(40kDa) and Gi-3a (41kDa) are ubiquitous but their relative amounts vary between 
tissues (Milligan, 1990). Gi-2a is generally thought to be the form responsible for 
inhibition of adenylyl cyclase (Bushfield et al. 1990a), though there is evidence both 
for (Pobiner et a l, 1991) and against (McClue et al., 1992) Gi-3a also having such a 
role. Gi-3a has also been proposed to regulate sodium channels (Cantiello et al.,
1990), potassium channels (Mattera et al., 1989) and Golgi trafficking (Stow et al.,
1991). G i-la (41kDa) has a more limited tissue distribution, notably present in cerebral 
cortex (where it is the most abundant Gi form), adipocytes and neural tissue-derived 
cell lines. Its function is at present undefined, but Attali and Vogel (1989) proposed that 
it may serve to couple opiate receptors to inhibition of adenylyl cyclase. Go-a another 
pertussis toxin substrate, is expressed predominantly in neural tissues where it is 
thought to regulate calcium channels (McFadzean et al., 1989). The pertussis 
toxin-insensitive Gq is a group of a  subunits thought to couple receptor activation to 
phospholipid hydrolysis by activating phospholipase C (Simon et al., 1991). 
Interestingly, only the B isoforms of PLC appear G-protein sensitive. Thus Gq shows a 
high degree of specificity in its effector coupling.
There is very strong conservation of a  subunit structure between species. For 
example only one residue out of 394 differs between rat and human Gs-a. The amino 
acid sequences of Gi-2a, Gi-3a and Go-a are 98% identical between mammalian 
species. This demonstrates that there is strong evolutionary pressure to maintain 
G-protein function.
At least four different B and five y subtypes exist on the basis of cDNA
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cloning (Bimbaumer, 1992). The significance of this heterogeneity is unclear but 
presumably different polypeptides may have different functions increasing the number 
of possibilities for specific interactions. By components have been considered to have 
roles in anchoring of a  subunits, promotion of GDP exchange and attenuation of a  
subunit functions. However, it is becoming clear that By components may activate 
effectors in their own right. They have been suggested to regulate potassium channels 
(Logothetis et al., 1987), phospholipase A l (Bourne, 1989), phospholipase C (Katz et 
al., 1992) and calmodulin (Katada et al., 1987). A recent study by Kleuss et al. (1992) 
showed that in rat pituitary GH3 cells which express four B isoforms, only two of the 
isoforms, Bi and 63 couple specific receptors to calcium channels. This demonstrates 
that By signalling can be hormone-specific, increasing the likelihood of its having a 
physiological role.
It has been proposed (Bimbaumer, 1992), that in certain tissues, signalling may 
occur both through a  subunit and By subunits at respectively low and high receptor 
occupancy. This dual signalling may account for the ability of certain receptors to 
stimulate both PLC and adenylyl cyclase at respectively low and high concentrations. 
Alternatively, receptors stimulating both effectors may be capable of coupling to both 
Gq and Gs.
1,3,4 AdeitYlYl cyclase subtypes
Although adenylyl cyclase signalling has been well studied in a range of tissues, 
characterisation of the enzyme itself has been relatively slow due to its presence in small 
amounts in biological membranes and difficulties in purification because of its 
hydrophobic nature. Major progress was made with the development of its affinity 
purification on forskolin agarose (Pfeuffer, 1991) and the cloning of 
calmodulin-sensitive adenylyl cyclase from brain (Krupinski et al., 1989). At least
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Fig. 1.5 The structure of eukaryotic adenvlvi cvclase
The adenylyl cyclase catalytic subunit consists of two hydrophobic 
membrane spanning regions (Mi and M2), an N terminal region representing a 
motif in eukaryotes and two 40kDa cytoplasmic domains (Cl and C2). Regions of 
homology between different subtypes are shown in bold. Cia and C2a are well 
conserved, forming the likely nucleotide binding site. Point mutations in these 
regions considerably reduce activity. The hydrophobic domains are the presumed 
site of forskolin binding. (Adapted from Tang and Gilman, 1992)
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six adenylyl cyclase isoforms have now been cloned from mammalian tissues and can 
be divided into four subfamilies on the basis of sequence homology (70-75% between 
members) and regulatory properties. All have similar overall structure (Fig. 1.5) with 
12 hydrophobic membrane spanning sequences, two hydrophilic intracellular domains 
essential for activity (Kelley Bentley and Beavo, 1992) and both N and C termini 
intracellularly located. All are regulated in a stimulatory fashion by Gs. Brain adenylyl 
cyclase was originally estimated to have a molecular weight of 200-250kDa (Neer et 
al., 1980) but the actual molecular weights of the cloned constituent species are now 
known to be approximately 120kDa. In vivo therefore, the molecule may function as a 
dimer, or in close association with other proteins.
AC-I (120kDa) is calmodulin sensitive, inhibited by G-protein By component 
(Gao and Gilman, 1991) and may have a role in long term potentiation of synaptic 
transmission. AC-III (129kDa) is present high levels in olfactory epithelia and has high 
homology with type I within the hydrophilic domains but is unaffected by By (Bakalyar 
and Reed, 1990). AC-II (123kDa) and AC-IV (llOkDa) have high sequence 
homology and are stimulated by By in the presence of Gs (Gao and Gilman, 1991). In 
the case of AC-II, this stimulation has been shown to occur in the intact cell 
(Federmann et al., 1992). This stimulatory effect of By on these isoforms may explain 
the ability of agonists which are not themselves activators of adenylyl cyclase to 
potentiate those that are, via release of By components from other G-proteins. AC-V 
and AC-VI have been recently cloned from rat liver (Premont et al., 1992). They appear 
widely distributed and are not stimulated by By.
Sensitisation of adenylyl cyclase to stimulation has been noted in response to 
phorbol ester treatment and attributed to PK-C phosphorylation of adenylyl cyclase 
(Simmoteit et al., 1991). A recent study by Jacobowitz et al. (1993) showed that 
cyclase subtypes differ in their sensitivity to phorbol ester treatment. The activities
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of AC-I, -II and -ID increased considerably in response to PK-C activation, while 
AC-IV, -V and -VI showed only very small increases in activity. Types I-m then, may 
be signal effectors for extracellular signals not mediated by activation of the stimulatory 
G-protein Gs.
The presence of multiple isoforms of adenylyl cyclase provides extra 
possibilities for control, both by selective expression of the isoforms in target tissues 
and by interaction with specific G-proteins and other regulatory influences. Thus, the 
number of mechanisms for regulating cAMP synthesis is probably considerably greater 
than previously imagined.
1.3.5 Forskolin
The lipid soluble diterpene forskolin (see appendix) was discovered when plant 
extracts were screened for cardiovascular activities (Bhat et al., 1977). Its ability to 
stimulate adenylyl cyclase activity in plasma membranes was discovered by Seamon et 
al. (1981) and noted to occur directly on the catalytic subunit Since then, forskolin has 
been widely used in investigating the role of cAMP in cell functioning and found to 
cause large increases in cAMP in almost all mammalian cells. The stimulation of 
adenylyl cyclase is rapid and potent, with lOpM forskolin generally giving half 
maximal activation. Maximal forskolin stimulation seen at lOOpM is generally greater 
than that achieved with fluoride or non-hydrolysable GTP analogues and there is little 
variation in the kinetics of its action between cell types. Forskolin-elevated intracellular 
cAMP usually reaches a maximum level after 5-10 minutes. Thereafter, any fall in 
cAMP can be attributed to cAMP phosphodiesterase activity or cAMP extrusion, as 
homologous desensitisation to forskolin has not been observed in any cell type.
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Forskolin can act synergistically with both weak and strong agonists in 
elevating cAMP (Seamon and Daly, 1983) and can reveal responses to hormones which 
are too low to observe in the absence of forskolin (Darfler et al., 1982). This 
synergistic action is more easily observed in intact cells than in plasma membranes and 
is half maximal at less than 0.1 p.M. These findings led to the suggestion that forskolin 
has two sites of action (Barovsky et al., 1984) viz. a low affinity site for its action on 
the catalytic subunit and a high affinity site responsible for its potentiation of hormone 
action. The physical nature of these sites is not known. However, studies with S49 
lymphoma mutants have shown that the high affinity response requires functional Gs 
(Darfler et al., 1982), suggesting that forskolin potentiates other hormones by an action 
on Gs. The finding that cycloheximide pre-treatment disrupted forskolin responsiveness 
(Brooker et al., 1983) prompted the suggestion that forskolin, in exerting its low 
affinity effect on the catalytic subunit, may act on a distinct protein susceptible to 
inhibition of protein synthesis. The majority of forskolin's pharmacological actions can 
be attributed to cAMP elevation as it alters cell physiology in a manner consistent with 
cAMP elevation and PK-A activation (Seamon and Daly, 1986). However, a number of 
cAMP-independent actions of forskolin have also been reported, for example its 
inhibitory effect on glucose transport (Klip et al., 1988).
1.3.6 Regulation o f G-orotein levels
Alterations in tissue G-protein expression can occur on agonist exposure, 
during differentiation and in a number of diseases. Some of these changes are 
discussed below.
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1.3.6.1 Hormonal regulation of G-protein levels
Whilst down regulation of plasma membrane receptors on prolonged exposure 
to agonist is responsible for reducing responses to specific hormones ie. homologous 
desensitisation, altered expression of G-proteins may play a role in heterologous 
desensitisation ie. desensitisation to multiple hormonal stimuli (Milligan and Green, 
1991).
Adaptive alterations in both Gs and Gi expression have been observed in a 
direction consistent with current knowledge of their effects on adenylyl cyclase. Gs-a 
can be down regulated by stimulatory signals. Prolonged exposure of NG108-15 cells 
(a neuroblastoma x glioma hybrid) to PGEi caused a down regulation of Gs-a whose 
time course paralleled that of the prostanoid receptor (McKenzie and Milligan, 1990). 
The levels of other G-proteins were unaltered. Rich et al. (1984) showed that exposure 
of an MDCK (canine kidney) cell line to glucagon caused a decrease in glucagon-, 
PGEi- and fluoride-stimulated adenylyl cyclase activity. A twofold increase in Gi was 
detected. Prolonged exposure of cardiac muscle cells to the B-adrenergic agonist 
noradrenaline resulted in down regulation of Bi-adrenoceptors and up regulation of Gi 
(Reithmann et al., 1989). These changes were accompanied by a reduction in both 
receptor-dependent and -independent (forskolin) stimulation of adenylyl cyclase.
Similarly, exposure to inhibitory agonists can cause down regulation of Gi. 
Treatment of adipocytes with the adenosine analogue N6-phenylisopropyladenosine 
down regulated all three Gi forms along with the B subunit, but there was no effect on 
Gs levels (Green and Johnson, 1989). Both the mechanisms by which receptor 
sequestration and altered G-protein expression are triggered remain unknown, though it 
has been suggested that up-regulation of Gi may be a relatively non-specific response to 
elevated cAMP levels (Reithmann et al., 1991). The transcription of a number of genes
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has been shown to be regulated by cAMP acting through cAMP regulatory elements 
(Roesler et al., 1988). It is conceivable therefore, that cAMP may have a direct 
influence on transcription of the Gi-2a gene. In support of this is the finding of 
Weinstein et al. (1988) that the promoter region of the Gi-2a gene contained binding 
sites for a factor (AP-2) which may mediate the transcriptional effects of cAMP. In 
contrast, no such cAMP response elements were observed on the gene for Gs-a 
(Kozasa et al., 1988). In S49 lymphoma cells, the increase in Gi-2a expression on 
prolonged adenylyl cyclase stimulation has been shown to be mediated by transcription 
of the Gi-2a gene (Hadcock et al., 1990). Interestingly, in a variant of these cells 
lacking PK-A, there was no up-regulation of Gi by stimulatory agonists, suggesting 
that this kinase is essential for control of the level of Gi expression. However, the 
cAMP analogue dibutyryl cAMP has been noted to cause a decrease in Gi levels in 
NG108-15 cells (Mullaney et al., 1988). Therefore, the up-regulatory effect of cAMP 
on Gi is not universal and cAMP is probably not the sole influence on expression of the 
Gi-2a gene.
Hormones not acting through G-protein activation can also affect the levels of 
G-protein expression in cells and consequently adenylyl cyclase signalling. 
Glucocorticoids can also increase Gs-a levels in pituitary GH3 cells (Chang and 
Bourne, 1987). Corticosterone has been noted to increase Gs forms and decrease 
Gi-la and Gi-2a in cerebral cortex, leaving 6 subunit levels unaltered (Saito et al., 
1989). All these changes are consistent with the ability of glucocorticoids to enhance 
hormonal stimulation in tissues (Davies and Lefkowitz, 1984) and the cAMP-elevating 
effect of these changes probably contributes to the diabetogenic effect of 
glucocorticoids. The molecular basis of cAMP elevation in liver from diabetic animals 
is further discussed in section 1.5.2.1 and the influence of insulin on G-protein 
expression in section 1.5.1.
30
1.3.6.2 G-proteins in differentiation
There is evidence that G-protein levels can alter in ageing (Green and Johnson, 
1989), during development of organs (Luetje etal., 1987) and cell types (Musk et 
al., 1992) and in response to a number of differentiation agents. Insulin and 
dexamethasone (Watkins etal., 1987,1989) can promote differentiation of 3T3 LI 
fibroblasts into adipocytes associated with an increased expression of Gs-a, Gi-a 
(except Gi-2a) and 6. These changes were accompanied by an increased adenylyl 
cyclase response to the B-adrenergic agonist isoproterenol. Retinoids inhibit 
proliferation and promote differentiation in various non-differentiated cell types. For 
example, in ROS 17/2.8 cells, an osteosarcoma cell line, retinoic acid was found to 
inhibit the increased adenylyl cyclase responses associated with cell growth and 
achieved this both by lowering stimulatory receptor number and levels of the 
G-proteins Gi and Gs. Dexamethasone, a potent glucocorticoid analogue, influenced 
stimulatory hormone receptor expression and Gs and Gi expression in the opposite 
direction (Imai et al., 1988). Differentiation of HL-60 cells by exposure to DMSO can 
produce an increase in Gi-2a levels (Uhing et al., 1987). Whilst it is clear that 
G-protein expression and cyclase functioning can be altered in differentiation, various 
factors are involved in this process, and it is not clear to what extent they are 
individually involved in the changes. Given these findings, it seems likely that 
G-proteins play an important role in differentiation in vivo and in altering the signalling 
capability of differentiated cells. However, the significance and mechanisms of these 
changes remain to be established.
1.3.6.3 G-proteins in disease
Tissue-specific alterations in G-protein expression and function have been 
noted in a number of endocrine and other diseases, which have extended our
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knowledge of the molecular basis of these diseases.
Hypothyroidism is associated with impaired stimulatory signalling by 
adrenaline resulting in reduced lipolysis and the obesity observed in the clinical state 
(Goodman and Knobil, 1959). Studies of animal models of hypothyroidism have 
consistently shown increases in adipocyte expression of all three Gi-a forms, Go-a 
and GB at the level of protein and mRNA (Saggerson, 1992). These changes are 
associated with increased Gi-mediated responses by N6-phenylispropyladenosine, 
PGEi and nicotinate and impaired stimulatory regulation by adrenaline through the 
B-adrenergic pathway (Saggerson, 1986). Significant increases in Gi-la, Gi-2a and 
Go-a have also been observed in areas in the brain from hypothyroid animal models 
(Orford et al., 1991). The mechanism of altered G-protein expression in 
hypothyroidism is unknown.
Both glucocorticoid excess and deficiency can have marked effects on adenylyl 
cyclase signalling (Hadcock and Malbon, 1992). Removal of the site of glucocorticoid 
production by adrenalectomy, impairs catecholamine-stimulated cAMP accumulation 
and lipolysis in adipose tissue (Ros et al., 1989a), a defect which is partly reversible by 
glucocorticoid replacement. These changes are accompanied by a fall in Gs-a, GBi and 
GB2 levels in tissues along with their associated mRNAs (Ros et al., 1989b).
In congestive cardiac failure in humans there is reduced B-adrenergic 
responsiveness in cardiac muscle along with reduced Gs function, increased Gi 
function and decreased GppNHp and fluoride-stimulated adenylyl cyclase activity 
(Urasawa and Insel, 1992). As only Gs defects have been observed in ischaemic heart 
disease alone, a role for the loss of Gi function is implicated in the progression to 
cardiac failure. G-protein-mediated signalling has also been extensively studied in 
primary hypertension. However, there is no evidence for any changes found in
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adenylyl cyclase signalling being associated with the pathogenesis of the condition.
Ethanol exposure of cultured cells has been shown to cause changes in 
G-protein expression and evidence is growing that impaired adenylyl cyclase signalling 
may play a role in alcoholism (Gordon et al., 1992). Prolonged exposure of cultured 
cells to ethanol impairs adenosine uptake. The excess extracellular adenosine stimulates 
intracellular cAMP accumulation through adenosine (A2) receptors, which ultimately 
leads to desensitisation of stimulatory receptors coupled to Gs by down-regulation of 
Gs protein and its mRNA (Mochly-Rosen et al., 1988). This heterologous 
desensitisation due to Gs-a down-regulation has also been observed in lymphocytes 
from alcoholic patients and may be considered a marker for the disease. Similarly, 
studies in platelets from these patients showed a significant reduction in PGEi- and 
fluoride-stimulated adenylyl cyclase (Tabakoff et al., 1988). A phenotypic abnormality 
may therefore predispose certain patients to alcoholism by resulting in a disturbance of 
G-protein mediated signalling.
1.3.7 G-proteins in growth factor signal transduction
G-proteins were first suspected to be involved in growth regulation in 1987 
when Vallar et al., on studying growth hormone-producing pituitary tumours, found 
that the high basal cAMP levels in these cells were due to a constitutively active Gs. The 
sequence of Gs-a from cells of these tumours was in each case found to contain a point 
mutation in the codon for Glutamine 227 or Arginine 201, the site of action of cholera 
toxin, which considerably reduced the GTPase activity of the protein, leading to a 
permanently active polypeptide (Landis et al., 1989). Evidence that constitutively active 
adenylyl cyclase can result in increased cell division came from the work of Zachary et 
al. (1990) who transfected Swiss 3T3 cells with Gs-a mutated at Glutamine 227. The 
transfected cells were exquisitely responsive to insulin as a mitogen, suggesting that
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constitutive cAMP production may potentiate growth factors.
There is extensive evidence that Gi-2a is involved in growth regulation. 
Serotonin, which acts through receptors negatively coupled to adenylyl cyclase is 
mitogenic in some cells (Seuwen et al., 1988) and this action is blocked by pertussis 
toxin. On transfection of the inhibitory o^-adrenergic receptor into fibroblasts, Seuwen 
et al. (1990) found that it conferred mitogenicity upon the cells. Hence a Gi-mediated 
reduction in intracellular cAMP may be the growth signal in certain systems. It is likely 
that Gi can also couple to effectors other than adenylyl cyclase in enhancing cell 
growth; the mitogenic effect of growth factors sensitive to pertussis toxin in NIH 3T3 
cells was not affected by cAMP (Taylor et al., 1988) or by transfection with mutant 
Gi-2a (Pace et al., 1991). Likewise, in smooth muscle cells, the stimulatory action of 
serotonin on DNA synthesis was blocked by pertussis toxin but did not involve any 
alteration in intracellular cAMP levels (Kavanaugh et al., 1988). Two likely effectors to 
which Gi-like proteins may couple in transducing mitogenic signals are the enzymes 
PLC and PI3-kinase, as there are numerous examples of PI turnover being stimulated 
by mitogens and its blockade by pertussis toxin (Ives, 1991).
Mutant Gi-2a can also lead to abnormal growth regulation. Cyclic AMP impairs 
growth in Rat-1 cells. Transfection of these cells with a constitutively active mutant 
Gi-2a increased the growth rate of the cells and increased their tumarigenic potential 
(Pace et al., 1991). Lyons et al. (1990) carried out an extensive study of different 
tumours and found that 5-10% of tumours had mutations in Gs-a or Gi-2a at the same 
sites as described above or in corresponding codons. It seems then, that G-protein 
mutations are not universal in tumour cells, but probably restricted to certain endocrine 
tumours where they may have a role in oncogenesis.
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1.3.8 G-proteins in the immune system
There is considerable evidence that G-protein-mediated signalling is involved in 
lymphocyte activation, though the precise roles of the individual G-proteins are elusive. 
In T cells, agents known to activate G-proteins such as aluminium fluoride (O'Shea et 
al., 1987) and GTPyS (Sasaki and Hasegawa-Sasaki, 1987) induce generation of 
inositol phosphates via PLC activity, a biochemical event characteristic of antigen 
receptor activation. Similarly, increases in GTP hydrolysis and GTPyS binding of T 
cell membranes result from treatment with mitogenic antibodies (Kvanta et al., 1989). 
Changes in G-protein expression are known to accompany T lymphocyte activation. On 
mitogenic activation, mRNAs for Gs-a and Gi-3a (but not for Gi-2a) were shown to 
increase, along with the levels of these a  subunits in plasma membranes (Holter et al.,
1991). The increased level of Gs-a and numbers of PGE2 receptors in these cells 
resulted in increased cAMP generation, which the authors proposed may be a 
physiological mechanism for limiting the immune response.
As agonists elevating cAMP can enhance immunoglobulin production by 
lymphocytes (Roper et al., 1990) (and see below in sections 1.4.1.2 and 6.1), it is 
likely that G-proteins play a role in B lymphocyte activation, though again their precise 
roles are unclear. The surface immunoglobulin signalling pathway in B cells exhibits 
features of a G-protein-coupled inositol phospholipid signalling pathway (Harnett and 
Rigley, 1992), in that signalling can be blocked in permeablised cells by the GDP 
analogue, GDPBS whereas the non-hydrolysable GTP analogue GTPyS stimulates 
inositol phospholipid hydrolysis. The G-protein involved is thought to be pertussis 
toxin-insensitive.
There is extensive evidence that neutrophil polymorphonuclear leucocyte and 
macrophage chemoattractant receptors interact with and have their signals transduced by
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G-proteins. Increases in cellular cAMP levels induced by hormones such as PGEi or 
B-adrenergic agonists or by forskolin, cholera toxin and dibutyryl cAMP antagonise 
neutrophil functions viz. granule enzyme release and superoxide generation (Bokoch, 
1990). Chemotaxis, shape change, aggregation, granule enzyme secretion and 
superoxide production by neutrophils have all been shown to be sensitive to pertussis 
toxin treatment These actions can be directly correlated with the ability of pertussis 
toxin to ADP-ribosylate a 40kDa toxin substrate in neutrophils (Bokoch and Gilman,
1984). Furthermore, inactivation of neutrophil Gi by pertussis toxin in a reconstituted 
system prevents binding of N-formyl peptide (a chemoattractant) (Kikuchi et al.,
1986). Non-hydrolysable GTP analogues and sodium fluoride enhance superoxide 
production (Ligeti et al., 1988). In addition, the N-formyl peptide chemoattractant 
receptor in neutrophils has been shown to copurify with a 40kDa pertussis toxin 
substrate, suggesting a direct interaction between the receptor and G-protein (Polakis et 
al., 1988). The pertussis toxin substrate present in neutrophil membranes consists of 
Gi-2a and Gi-3a, 80-90% of which is Gi-2a (Bokoch, 1990). One of these must be 
responsible for transduction of the response, as neutrophils do not contain any Go or 
Gi-1 (Bokoch et al., 1987, Goldsmith et al., 1987).
1.3.9 G-protein phosphorylation
Phosphorylation, a major control mechanism in metabolic regulation has been 
implicated in regulation of G-protein function (Houslay, 1991a). Phosphorylation of 
GDP-bound Gi and Go-a subunits by the purified insulin receptor tyrosine kinase 
(O'Brien et al., 1987) and phosphorylation of Gi-2a (Krupinski et al., 1988) have 
been recorded, but not the phosphorylation of Gs-a. Insulin however, does not appear 
to elicit Gi phosphorylation in intact cells (Pyne et al., 1989a), raising the possibility 
that the action of the insulin receptor is only an in vitro phenomenon. Phosphorylation 
of Gi-2a has also been detected in response to the phorbol ester, TPA and
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and calcium-mobilising hormones, which cause the production of diacylglycerol, 
suggesting that PK-C may elicit the phosphorylation .
It is unclear what role these phosphorylations play in vivo, but considering the 
amount of evidence emerging for interactions between G-proteins and the insulin 
receptor (discussed below in section 1.5.1) it seems likely that phosphorylation 
represents a real form of control. Whilst receptor interaction and GTP hydrolysis 
account for the major part of G-protein regulation, phosphorylation may be a more 
subtle form of regulation in response to certain hormones and disease states, indicative 
of crosstalk between the two signalling systems (Houslay, 1991b). The role of Gi-2a 
phosphorylation in diabetes is discussed in section 1.4.2.
1.4 Prostaglandins
Prostaglandins are a family of potent, locally and short acting (autocrine) 
hormones, synthesised by almost every tissue in the body, in response to various 
hormonal and neural stimuli and in inflammation and disease (Norman and Litwack,
1987). All are derived from fatty acids stored in cellular membranes as phospholipids. 
Following an appropriate signal, phospholipases are activated yielding arachidonic acid 
and fatty acids, which are acted upon by prostaglandin synthetase to yield cyclic 
endoperoxides. A series of synthetic reactions then give rise to prostaglandins. The 
prostaglandins synthesised may either bind to membrane receptors or be released from 
the cell, producing effects on neighbouring cells. The main site of their metabolism is 
lung, but different prostaglandins are also rapidly metabolised in tissues such as spleen, 
liver, kidney and small intestine.
All have the same general structure of a 5-membered ring with two chains
37
extending from the ring. Members of each subclass have the same ring substituents but 
different numbers of double bonds in the chains, denoted by the subscript number. 
Prostaglandins are bound in serum by non-covalent interactions, the tightness of 
binding being in reverse order to their polarity.
There are thought to be five main types of PG receptors, viz. DP, EP, FP, IP 
and TP ie. one for each naturally occurring prostanoid (Coleman, 1987). Their most 
potent agonists are prostaglandin D2, E2, F2a, 12 and A2 respectively. In addition there 
are subclasses for the different types of receptor.
1.4.1 The E series prostaglandins
PGE (see appendix) is intermediate in solubility between PGA (lipid soluble) 
and PGF (water soluble) and shares ring substituents and activities with both these 
subclasses. The biosynthetic pathway for PGEi is shown in Fig. 1.6. Receptors for 
PGEi are present in liver, adipocytes, endocrine tissue and smooth muscle. PGEi 
lowers arterial blood pressure, inhibits gastric acid secretion, inhibits platelet 
aggregation and has a bronchodilatory action. By producing vasodilatation in vascular 
beds and inducing vascular leakage it has a pro-inflammatory effect. Of particular 
medical interest are its stimulation of bone resorption, its cytoprotective effect on gastric 
and duodenal mucosa and production of fever. PGEi has been used therapeutically in 
Raynaud's disease, vascular insufficiency resulting from connective tissue disorders 
and in cardiac malformations of the newborn. It has an important 'algesic' effect in 
sensitising pain receptors to stimuli. The stimulus producing pain also causes release of 
fatty acids from membranes leading to the formation of PGEs. However, it is unclear 
how cAMP elevation thereafter leads to the production of pain.
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Fig. 1.6 Biosynthesis of PGEi
The pathway shows the biosynthesis of PGEi from 8,11,14-Eicosatrienoic 
acid (dihomo-y-linoleic acid). All enzymes catalysing the reactions form part of the 
complex of enzymes constituting PG synthetase. The synthesis of both PGE2 and 
PGE3 proceed through similar pathways involving oxygenation and cyclisation 
reactions which yield cyclic endoperoxides. These are acted upon by isomerases to 
produce prostaglandins. The synthesis of PGE2 starts with 5,8,11,14-Eicosatetraenoic 
acid (arachidonic acid) and PGE3 synthesis starts with 5,8,11,14,17-Eicosapentaenoic 
acid). (Adapted from Norman and Litwack, 1987)
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Both inhibition (Engelhard et al., 1978) and stimulation (Kassis and Fishman,
1982) of cAMP formation by PGE have been observed in tissues. In most cell types 
including platelets and Fibroblasts, PGEi potently elevates intracellular cAMP which 
mediates its intracellular effects. By this mechanism it impairs reabsorption of water 
and electrolytes by the small intestine and like cholera toxin has a diarrhoea-inducing 
effect. In adipocytes, where the receptor is negatively coupled to adenylyl cyclase 
(Green and Johnson, 1991) its action is antilipolytic. PGEi is also known to impair 
cAMP extrusion from pigeon erythrocytes (Brunton and Mayer, 1979) and to be 
involved in the action of releasing hormones on pituitary cells (Norman and Litwack,
1987).
Stimulation of PGEi release is itself under hormonal and neural control. 
Glucagon stimulates its release from liver and stimulation of the sympathetic nervous 
system is the signal for its release from various other tissues. As a result of the 
widespread expression of prostanoid receptors coupled to adenylyl cyclase in tissues 
and cell lines, PGEi has proven a useful tool in studying hormonal regulation of 
adenylyl cyclase activity.
1.4.1.1 PGE action in hepatocvtes
In hepatocytes the physiological role of the E series prostaglandins remains 
rather unclear, but evidence supports PGEi having a regulatory effect on hepatic 
glucose metabolism and output The E series prostaglandins have been reported to 
impair glucagon-stimulated glycogenolysis in isolated hepatocytes (Okamura etal.,
1988) and glucagon-stimulated cAMP accumulation and fatty acid oxidation (Brass et 
al., 1988). The transition from the fed to the fasted state has been found to cause a 
significant decrease in PGE binding site density in rat hepatocytes (Garrity etal.,
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1988). One possible explanation for this finding is that hepatic PGE levels may rise 
during starvation. In addition, PGE is rapidly degraded in liver, implying that it does 
have an important regulatory role (Garrity et al., 1984).
Receptors for E series prostaglandins have been described in isolated 
hepatocytes (Robertson etal., 1980). Both high affinity (Kd = 9.9 x 10*10M) and low 
affinity (Kd = 8 x 10*9M) binding sites have been demonstrated. Garrity et al. (1988) 
showed that guanine nucleotide analogues inhibited the binding of PGE to its 
hepatocyte receptors. This inhibition was absent in membranes from animals pre-treated 
with pertussis toxin, suggesting that receptor-binding of PGEi in hepatocytes is 
regulated by Gi.
1.4.1.2 PGE action in the immune system
E series prostaglandins are generally considered to suppress immune 
responsiveness by inhibiting lymphocyte proliferation (Simkin et al., 1987, Galizzi et 
al., 1988, Phipps et al, 1989). If exposed to T lymphocytes after mitogenic stimulation, 
they inhibit interleukin production and cell proliferation. This is probably achieved via 
elevation of intracellular cAMP (Rodbell, 1980, Rappaport and Dodge, 1982) as a 
number of agents elevating cAMP have been shown to inhibit lymphocyte proliferation. 
However, E series prostaglandins have been shown to have stimulatory effects on 
antibody production. Roper et al. (1990) demonstrated that both PGEi and PGE2 
increased IgE and IgG production by murine B lymphocytes. At least three cell types in 
the spleen are known to secrete PGE viz. monocytes (Kurland and Bockman, 1978), 
follicular dendritic cells (Heinen etal., 1986) and fibroblasts (Frey etal., 1986). This 
may provide a mechanism by which these cells are able to favourably affect immune 
responsiveness.
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PGE may also play a role in atopy in vivo, where PGE-secreting cells can 
promote increased IgE synthesis by B lymphocytes. Monocytes from patients with 
atopy due to hyper-IgE syndrome secrete constitutively high levels of PGE (Leung et 
al., 1988). Interestingly, T lymphocytes from atopic subjects possess fewer PGE 
receptors and respond less to PGE in functional assays than T lymphocytes from 
normal controls (Rocklin and Thistle, 1986). This may represent a form of 
desensitisation following prolonged elevation of PGE levels.
1.4.1.3 Interactions between PGE and insulin signalling
Prostaglandins have been shown to produce a regulatory effect on pancreatic 
beta cell function through the inhibition of glucose-stimulated insulin secretion 
(Robertson and Chen, 1977). This may account for the ability of certain inhibitors of 
prostaglandin synthesis to augment the secretion of insulin (Widstrom, 1977).
Human erythrocyte membranes contain highly specific PGEi binding sites 
(Dutta-Roy and Sinha, 1985). On exposure of these membranes to PGEi there is an 
increase in insulin receptor number, without any apparent change in receptor affinity 
(Ray et al., 1986). Interestingly, this effect was specific for PGEi. In addition, the 
presence of nM concentrations of PGEi decreases the concentration of insulin required 
for reduction in membrane microviscosity in erythrocytes. As erythrocyte 
deformability, which is inversely related to membrane microviscosity is important for 
Dxygenation of tissues in the microcirculation (Brownlee and Cerami, 1981), this effect 
pf PGEi may allow it to modify favourably tissue oxygenation by erythrocytes, by 
lowering the concentration of insulin required for decrease in membrane viscosity. Ray 
it al. (1986) also reported that PGEi increased the binding of insulin in human 
ymphocytes.
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1.5 Interactions between insulin and adenvlvl cvclase 
signalling
As discussed above, insulin is thought to signal primarily by activation of its 
receptor tyrosine kinase. However, insulin has been shown in various tissues and cell 
culture systems, to modulate adenylyl cyclase signalling, suggesting that it may exert 
some its actions on cells by modifying the activity of this signalling system. There is 
evidence for its modulation at the level of the receptor, G-protein and adenylyl cyclase 
catalytic subunit itself. Examples of each are discussed below.
1.5.1 Insulin's modulation o f adenvlvl cvclase signalling
Insulin cannot modify unstimulated cAMP levels in intact hepatocytes (Pilkis et 
al., 1975) nor was it noted to affect basal cAMP levels (Illiano and Cuatrecasas, 1972). 
However, it is well known that insulin can lower cAMP levels which have been 
previously raised by another hormone and that it can accomplish this both by activation 
of cAMP phosphodiesterases (Beavo, 1990) and by an inhibitory effect on adenylyl 
cyclase (Heyworth and Houslay, 1983). At least three high affinity hepatic 
phosphodiesterases are known to be activated in response to insulin and its activation of 
a 52kDa plasma membrane phosphodiesterase is thought to be achieved by tyrosyl 
phosphorylation (Pyne et al., 1989b). The mechanism of activation of other 
phosphodiesterases is less clear. The direct, high affinity, inhibitory effect of insulin on 
the adenylyl cyclase catalytic subunit was found to be GTP dependent, overcome by 
high concentrations of glucagon and dose dependent for insulin with concentrations 
higher than lOnM abolishing the inhibition. Inhibition was demonstrable on isolated 
plasma membranes as well as intact cells. These findings, along with the knowledge 
that pertussis toxin pre-treatment blocks this effect of insulin (Heyworth et al., 1986) 
led to the proposal that insulin might exert its action on adenylyl cyclase through an
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insulin-specific G-protein.
Insulin has been shown to modulate adenylyl cyclase signalling in various 
blood cell types. Challenge of whole platelets with insulin enhanced stimulation of 
adenylyl cyclase by PGEi in plasma membranes made from these platelets but insulin 
had no effect on the response when membranes alone were exposed to the hormone. 
Increased PGEi binding in these membranes was shown to be a result of increased 
receptor number, rather than increased affinity of the binding site (Kahn and Sinha, 
1990). More importantly, insulin treatment decreased by 50% the amount of PGEi 
required to inhibit platelet aggregation suggesting that this action of insulin is indeed 
relevant to platelet physiology. Diabetes is known to be associated with increased 
responsiveness of platelets to agents promoting aggregation (Halushka et al., 1985) and 
diabetic subjects have impaired responsiveness to the anti-aggregatory effect of 
prostaglandins (Davi et al., 1982). It may be that in the absence of insulin, platelets are 
less sensitive to the anti-aggregatoiy effect of PGEi because of an impairment of the 
ability of PGEi to elevate intracellular cAMP. However, no studies have yet examined 
the correlation between platelet function and PGEi binding in diabetic subjects.
In mononuclear leucocytes, insulin exposure did not alter the basal cAMP level 
(Sager et al., 1990) but acutely increased the number of cell surface 6-adrenoceptors 
and the response to isoproterenol, which thereafter showed a time dependent decline. 
The authors proposed that insulin altered both B-adrenoceptor density and coupling to 
adenylyl cyclase. However, the relevance of this particular effect to leucocyte function 
is unclear.
A recent study on ♦ ‘adrenoceptor function in DDTMF-2 cells, a smooth muscle 
cell line, showed insulin to phosphorylate and attenuate functioning of the 
B-adrenoceptor (Hadcock et al., 1992). This may be part of the mechanism by which
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insulin can antagonise catecholamine action in these cells, though it remains to be seen 
whether such a mechanism will apply to insulin's action in other cell systems.
There are various reports of insulin inhibiting pertussis toxin-catalysed 
ADP-ribosylation of G-proteins. Rothenberg and Kahn (1988) showed a 50% 
reduction in labelling after a short (10 minute) exposure of isolated hepatocytes to 
insulin. The effect was half maximal at 20nM insulin (a supraphysiological 
concentration) and independent of GTP. This suggested a functional link between the 
insulin receptor and G-protein system, possibly altering conformation or dissociation of 
the heterotrimer. Given the relatively high concentrations of insulin required for the 
effect however, it is doubtful whether this interaction represents a physiological 
phenomenon. Pyne et al. (1989a) showed a similar inhibition of labelling by insulin in 
hepatocyte plasma membranes, demonstrating that all the components required for this 
effect are located within the plasma membrane. A short exposure of whole cells to 
insulin prior to making membranes had no effect on labelling.
There are a number of reports of exposure of cultured cells to insulin and IGF-1 
causing alterations in G-protein expession. Both hormones enhanced intracellular 
cAMP elevation by adrenocorticotrophic hormone in cultured bovine adrenal cells and 
this was shown to be as a result of increased expression of Gs. At physiological 
concentrations, IGF-1 was more potent in its action than insulin and the increase 
affected both high and low molecular weight forms of Gs-a (Begeot et al., 1989). In 
the same cell type, both peptides have been shown to increase Gi expression (Langlois 
et al., 1990). Functionally this change was effected as an increase in phosphoinositide 
breakdown in response to the hormone angiotensin-II.
Evidence in various other forms has been produced, implicating G-protein 
involvement in insulin action. Firstly, a number of recent studies have shown that GTP
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analogues can modulate insulin binding and action. In rat adipocytes, the 
non-hydrolysable GTP analogue GTPyS can modulate both insulin binding and 
receptor tyrosine kinase activity (Davis and McDonald, 1990). Mortensen et al. (1992) 
showed that GTPyS decreased insulin binding in turkey erythrocytes but only in 
membranes reduced beforehand by dithiothreitol exposure. Kellerer etal. (1991) found 
that in adipocyte and skeletal muscle plasma membranes, insulin at low concentrations 
rapidly increased GTPyS binding which inhibited subsequent insulin binding and 
receptor tyrosine kinase activity. On further examinination using a photoreactive 
GTPyS analogue, the binding site was found to be a 40kDa GTP-binding protein. The 
authors proposed that the insulin receptor may interact with this 40kDa G-protein but 
did not identify the protein. Secondly, insulin has been reported to stimulate a high 
affinity GTPase in human platelets suggesting an interaction of the insulin receptor with 
the G-protein system (Gawler and Houslay, 1987). However, this finding has not been 
observed in other systems. All these examples provide evidence that aspects of insulin 
signalling may involve the adenylyl cyclase second messenger system and that crosstalk 
can occur between the two signalling systems. However, the form of interaction 
between insulin signalling and G-proteins is taking longer to unravel than the 
interaction between the classical G-protein-linked receptors and their G-proteins. This 
may be because the effect of insulin on the system is more subtle, providing fine tuning 
of the responses to other hormones, rather than producing a signal in its own right.
1.5.2 Adenvlvl cvclase signalling in diabetes
Diabetes is a major health problem, accounting for 2-5% of mortality in the 
western world. Around 80-90% of diabetics in developed countries have type 2 
(non-insulin dependent) diabetes. These patients have persistent hyperglycaemia in the 
presence of normal or elevated levels of insulin and therefore by definition some degree 
of insulin resistance, though the relative contributions of defective insulin secretion and
46
peripheral insulin resistance to the pathogenesis of type 2 diabetes is still a matter of 
debate. Insulin resistance is present in the major insulin target tissues viz. adipose 
tissue, muscle and liver, that in liver being most responsible for the fasting 
hyperglycemia observed in diabetes (Gerich, 1990). At the molecular level, insulin 
resistance probably encompasses a number of defects, including impaired receptor 
tyrosine kinase activity, reduced glucose transport, reduction in activities of enzymes 
involved in glucose metabolism and abnormal responses to other hormones. The 
relative contributions of these various factors are not known with certainty.
Diabetics have long been known to have higher stress responses than 
non-diabetics ie. the catabolic pathways of glycogenolysis and lipolysis are more 
readily activated in response to catecholamines (Shamoon et al., 1980). In recent years 
the molecular basis of this increased responsiveness has started to become apparent, 
particularly in liver. Firstly, as glucagon, catecholamines and insulin are all involved in 
regulation of hepatic cAMP levels, removal of insulin's acute restraint results in 
elevated levels of the second messenger and enhanced gluconeogenesis, glycogenolysis 
and ketogenesis. Secondly, defects at all levels of the signal transduction cascade are 
well documented, which result in elevated basal cAMP levels and increased responses 
to stimulatory agonists.
1.5.2.1 Defects in hepatocvte adenvlvl cvclase signalling in
diabetes
Liver, being an insulin sensitive tissue has been extensively used for studies of 
adenylyl cyclase signalling in diabetic animals. In diabetes, liver turns from a 
glucose-storing to a glucose-producing tissue. This follows a decrease in plasma 
insulin and increased plasma levels of the anti-insulin hormones, noradrenaline, 
adrenaline, glucagon and cortisol (Tamborlane etal., 1979, Cryer, 1980). This
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increased liver responsiveness to anti-insulin hormones has also been observed in 
insulin-treated diabetic animals (Shamoon et al., 1980).
A common event in animal models of diabetes appears to be elevation of resting 
intracellular cAMP levels in liver. Elevated cAMP was observed in liver from animal 
models of both type 1 diabetes eg. streptozotocin diabetic rats (Pilkis et al., 1974) and 
type 2 diabetes eg. the obese Zucker rat and db/db mice (Herberg and Coleman, 1977). 
The molecular mechanism by which this elevated liver cAMP is achieved is hody 
debated (Lynch and Exton, 1992) and probably varies beween systems.
Studies of diabetic rats have revealed either increased (Soman and Felig, 1978), 
decreased (Srikant et al., 1977, Bhathena et al., 1978) or unchanged (Chamras et al., 
1980) numbers of hepatic glucagon receptors, as well as elevated (Lynch et al., 1989) 
or reduced (Pilkis et al., 1974) basal and agonist-stimulated adenylyl cyclase activity in 
liver plasma membranes from chemically-induced diabetic rats. One possible 
explanation for these discrepancies is that animals differ in their toxic responses to 
diabetogenic agents. There is ample evidence for changes in G-protein expression and 
functioning in liver from diabetic animals as being in part resposible for the altered 
adenylyl cyclase signalling. Bushfield et al. (1990b) found a reduction in the levels of 
Gi-2a, Gi-3a and the 42kDa form of Gs-a in hepatocyte plasma membranes from 
diabetic rats, as well as increased expression of the adenylyl cyclase catalytic subunit 
The findings of Lynch et al. (1989) are in contrast to the above changes. These workers 
found no change in Gi-a expression and increased Gs-a expression in diabetic 
animals. Whether these inconsistencies have arisen from differences in the 
methodology or from genuine differences between diabetic animals is a matter not yet 
resolved. Bushfield et al. (1990b) also reported an abnormality of Gi function in 
diabetic animals, resulting in a reduced ability of low concentrations of GppNHp to 
inhibit forskolin-stimulated adenylyl cyclase activity. As Gi-la is not expressed in liver
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and Gi-3a is not thought to mediate adenylyl cyclase inhibition this finding suggested 
a dysfunctional Gi-2a. It was suggested that this dysfunction may be as a result of 
phosphorylation of the a  subunit under basal conditions. Since such phosphorylation 
can be mimicked by phorbol ester-activation of PK-C, an abnormally active kinase may 
be the causal factor. Activated PK-C has indeed been reported in diabetes as a result of 
increased diacylglycerol levels formed from excess glucose (Greene et al., 1987) and 
may impair insulin action by increasing insulin receptor phosphorylation.
Changes in the ability of G-proteins to be labelled by pertussis toxin have been 
observed in animal models and human diabetes. Lynch et al. (1989) found reduced 
pertussis toxin-catalysed ADP-ribosylation of total Gi in hepatocyte membranes from 
diabetic animals. The ability of pertussis toxin to label Gi in human diabetic liver has 
also been noted to be impaired (Caro et al., 1991). These authors also showed that the 
ability of insulin to attenuate pertussis toxin-catalysed ADP-ribosylation of Gi was 
impaired in liver tissue from diabetic humans. These findings are interesting in view of 
the work by Rothenberg and Kahn (1988) demonstrating insulin's ability to inhibit 
pertussis toxin-labelling of G-proteins which suggested a functional interaction between 
the two signalling systems, possibly by insulin influencing Gi conformation. This 
again raises the possibility of an abnormality of Gi function in diabetes.
As well as defects at the level of the membrane, decreased cAMP 
phosphodiesterase activity may account in part for the increased catecholamine and 
glucagon responsiveness of diabetic liver. Solomon et al. (1986) found a reduction in 
activity of the high affinity low Km cAMP phosphodiesterase in liver from 
streptozotocin diabetic rats which would allow exaggerated intracellular cAMP 
responses to stimulatory hormones. This is an area which has been given less attention 
than the membrane protein defects occurring in cAMP generation, but is undoubtedly 
an important facet of insulin action, which is potentially defective in diabetes.
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1.5.2.2 Defects in adipocyte adenvlvl cvclase signalling in 
diabetes
In adipose tissue, B-adrenoceptors and glucagon receptors couple through Gs to 
adenylyl cyclase, mediating the stimulatory effects of these hormones on lipolysis 
(Zaagsma and Nahorski, 1990). As in liver, adenylyl cyclase in adipose tissue from 
chemically induced diabetic animals shows increased sensitivity to the anti-insulin 
hormones (Zapf et  al.y 1978) and unstimulated cAMP levels are elevated both in the 
basal state and in response to stress (Schimmel, 1976). Increased sensitivity and 
expression of the adipocyte B-adrenoceptor has been noted in streptozotocin-induced 
and human diabetes (Wahrenberg et al.y 1989, Solomon et al.y 1990), but glucagon 
receptor numbers appear to be decreased (Sato etal.y  1989). No changes have been 
noted in Gs-a, G i-la or Gi-2a levels in adipocytes from diabetic animals (Strassheim 
et al.y 1990). Interestingly, there is an increase in Gi-3a expression and mRNA for 
both Gi-3a and Gi-la, though it is difficult to assess the significance of this finding, as 
it is not known to which effector Gi-3a couples in adipocytes. In one study on 
adipocytes from human type 1 diabetic subjects, no changes in G-protein levels were 
noted, though the study was too small to be conclusive and did not investigate adenylyl 
cyclase activity and G-protein function in the adipocyte membrane preparations 
(Ohisalo e t al., 1989).
In db/db mice, a genetic animal model of diabetes and obesity an elevation of 
Gi-la was noted in adipocyte plasma membranes as compared to lean controls but no 
change in the other Gi-a subtypes, Gs-a or B subunit. The change in G i-la expression 
had little effect on regulation of adenylyl cyclase by inhibitory hormones, though the 
functioning of specific stimulatory receptors was attenuated in the animals (Strassheim 
et al.y 1991). Palmer et al. (1992), on studying adipocyte adenylyl cyclase from obese
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diabetic CBA/Ca mice, an animal model of insulin resistance, noted impaired 
receptor-mediated stimulation of adenylyl cyclase by isopoterenol and glucagon. Levels 
of all three Gi forms were reduced in adipocyte plasma membranes from the diabetic 
animals, but Gs levels were unaltered. These changes correlated with measurements of 
impaired Gi function.
It seems likely that Gi dysfunction may contribute to the increased stimulatory 
agonist responsiveness observed in adipocytes from diabetic animals and humans. 
Strassheim et al. (1990) reported loss of GTP dependent- but not receptor-stimulated 
Gi function in adipocytes from diabetic animals. As in liver, an increase in Gi-2a 
phosphorylation has been proposed to account for the reduction in Gi function 
(Bushfield et al., 1990c). Green and Johnson (1991) found a functional uncoupling of 
Gi from the inhibitory PGEi and Ai-adenosine receptors in adipocytes from diabetic 
rats. This change was accompanied by reduced pertussis toxin labelling of Gi-a 
labelling in plasma membranes from the adipocytes.
1.5.2.3 Defective adenvlvl cvclase signalling in other tissues
in diabetes
Stimulation of 6-adrenoceptors in cardiac muscle normally increases heart rate 
and contractility. In cardiac muscle from diabetic humans and rats which have some 
degree of diabetic neuropathy, there is reduced cardiac responsiveness to 6 agonists 
(Zola et al., 1988, Berlin et al., 1986, Almira and Misbin, 1989). There is a well 
documented reduction in cAMP responsiveness (Gotzsche, 1983) and 6-adrenoceptor 
number (Ingebretsen et al., 1983), which is probably largely responsible for the 
impaired 6-adrenergic responsiveness in this tissue, as Gs-a and Gi-a expression have 
been noted to be unaltered in this tissue (Bushfield et al., 1990c). In diabetic skeletal 
muscle there is reduced 6-adrenergic stimulation of adenylyl cyclase (Garber, 1980).
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Decreased Gs and Gi expression have also been noted, but with their ratio unaltered, 
therefore the significant change is probably at the level of the receptor.
Absent Gi-mediated inhibition of adenylyl cyclase has also been noted in areas 
of the brain (Abbracchio et al., 1989) and retina and labelling of the G-protein 
transducin was reduced, in rod outer segments from diabetic animals (Kowluru et al.,
1992). Therefore, this is not a phenomenon which is restricted to the main target tissues 
of insulin. No detailed study has been made of G-protein expression in specific areas of 
the brain in diabetes.
Observations of G-protein mediated signalling defects have also been made in 
platelets from diabetic animals and humans (Abraham etal., 1986, Connell et al., 1986, 
Livingstone et al., 1991). Although many signalling defects have been reported which 
may be responsible for the altered physiology in animal models and diabetic patients, it 
is still unclear how these changes come about. Blood cell functioning in diabetes is 
further discussed in section 6.1.
1.6 Cell culture systems in the study o f hepatocvte signal 
transduction
Studies on hepatocytes can be carried out on primary cultured cells, tumour cell 
lines, or virally-immortalised cells. Each of these is discussed in detail below, with 
regard to the study of hepatocyte function.
1.6.1 Native hepatocvtes
Hepatocytes isolated by collagenase perfusion closely resemble in vivo adult 
liver cells both structurally (Sattler et al., 1978) and biochemically (Tanaka et al., 1978)
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and preparations are relatively free from non-parenchymal cells (Berry and Friend, 
1969), despite the number of other cell types present in whole liver. They can be 
seeded out on collagen coated plates in order to increase the lifespan of the cells in 
culture (Strom and Michalopoulos, 1982). Hepatocytes plated on collagen membranes 
do not flatten out like those seeded on a rigid substratum, and retain endoplasmic 
reticulum, Golgi apparatus and desmosomes for at least ten days (Sattler et al., 1978). 
However, all these monolayer cultures have the major disadvantage that they do not 
proliferate (Richman etal., 1976), so that studies on signal transduction are limited to 
this time period during which cells retain relatively hepatocyte-like features and shorter 
still (a few hours) if cells are isolated under non-sterile conditions. As a result of this 
short lifespan in primary culture, fresh cells must be prepared on each occasion of 
experiment.
Many features distinguish native hepatocytes considerably from undifferentiated 
cells. Notably, native hepatocytes are highly specialised and polarised cells with 
specific functions in particular areas of plasma membrane. For example, it is possible 
to isolate distinct plasma membrane fractions with different protein levels, Gi-a and 
G-protein B subunit being highest in the bile canalicular fraction than in the sinusoidal 
membrane fraction (Ali et al., 1989). Secondly, liver tissue is thought to show zonal 
heterogeneity regarding metabolic processes (Jungermann, 1985), with 
gluconeogenesis, oxidative energy metabolism and urea synthesis concentrated in the 
periportal zone and glucose uptake, glycolysis, glycogen synthesis and lipogenesis 
predominating in the perivenous zone. Zonal differences are also apparent in enzyme 
distribution (Katz et al., 1977) and hormone responsiveness with glucagon-stimulated 
adenylyl cyclase located predominantly in the perivenous area. The presence of these 
highly differentiated features in hepatocytes means that de-differentiated cells, if chosen 
for study, will only be to a limited extent comparable with native cells and also makes it 
possible that there will be considerable heterogeneity amongst cell lines derived from
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hepatocytes.
1.6.2 Hepatoma cell lines
Clearly there are numerous advantages of having a hepatocyte cell line as a 
model system for studying signal transduction. Cells are uniform and can be passaged 
continuously, as they proliferate spontaneously, providing a large amount of material 
and avoiding the repeated use of animals. Cultured cells can be grown under controlled 
conditions and unlike rat hepatocytes or whole animal studies, are free from the 
influences of counter-regulatory hormones if experiments are performed in serum-free 
media. However, hepatocyte cell lines have a number of disadvantages, in particular 
their lack of comparability to the native cell type. They may de-differentiate or diverge 
phenotypically, as indicated by the lack of cell specific markers (Naim et al., 1990) and 
the uniform monolayers lack the characteristic features of native liver cells discussed 
above viz. polarisation and zonation.
Though their responses are not entirely similar to those of hepatocytes, 
hepatoma cell lines have been extensively used in the study of insulin action and have 
proven useful as model systems. For example, the H4-II-E cell line (Straus and 
Takemoto, 1987) and Hep G2 (Hatada et al., 1989) cells have been widely used in 
studying transmembrane signalling by insulin, and regulation of gene transcription. The 
H-35 hepatoma cell line has been used in studies on hormonal regulation of serum 
protein secretion (Tsukada et al., 1985) and in identification of an insulin-sensitive 
glycophospholipid (Mato et al., 1987). The hepatoma line Fao was the cell system first 
used in studies on the insulin receptor tyrosine kinase substrate IRS-1 (White et al.,
1985) and another hepatoma cell line ZHC, has been used in studies on the effects of 
membrane lipid composition on insulin signalling (Staedel et al., 1990).
54
1.6.2 SV40-immortalised hepatocytes
Immortalisation means acquisition of an unlimited proliferative potential. Cell 
cultures can be defined as immortalised when they are capable of growth for at least 
100 doublings as compared to a maximum lifespan of about 30 doublings in control 
cells (Spandidos and Wilkie, 1984). It can be measured by the ability of cells to grow at 
low cell density (Petit et al, 1983), a technique based on the finding that native rodent 
cells do not multiply at low density (Todaro and Green, 1963). Immortalisation is 
generally considered to be an early event in the process of malignant transformation, as 
treatment of embryonic cells with carcinogens established cell lines, which although 
untransformed at low passage number, progressed to anchorage independence and 
malignancy after in vitro culture (Newbold et al., 1982).
Several viral and cellular oncogenes have been shown to immortalise cells, 
suggesting that various mechanisms may lead to escape from senescence (Linder and 
Marshall, 1990). In order to replicate in non-dividing host cells, small DNA viruses 
induce cellular DNA synthesis. They accomplish this by encoding proteins which relax 
growth control. Specific immortalising genes have been identified for adenovirus 
(Houweling et al., 1980), polyoma virus (Jat and Sharp, 1986), SV40 (Petit et al.y
1983) and papillomavirus (Matlashewski et al., 1987). The SV40 virus can be used to 
immortalise and transform various cell types by transfection, using genetic material 
prepared from virions. This leads to the establishment of a stable cell line (Chou,
1989). Alternatively, DNA contained within a plasmid vector can be used.
Immortalised cells which have not acquired the non-differentiated phenotype of 
transformed cells can be isolated at low passage (Nagata et al., 1983).
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On integration into the host cell genome, two proteins can be expressed, the 
large and small T antigens, 19kDa and 17kDa in size, respectively. The large T antigen 
induces changes in the host cell, bringing about immortalisation and eventually 
transforming them to tumorigenicity. It is a 708 amino acid protein with several 
domains possessing different functions (Livingston and Bradley, 1987). It binds DNA 
(Fanning et al., 1989) and in a separate domain possesses an ATPase thought to be 
required for its unwinding of double stranded DNA, prior to its induction of gene 
expression (Beard and Bruggmann, 1989). A high concentration of T antigen is 
thought to be required for immortalisation (Lanford et al., 1985) and expression above 
a certain level is necessary for tumorigenicity (Efrat and Hanahan, 1989). T antigen is 
also able to associate with various cellular proteins such as DNA polymerase and 
transcription factors (Knippers, 1989). The SV40 large T antigen can cooperate with 
activated oncogenes to induce the conversion of normal embryonal fibroblasts to 
tumour cells. Glucocorticoid hormones can substitute for T antigen in the 
immortalisation of rodent fibroblasts (Martens et al., 1988). The mechanism of this 
action is unknown but it may be related to their ability to regulate the transcription of the 
same genes as viral gene products (Offringa et al., 1988).
Woodworth et al. (1986) generated cell lines by transfection of rat hepatocytes 
with SV40. These cells did not initially show a fully transformed morphology, but 
developed this after a time in culture. The cells produced albumin in amounts 
comparable to rat hepatocytes and, as albumin synthesis is a major feature of 
hepatocytes accounting for 11% of protein synthesis, this was an indication that the cell 
line retained at least one feature of differentiated cells. However, the cells were all 
fibroblast-like in morphology and in this respect more closely resembled hepatoma cell 
lines than primary cultured hepatocytes. Native hepatocytes produce many proteins 
associated with their differentiated state, a feature advantageous in monitoring the
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effects of S V40 transfection on phenotype. Various markers have been identified in 
transfected hepatocytes, for example tyrosine aminotransferase (Isom et al., 1980) and 
transferrin, hemopexin and glucose-6-phosphatase (Woodworth et al., 1986) but are 
present in differing amounts between cell lines generated (Isom et al., 1980). 
Woodworth et al. (1988) showed that a variety of liver-specific gene products were 
expressed in S V40-immortalised cells, at levels similar to those in native hepatocytes, 
for up to 22 passages after transfection. Reduction in expression of these genes 
occurred with time in culture and correlated with increased tumorigenic potential. A 
large number of these cell lines have now been generated and proven particularly useful 
in the study of changes in gene expression on progression from a normal cell to 
hepatocellular carcinoma and mechanisms regulating gene expression and 
differentiation.
Chromosomal damage and cytogenetic abnormalities observed in 
SV40-immortalised cells as compared to native rat hepatocytes are lower than in other 
established cell lines (MacDonald et al., 1991). This closer genotypic relation to native 
cells has caused workers to consider the value of S V40-immortalised cells as model 
systems. One such cell line, SV40 RH1, has been examined as a model system for 
studying drug metabolism, as non-differentiated tumour cell lines have reduced 
glutathione synthesis and are therefore a poor substitute for native hepatocytes in this 
case. Interestingly, the immortalised cell line was found to retain the pathway for 
glutathione synthesis and possessed glutathione S-transferases, comparable to rat 
hepatocytes (Naim et al., 1990). This cell line then, at least at low passage, is more 
useful than hepatoma cells as a model system for the study of drug metabolism.
As cell lines differ phenotypically from their native cell types, some have been 
subjected to agents and conditions which promote differentiation in order to produce 
cells with more native characteristics. This may allow their responses to be more readily
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compared to those of adult, non-proliferating cells (Watkins et al., 1987). Conditions 
favouring cell differentiation include high cell density (more than 105 cells /cm2) 
(Frame et al., 1984), high intracellular calcium-ion concentration and the presence of 
various differentiation inducers. These include glucocorticoid hormones, insulin, nerve 
growth factor, the polar solvent DMSO and IBMX, a phosphodiesterase inhibitor (see 
appendix). Matrix interaction can also promote differentiation. For example, collagen 
and fibronectin substrata can be used to aid adherence of cells and allow the 
development of cell polarity (Strom and Michalopoulos, 1982), avoiding the use of the 
above agents. However, the ability to differentiate under the conditions mentioned is a 
feature only of certain cell types.
Rapid proliferation in a cell line and the maintenance of a fully differentiated 
state are mutually exclusive. However, in generating cell lines for study, the hope is to 
obtain cells which, having a capacity to divide, retain at least some of the features of 
differentiated cells.
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1.7 Aims of project
In contrast to hepatoma cell lines, S V40-immortalised hepatocytes have some 
phenotypic similarity to native hepatocytes. SV40-immortalised cells then, are 
potentially a useful model system for studying signal transduction mechanisms. The 
aim of this project at the outset was to characterise adenylyl cyclase signalling in one 
SV40-immortalised, hepatocyte-derived cell line, P9, comparing it with native 
hepatocytes and to consider the value of this line as a model system for studying this 
second messenger system. Secondly, the project sought to examine aspects of insulin's 
modulation of the signalling system in this cell line. A separate aim of the project, but 
still in the area of insulin signalling was to examine adenylyl cyclase signalling and 
G-protein expression in human diabetic subjects. Mononuclear leucocytes were chosen 
as the tissue for study.
59
Chanter 2 
Materials and Methods
2.1 Materials
Reagents were obtained from the following suppliers:
2.1a Generalreagents
Sigma chemical Co. 
Poole, Dorset
Alumina (neutral)
ANSA
Arginine hydrochloride 
ATP (disodium salt)
BSA
Bromophenol blue
Cyclic AMP (disodium salt) and 8-bromo-cAMP 
Charcoal (Norit A)
Cholera toxin
Collagen (Rat tail, type 1, acid soluble)
Dexamethasone
Dextran T-500
Dowex (AG50W-X4,200-400 mesh)
Glucagon
Imidazole
Insulin (porcine pancreas)
Nonidet-P40
O-dianisidine
Phosphoserine
Phosphothreonine
PGEi
Protein A-agarose 
TEMED 
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Boehringer (UK) Ltd 
Lewes, East Sussex
Calbiochem, Cambridge
National Diagnostics,
Aylesbury,
Buckinghamshire
Porton products,
Porton Down,
Salisbury,
Wiltshire
Koch Light Lab Ltd, 
Haverhill,
Suffolk
Thimerosal
TPA
Triton X-100 
Trypsin
Creatine phosphate
Creatine phosphokinase
Dithiothreitol
GTP
GppNHp
Triethanolamine hydrochloride 
Tris
Thymidine
Forskolin
'Ecoscint' scintillation fluid
Pertussis toxin
DMSO
Sodium potassium tartrate
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FSA Lab Supplies N,N'-methylenebisacrylamide
M and B, Ammonium persulphate
Dagenham, UK.
Whatman International 3mm chromatography paper
Ltd.
BRL, Paisley, UK Pre-stained molecular weight markers
Pharmacia Ltd., Milton Ficoll-Paque
Keynes, Bucks. UK.
Antibody production HRP-linked sheep anti-rabbit IgG
Unit, Law Hospital,
Lanarkshire, Scotland
BOC Carbon dioxide
Analytichem International Frits
Chromatography columns
2.1b Tissue culture olasticware
Costar Cryotubes
Filters (0.22pm)
Becton Dickenson Falcon tissue culture plates 
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Coming Multiwell plates
Elkay Products 50ml centrifuge tubes 
Tissue culture pipette tips
2.2 Tissue culture media
Gibco Life Technologies, 
Paisley, UK
Dulbecco's modification of Eagle’s medium 
Foetal calf serum 
Glutamine (200mM)
Sodium bicarbonate (7.5%)
Penicillin (lOW/ml)
Streptomycin (lOOmg/ml)
2.3 Radiochemicals
Amersham pic
Amersham,
Buckinghamshire
Du Pont
[8-3H] Adenosine 3’, 5'-cyclic monophosphate. 
[5',8-3H] Adenosine 3’, 5'-cyclic monophosphate 
[oc-32P] -Adenosine 5’-triphosphate 
[125I]-Glucagon 
[32P]Pi
[125I]-Sheep anti-rabbit IgG
[5-Me-3H]-Thymidine
[Adenylate-32P]-NAD
All other reagents were from BDH, Poole, Dorset, England.
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2.4 Standard buffers
Phosphate-buffered saline: 
(PBS)
Tris-buffered saline:
(TBS)
Hepes-buffered salt solution: 
(HBSS)
Trypsin solution:
Laemmli buffer:
Rat hepatocyte plasma 
membrane preparation 
buffer:
NaCl 145mM 
KC15.4mM 
KH2P04 1.5mM 
Na2HP04 8.1mM,pH 7.4
NaCl 500mM
Tris HC120mM, pH 7.5
NaCl 145mM 
KQ6mM 
Glucose lOmM 
Hepes 25mM, pH 7.4
Trypsin 0.1% (w/v)
Glucose lOmM 
EDTA 0.025% (w/v)
Urea5M 
SDS 0.17M 
Dithiothreitol 0.4M 
Bromophenol blue 0.01% (w/v) 
Tris HC150mM, pH 8.0
EDTAlmM 
EGTA ImM 
Benzamidine 2mM 
6-glycerophosphate lOmM 
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Krebs /Henseleit /BS A:
Cell-solubilising buffer:
Sucrose 0.25M 
Phosphoserine ImM 
Phosphothreonine ImM 
Tris HC1 lOmM, pH 7.4
NaCl 120mM 
NaHC03 25.3mM 
KC1 4.8mM 
MgS04 1.2mM 
KH2P04 1.2mM 
CaCl2 1.28mM 
Glucose 5mM 
Lactate lOmM 
Glutamine 2mM 
BSA 2% (w/v), pH 7.4.
Triton X-100 1% (v/v) 
SDS 1% (w/v)
EDTA lOmM 
NaH2P04 lOmM 
NaF lOmM 
Na3V04 100|iM 
B-glycerophosphate lOmM 
Phosphoserine ImM 
Phosphothreonine ImM 
Hepes 50mM, pH 7.2
Wash buffer: Triton X-1001% (v/v) 
SDS 0.1% (w/v) *
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NaCl lOOmM 
NaF lOOmM 
NaH2P04 50mM 
Hepes 50mM, pH 7.2
2.5 Henatocvte preparation
2.5a Hepatocyte isolation and culture
Rat hepatocytes were routinely available in the laboratory. They were isolated 
by the method of Berry and Friend (1969) involving a two step perfusion of the liver in 
situ. Cells for agonist stimulation were cultured as described in section 2.14b.
2.5b Transfection
The P9 cell line was generated by Dr C. MacDonald, University of Strathclyde, 
Glasgow, U.K., according to the method of Woodworth etal. (1986). Briefly, cells 
were incubated in a 1: 1 mix of William's medium E and Ham's FI 2 (Gibco BRL) 
supplemented with 5% (v/v) FCS and 2mM glutamine. Transfection was achieved by 
exposure of the rat hepatocytes to a precipitate of SV40 viral DNA for five hours. After 
this period the monolayer was washed with fresh medium. Immortalised cells were 
selected by their ability to grow at low cell density after subculturing (Petit et al.,
1983), as discussed in section 1.6.3. Thereafter, cells were maintained and cultured as 
described in section 2.6.
2.5c Plasma membrane preparation
Cells were pelleted by centrifugation for two minutes at 800 x g in a Centaur-2 
bench centrifuge. Three volumes of ice-cold membrane preparation buffer were added
66
and cells homogenized with 30 strokes of a Potter-Elvejhem teflon /glass homogeniser. 
The homogenate was centrifuged at 1000 x g for 10 minutes at 4°C. The supernatant 
was collected and centrifuged at 100 000 x g for one hour. The resulting plasma 
membrane pellet was resuspended in 5ml of buffer A, aliquoted and stored at -80°C 
until use.
2.5d Cell counting
Both rat hepatocytes and P9 cells were counted using a Neubauer 
haemocytometer.
2.5e Collagen coating o f plasticware
The method used was that of Strom and Michalopoulos (1982). Type-1 (acid 
soluble) collagen from rat tail was dissolved in 3% (v/v) acetic acid at lOmg/ml and 
stored at 4°C. Before use it was diluted to 0.03% (w/v) collagen in 3% acetic acid and 
applied to plasticware using a needle and syringe. Plates were allowed to dry overnight 
under UV irradiation in the laminar flow hood. Before use, plates were rinsed with 
sterile PBS to remove any residual acetic acid.
2.6 Tissue culture
2.6a Cell growth
Cells were grown in 100 x 20mm cell culture plates in 0.0375% (w/v) sodium 
bicarbonate-buffered Dulbecco's modification of Eagle's medium (DMEM), containing 
10% (v/v) foetal calf serum which was heat-inactivated at 56°C for 30 minutes before 
use (complete medium). The medium was supplemented with glutamine (2mM), 
penicillin (lOOIU/ml) and streptomycin (lmg/ml). Cells were grown in a humidified
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atmosphere of 5% C02/95% air. Medium was changed every two days.
2.6b Cell subculture
Confluent cells (3.8 x 105 cells/cm2) were passaged by removing medium and 
adding 3ml of trypsin solution to the monolayer. When cells had detached from the 
plate, trypsinisation was stopped by the addition of 10ml complete medium. Cells were 
removed from the plate and centrifuged at 800 x g for two minutes in an MSE 
Centaur-2 bench centrifuge. The cell pellet was resuspended in complete medium and 
seeded at a split ratio of 1:10 into cell culture plates.
2.6c Cell freezing
The procedure for subculturing the cells was followed up to centrifugation after 
which cells were suspended in 'freezing medium' (10% (v/v) DMSO and 25% (v/v) 
FCS in complete medium) at a final concentration of 5 x 106 cells/ml or greater. 
Aliquots of the cell suspension (1ml) were placed in cryotubes and frozen to -80°C at a 
rate of 1°C per minute. The cryotubes were transferred to liquid nitrogen until required. 
Cells were thawed rapidly by placing the frozen vial at 37°C. The aliquot of cell 
suspension was transferred to a cell culture plate and made up to a volume of 10ml by 
slow addition of complete medium. Cells were incubated overnight to allow adherence 
to the plate and the following day medium changed to remove DMSO and the cells 
grown to confluence.
2.6d Cell harvesting
Complete medium was aspirated off and the monolayer rinsed twice with 
HBSS. Cells were then scraped off the plates in HBSS and the cell suspension 
centrifuged as for subculturing. The resulting cell pellet was washed with buffer,
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re-centrifuged and stored at -80°C until use.
2.6e Plasma membrane preparation
Membranes were prepared according to Koski and Klee (1981). Frozen cell 
pellets were thawed and suspended in 2ml ice-cold ImM EDTA, lOmM Tris HQ, pH
7.4 containing freshly added protease inhibitors, ImM PMSF, 3mM benzamidine, 
ljiM leupeptin, 2|ig/ml aprotinin and 0.5}ig/ml pepstatin A and homogenised with 15 
strokes of a Potter/Elvehjem teflon/glass homogeniser. The homogenate was 
centrifuged at 500 x g for 10 minutes in a Beckman L5-50B centrifuge in a Ti50 rotor, 
to sediment unbroken cells and nuclei. Plasma membranes were collected by 
centrifugation of the supernatant at 48 000 x g for 10 minutes, washed in 10 volumes 
of the same buffer and after a second centrifugation were resuspended in the same 
buffer to a final protein concentration of 2-4 |ig/ml, aliquoted and stored at -80°C until 
required.
2.6f Toxin treatment o f  cells
After removing complete medium the monolayer was washed with serum-free 
medium then the cells incubated with serum-free medium supplemented with pertussis 
toxin at the concentration required, before agonist challenge.
2.6s Mycoplasma screening
Cells were screened for mycoplasma by the fluorescence staining method 
described by Hay (1989).
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2.7 Rat cerebral cortex plasma membrane preparation
This was done by the method of Milligan et al. (1987). Animals were killed by 
cervical dislocation after which the cerebral cortex was dissected out and transferred to 
0.32M sucrose on ice. The tissue was hand homogenised in ice-cold 0.32M sucrose 
using 35 up and down strokes of a Potter/Elvehjem teflon/glass homogeniser. This was 
centrifuged at 500 x g for 10 minutes and the supernatant collected and recentrifuged at 
48 000 x g for 10 minutes. The pellet from this spin was washed in 0.32M sucrose, 
re-centrifuged under the same conditions and the final pellet resuspended in 3ml of
0.32M sucrose buffer. The sample was aliquoted and stored at -80°C until use.
2.8 Antibody production
Antisera used for immunoblotting were raised in New Zealand White rabbits 
against synthetic peptides conjugated to keyhole limpet haemocyanin as described by 
Goldsmith et al. (1987). Decapeptides used are listed in table 2.1 below.
Table 2.1
Antiserum Peptide used G-protein sequence Antiserum
identifies
CS1/CS2 RMHLRQYELL Gs-a 385-394
KNNLKECGLY Gi-3a 345-354
Gs-a
I3C Gi-3a
1432 KNNLKDCGLF Gi-2a 345-354 Gi-la, Gi-2a
BN1/BN3 MSELDQLRQE 61-10 61,62
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Peptides RMHLRQYELL and MSELDQLRQE were from Dr C.G. Unson, 
Rockerfeller University, New York, USA. The other peptides were synthesised by 
Biomac Ltd., Glasgow, UK.
2.9 Protein determination
The method used was based on that of Lowry et al. (1951). Stock solutions:
1.Copper tartrate carbonate (10% (w/v) Na2C03, 0.1% CuS04. 5H20 , 0.2% 
sodium potassium tartrate)
2. 0.8M NaOH
3. 10% SDS
Immediately before use, one part of each of these solutions was mixed along 
with one part H20  to give reagent 'A', which was gently warmed to dissolve any 
precipitate. Standard solutions of BSA were prepared in duplicate containing 0-100pg 
of protein per ml and unknown protein solutions in triplicate. All samples were made 
up to 1ml with H20  and then 1ml reagent 'A' added to each sample. After 10 minutes 
0.5ml reagent 'B' was added (Folin and Ciocalteau's reagent diluted 1:6 with distilled 
H20), mixed and colour development allowed to occur for 30 minutes before 
measuring absorbance at 750nm in an LKB Ultrospec-2 spectrophotometer.
2.10 Gel electrophoresis
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) 
was carried out by the method of Laemmli (1970).
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2.10a Resolving gel preparation
All stock solutions were stored at 4°C. Acrylamide solutions were filtered 
through Whatman No. 1 filter paper.
Buffer 1: 0.4% (w/v) SDS, 1.5M Tris HC1, pH 8.8 
Buffer 2: 0.4% (w/v) SDS, 0.5M Tris HC1, pH 6.8
Acrylamide 'A': 30% (w/v) acrylamide, 0.8% (w/v) N.N’-methylene bisacrylamide 
Acrylamide 'B': 30% (w/v) acrylamide, 0.15% (w/v) N,N,-methylene bisacrylamide 
50% (v/v) glycerol
10% (w/v) APS (made immediately before use)
TEMED
Running buffer 0.025M Tris
0.192 Glycine 
0.1% (w/v) SDS
10% (w/v) acrylamide/0.27% N,N’-methylenebisacrylamide (w/v) gels were prepared as 
follows:
Volume (ml)
Distilled H20 8.2
Buffer 1 6
Acrylamide 'A' 8
50% glycerol 1.6
APS 0.16
TEMED 0.028
The solution was mixed and poured between 180 x 160mm glass plates separated by 
1.5mm spacers. The gel was layered with 25% (v/v) buffer 1 to exclude air and left to set
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at room temperature.
12.5% (w/v) acrylamide/0.0625% (w/v) NjN’-methylenebisacrylamide gels were 
prepared as follows:
Volume (ml)
Distilled H20 11.6
Buffer 1 12
Acrylamide 'B' 20
50% glycerol 4
APS 0.16
TEMED 0.028
The solution was mixed and poured between 200 x 200mm glass plates separated by 
1.5mm spacers. The gel was layered with 25% (v/v) buffer 1 to exclude air and left to 
set at room temperature.
2LIQiLSta.cKing gelprepacatifln
Stacking gels were prepared as follows:
Volume (ml)
Distilled H20 9.75
Buffer 2 3.75
Acrylamide 'A' 1.5
APS 0.16
TEMED 0.028
The solution was mixed, layered on top of the resolving gel and allowed to set around 
a 10-well teflon comb. Electrophoresis was performed at 60mA over three hours in the
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case of the 10% acrylamide gel system and 40mA overnight in the case of the 12.5% 
acrylamide gel system.
2.10c Sample preparation
Protein was precipitated from plasma membranes by addition of 6.25|il of 2% 
(w/v) sodium deoxycholate, followed by 250jil of 24% (w/v) TCA then samples were 
made up to 1.15ml with H20  and centrifuged at 13 000 x g for 20 minutes in an MSE 
Microcentaur centrifuge. Supernatants were discarded and 20}il of 1M Tris base added 
to the pellets which were then solubilised by addition of 20pl of Laemmli buffer. 
Laemmli buffer (50pl) was also added to the marker proteins then all samples vortexed 
and boiled for five minutes before loading onto the gel.
2.10d Gel protein staining
The gel was covered in stain solution which consisted of 0.1% (w/v) 
Coomassie blue in 50% (v/v) H20 , 40% (v/v) methanol, 10% (v/v) glacial acetic acid 
and placed on a shaker for one hour. The stain solution was then discarded and the gel 
shaken overnight in destain solution (identical to stain solution but without Coomassie 
blue).
2.10e Autoradiography
Gels to be autoradigraphed were stained for protein and dried down onto 
Whatman 3mm filter paper at 80°C for two hours under vacuum. The dried gel was 
placed against Fuji NIF RX 100 X-Ray film in a cassette with intensification screens 
for 3-4 days at -80°C. Films were developed using a Kodak X-OMAT developer.
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2.1 Of Densitometry
Densitometric scanning of autoradiographs and blots was performed using a 
Shimadzu CS-9000 densitometer. Absorbance for autoradiographs and reflectance for 
blots were measured in arbitrary units.
2.11 Immunoblotting
Proteins were electrophoresed from SDS gels to a nitrocellulose sheet in an 
LKB transblot apparatus (Towbin et al., 1979) at 350mA for two hours. The tank 
buffer consisted of 0.192M glycine, 25mM Tris and 20% (v/v) methanol. The 
nitrocellulose sheet was 'blocked' for 90 minutes in 5% dried skimmed milk in TBS 
after which the blot was washed in distilled H20  and incubated overnight with the 
antiserum, appropriately diluted in 1% (w/v) dried skimmed milk in TBS. The 
antiserum was then removed and the sheet subjected to washes in distilled H20 , 0.2% 
(v/v) Nonidet-P40-containing TBS and TBS alone for 10 minutes each, after which 
the blot was incubated with a second antibody (peroxidase-conjugated sheep 
anti-rabbit IgG or 125I-labelled sheep anti-rabbit IgG) for two hours at room 
temperature. The second antibody was then removed and the sheet subjected to the 
same series of washes. In the case of the peroxidase-conjugated second antibody, the 
blot was developed in 40ml of lOmM Tris pH 7.5 with 0.025% (v/v) H20 2 and 
0.025% (w/v) o-dianisidine as a substrate. Where 125I-labelled second antibody was 
used, the blot was autoradiographed as described in section 2.10e. Both first and 
second antibodies could used up to three times and were stored at 4°C using 0.004% 
(w/v) thimerosal as an antibacterial agent.
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2.12 Toxin ribosvlation of membranes
2.12a Toxin ore-activation
This was done by the method of Hildebrandt et al. (1983). Stock pertussis 
toxin was added to an equal volume lOOmM dithiothreitol and vortexed. The solution 
was incubated for one hour at room temperature and the incubation terminated by 
placing the sample on ice. Cholera toxin was pre-activated in a similar manner. Final 
concentrations in the assay mixture were 10|ig/ml for pertussis toxin and 20)ig/ml for 
cholera toxin.
2.12b APP-ribosvlation
Membranes to be ADP-ribosylated were diluted in ImM EDTA, lOmM Tris 
HC1, pH 7.4 to a protein concentration of l-2.5mg/ml. 20pl aliquots of diluted 
membrane protein were assayed in a final volume of 50|il containing :
[32P]-NAD, 2fiCi per assay 
20mM Thymidine 
ImM ATP, pH 7.5 
100|iM GTP, pH 7.5 
20mM Arginine HC1
0.25M Potassium phosphate buffer, pH 7.0
The ribosylation assay was initiated by addition of membranes and continued 
for one hour at 37°C. Assays were terminated by transfer to ice followed by addition 
of sodium deoxycholate and TCA precipitation as detailed in section 2.10c. Proteins 
were then resolved using SDS PAGE and gels dried, stained and autoradiographed as 
described in sections 2.10d. and e.
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2.13 Adenvlvl cvclase assay
2.13a Assay conditions
Assays were carried out by the method of Johnson and Salomon (1991) using 
sequential chromatography on dowex and alumina columns to separate the labelled 
product, [32P]-cAMP from labelled substrate, [a32P]-ATP. Assays were carried out in 
an incubation medium containing at final concentrations in a lOOpl volume:
2mM MgCl2
O.lmMEGTA
lmMffiMX
ImM dithiothreitol
50mM triethanolamine HC1, pH7.4
The assay also contained creatine phosphate (5mM) and creatine 
phosphokinase (140U/ml) as an ATP regenerating system and BSA (2mg/ml), cAMP 
(O.lmM), ATP (50|iM) and [a-32P]-ATP (lpCi per assay). Ligands and GTP were 
present at the concentrations required. Plasma membranes for assay were diluted in 
ImM EDTA,10mM Tris, pH7.4. Reaction tubes were set up on ice and the reaction 
started by transfer to a 30°C water bath and addition of membrane protein at a final 
concentration of 5-10fig per assay. Reactions were terminated by addition of ice-cold 
stopping solution which consisted of 2% (w/v) SDS, 40mM ATP and 1.4mM cAMP, 
pH7.5. This was followed by lOOpl [8-3H]-cAMP (about 5000cpm per sample) and 
700jil H20. Total counts of [a-32P]-ATP and [8-3H]-cAMP were retained as well as 
assay blanks, where no membrane protein was added, so that unseparated 
[a-32P]-ATP counts could be subtracted from sample counts.
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2.13b Preparation of chromatography columns
Dowex AG50W-X4 resin (200-400 mesh, H+ form) was washed by mixing 
in 1M HC1. After allowing it to settle and decanting the supernatant the wash process 
was repeated several times with distilled H20. The resin was resuspended in H20  at 
twice its packed volume and 2ml of the slurry added to glass wool-plugged plastic 
columns to give a packed bed volume of 1ml per column. The columns were then 
washed with 2ml of 1M HC1. Before use, the columns were washed with 2 x 1ml of 
HC1 and then 3 x 10ml of distilled H20 . Alumina columns used for the second stage 
were plugged with glass wool and filled with lg of neutral alumina. Before use the 
columns were washed with 8ml of 0.1M imidazole HC1 buffer, pH 7.5.
2.13c Calibration of chromatography columns
Elution profiles of dowex and alumina columns were determined before use 
in sample chromatography in order to allow for variation between batches of resin and 
obtain optimal recovery of labelled product. A mixture of [8-3H]-cAMP and 
[a-32P]-ATP was applied to a dowex column in 1ml of H20 . Water was added in 1ml 
fractions and 1ml volumes of the eluate collected as shown in Fig. 2.1a. 3ml 0.1M 
imidazole, pH 7.5 and 8ml 'Ecoscinf were added and the samples counted using a 
dual label program. For the alumina columns only [8-3H]-cAMP was added to the the 
dowex column and eluted onto alumina using 3ml H20. Counts were eluted from the 
alumina column by successive additions of 1ml volumes of 0.1M imidazole, pH 7.5. 
The recovery and optimal elution volumes could then be determined, Fig. 2.1. 
Recovery of [8-3H]-cAMP was generally 60-80%. After the recovery fell to 40%, 
dowex was discarded and new columns prepared. Alumina columns were discarded 
when, after progressive accumulation of [a-32P]-ATP, the radioactivity level became 
unacceptably high.
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2.13d Isolation of cAMP on chromatograph v columns
Samples were carefully layered onto the surface of the dowex resin using 
Pasteur pipettes. Two 1ml volumes of H20  were added and the eluate from these 
additions containing most of the [a-32P]-ATP was discarded. The remaining label was 
then eluted onto alumina columns with 3ml of water and the eluate discarded. Cyclic 
AMP was eluted from the alumina columns into scintillation vials by addition of 4ml 
0.1M imidazle, pH7.5 to the columns. The eluate was collected in scintillation vials, 
mixed with 8ml ’Ecoscint’ and counted using the dual label program. Columns were 
then regenerated before the next assay as described in section 2.13b.
2.14 Assay o f cAMP
2.14a Cell stimulation and cAM P extraction
Cells were grown to confluence in 24-well plates then the medium removed, 
the monolayer washed in serum-free medium then incubated with 0.5ml serum-free 
medium for 16 hours before agonist stimulation. The cells were then incubated on a 
heated plate at 37°C and agonist added to the medium, generally in a 5pl volume, but 
occasionally in a greater volume when high agonist concentrations were required.
After the desired period, medium was aspirated and 2% (w/v) ice-cold perchloric acid 
(150pl per well) was added to the monolayer in order to extract the cAMP. Each well 
contained approximately 9.66 x 105 cells.
In the case of rat hepatocytes, cells were loaded onto collagen coated 6-well 
plates in Krebs/BSA and left for 40 minutes in the tissue culture incubator. Cells 
adhered at a density of approximately 9.7 x 105 cells per well. After this time period 
non-adherent cells were aspirated off and the monolayer washed with buffer. This was
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then replaced with medium containing agonist, added in a 5 or 10|il volume. After the 
desired time period, the buffer was aspirated off and cAMP extracted in 2% (w/v) 
ice-cold perchloric acid (250pl per well). All plates were incubated for 15-30 minutes 
on ice then the cell debris scraped off and centrifuged at 13 000 x g for two minutes in 
an MSE Microcentaur centrifuge. The supernatant was neutralised with 0.5M 
triethanolamine in 2M potassium hydroxide. Neutrality was checked with universal 
indicator after which the precipitate was pelleted as above and an aliquot of supernatant 
taken for assay of cAMP by the binding protein method.
2.14b Preparation o f bovine adrenal cAM P binding protein
The method used was that of Brown et al. (1972). Bovine adrenal glands 
(about 20-30) were transported to the laboratory on ice. After removal of excessive fat, 
the glands were hemisected and the medulla removed. Cortex was scraped from the 
gland capsule, pooled and transferred into a pre-cooled Waring blender along with 1.5 
volumes of ice-cold homogenisation buffer (0.25M sucrose, 25mM KC1,5mM MgCl2 
and 50mM Tris HC1, pH7.4). The tissue was homogenised at maximum speed then 
transferred to centrifuge tubes on ice and centrifuged at 2000 x g for five minutes at 
4°C. The supernatant was re-centrifuged at 6000 x g for 15 minutes at 4°C and the 
final supernatant pooled, aliquoted and stored at -20°C until use.
2.14c Cyclic AM P determination
The method used was based on the binding assay described by Tovey et al. 
(1974). The assay depends on competition of labelled and unlabelled cAMP for a 
limited number of binding sites on a binding protein purified from bovine adrenal 
glands, as described in section 2.14b. Increasing amounts of unlabelled cAMP 
(0-320pmols/ml) were incubated with a fixed amount of [5',8-3H]-cAMP and binding
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protein. Standard solutions of cAMP were prepared in assay buffer containing 4mM 
EDTA and 50mM Tris, pH7.4. [5',8-3H]-cAMP was diluted in assay buffer to give 
approximately 500 OOOcpm/ml. Labelled cAMP (0.1ml) was added to all standards and 
unknowns and the volume made up to 0.2ml with assay buffer. The incubation was 
started by addition of binding protein (0.1ml) which had been diluted 1: 30 in assay 
buffer before use. After incubation for 2-3 hours at 4°C, the binding reaction was 
terminated by addition of 0.25ml of a suspension of 2% (w/v) Norit-GSX charcoal 
and 1% (w/v) BSA in ice-cold assay buffer which had been allowed to mix for 45 
minutes beforehand. Tubes were rapidly mixed and centrifuged at 13 000 x g in an 
MSE Microcentaur centrifuge to pellet the charcoal, after which 0.3ml of each 
supernatant was taken for counting by addition to 4ml of 'Ecoscint* in a scintillation 
vial. Vials were then counted using an curve-fitting program which constructed a 
standard curve allowing unknown cAMP values to be calculated. A typical standard 
curve is shown in Fig. 2.2.
2.15 Assay of glucose-6-phosphatase activity
Glucose-6-phosphatase activity was assayed by the method of Houslay and 
Palmer (1978). The assay contained in a final volume of 75|il: 20mM 
glucose-6-phosphate in 40mM sodium cacodylate HC1, pH6.5 and 35|il of crude cell 
homogenate. For each sample a boiled blank was also assayed in order to allow for 
endogenous phosphate present in the sample. The reaction was started by addition of 
homogenate, allowed to continue for 30 minutes at 37°C then stopped by addition of 
50|il of ice-cold 20% (w/v) TCA. Samples were centrifuged at 13 000 x g for two 
minutes in an MSE Microcentaur centrifuge and a sample of supernatant taken for 
assay of phosphate.
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Phosphate was assayed by the method of Fiske and Subbarow (1925). 
Distilled H20  (0.1ml) along with 0.1ml 2.5% (w/v) ammonium molybdate in 5N 
sulphuric acid, 40|il of ANSA reducing agent then 0.685 ml of distilled H20 . A 
standard phosphate sample was also prepared containing 19.25nmols of phosphate in 
order to calculate unknown Pi. Samples were vortexed and heated at 37°C for 30 
minutes and absorbance measured at 660nm in an LKB spectrophotometer. In this 
assay there was shown to be a linear increase in absorbance over two orders of 
magnitude of phosphate concentration (Fig. 2.3). All unknowns were within this 
range.
2.16 Measurement of r2Hl-Thvmidine uptake
This was done according to the method of McNulty et al. (1990). After 
growing cells to confluence in 24 well plates, medium was removed and the 
monolayer rinsed with serum-free medium. The cells were incubated for 16 hours in 
serum-free medium containing l|iCi/ml of [3H]-Thymidine along with the agonist of 
interest. The medium was removed and the monolayer washed twice with HBSS.
Cells were washed twice with ice-cold 5% TCA, twice with ethanol then solubilised in
0.5ml of 0.3M NaOH. This was added to a scintillation vial containing 0.1ml 1.5M 
HC1 and 4ml 'Ecoscint' and the samples counted.
2.17 Measurement of G i-2a subunit phosphorylation
Cells were grown to confluence in 6 well plates and preincubated for 16 hours 
in serum-free medium. Cells (3.9 x 106 cells per well) were then labelled for three 
hours in a 1ml volume of medium, with 0.25mCi of [32P]Pi. During this period the 
cells were kept in the tissue culture incubator under the conditions described for 
growth (section 2.6a). Ligands were added in a lOjil volume. After the appropriate
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time period, reactions were stopped by removal of medium and addition of 1ml of 
ice-cold cell solubilising buffer to each well. Cells were scraped and left at 4°C for one 
hour then centrifuged at 13 000 x g for five minutes at 4°C in an MSE Microcentaur 
centrifuge in order to pellet any insoluble material. The supernatant was taken and 
incubated for 16 hours at 4°C with 50|il of antiserum 1432. After this period, 50pl of 
protein A-agarose was added and incubation continued for three hours with frequent 
vortexing of samples. The agarose with attached immune complex was pelletted by 
centrifugation as above and the pellets washed three times in wash buffer then once in 
SDS-free wash buffer. Immune complex was detached from the pellets by boiling for 
five minutes in 50pl of Laemmli buffer. Agarose was sedimented by centrifugation as 
above, but at room temperature and proteins in the supernatant resolved by SDS 
PAGE as described in section 2.10.
2.18 Measurement of labelled glucagon binding
Measurement of [125I]-glucagon binding to plasma membranes was by the 
method of Rojas and Bimbaumer (1985). Briefly, membranes were diluted to a protein 
concentration of 1 mg/ml with 5mM EDTA/20mM Tris, pH7.5 then incubated in a 
total volume of lOOpl containing 50|il of 2 x binding buffer, 5|il plasma membranes, 
5|il unlabelled glucagon in wash buffer (lpM final concentration) and 10|il of 
[125I]-glucagon (3 x K^cpm). Binding buffer was 0.2% BSA, 2mM EDTA and 
40mM Tris, pH7.5. The reaction proceded for 20 minutes at 32°C after which it was 
stopped with 5ml of wash buffer and samples filtered immediately. Cellulose acetate 
filters (0.45p.m) which had been pre-soaked in 10% BSA were washed once with 
wash buffer before use. After filtering of samples, the filters were washed with 5ml 
wash buffer then removed and counted using an LKB-1275 Minigamma y counter.
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2.19 Methods used in study of leucocytes from diabetic 
subsets*
2.19a Suhiects
Type 2 diabetic subjects were recruited at the diabetic out-patient clinic. All 
had a diagnosis established on the basis of fasting hyperglycemia (the hospital quote a 
reference range for normal plasma glucose of 2.8-6.0mmols/l). All were 
hyperglycemic at the time of sampling and were either newly diagnosed or had been 
managed by dietary measures alone since the time of diagnosis. Patients were chosen 
who were as far as possible free from other disorders and taking a minimum of 
medications. None had clinical signs of active infection at the time of sampling. The 
male diabetics ranged from 30-73 and female diabetics from 40-77 years of age. 
Control subjects were recruited from the general surgical out-patient clinic, attending 
with minor surgical conditions. They were sex-matched with the diabetic patients and, 
within the limitations of the patients available, also age-matched.
2.19b Leucocyte isolation
Leucocytes were isolated by the method of Boyum (1968). Approximately 
80ml of blood was taken from the antecubital vein, anticoagulated by the addition of 
lml of 0.2M EDTA per 10ml of blood and transported within one hour to the 
laboratory. A high molecular weight dextran solution (6% dextran T-500,149mM 
NaCl, 5mM KC1) was added (5ml per 20ml whole blood) and samples incubated for 
30 minutes at 37°C. The leucocyte-rich plasma was removed by Pasteur pipette and 
loaded onto 'Ficoll-Paque' solution (5.7% Ficoll-400,9% diatrizoate sodium with 
calcium edetate) at approximately 15ml plasma per 10ml Ficoll. This was centrifuged 
at 1500 x g for 30 minutes at room temperature to obtain:
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1. A neutrophil and erythrocyte pellet (also containing basophils and 
eosinophils)
2. Platelet-containing plasma as supernatant.
3. A lymphocyte/monocyte/platelet-containing band at the interface between 
plasma and Ficoll.
The lymphocyte/monocyte band was removed by Pasteur pipette, taking as 
little Ficoll as possible and three volumes of HBSS added This was centrifuged for 
five minutes at 1000 x g to pellet the lymphocytes, leaving a platelet-containing 
supernatant. The cell pellet was washed in HBSS and the centrifugation repeated after 
which supernatants were pooled for platelet membrane preparation and the leucocyte 
pellet stored at -80°C until required for membrane preparation.
2.19c Leucocyte plasm a m em bran^preparation
Leucocytes isolated by density gradient centrifugation were resuspended in 
ice-cold lysing buffer (lOmM Tris, ImM EDTA, pH7.4, containing O.lmM PMSF, 
2mM benzamidine and 2pg/ml of aprotonin). This was homogenised by 10 up and 
down strokes of a Potter/Elvehjem teflon/glass homogeniser and the sample 
centrifuged at 500 x g for 10 minutes in a Beckman L5-50B centrifuge in a Ti50 rotor, 
in order to sediment unbroken cells and nuclei. Plasma membranes were collected by 
centrifugation of the supernatant at 48 000 x g for 10 minutes, washed in lOmM Tris, 
pH7.4 (containing protease inhibitors at the same concentrations as above) and 
recentrifuged under the same conditions to give a final membrane pellet. This was 
resuspended in 50|il of lOmM Tris buffer per 10ml original whole blood and aliquoted 
for storage at -80°C until used for immunoblotting or assay of plasma membrane 
adenylyl cyclase activity.
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2.20 Data analysis
Where appropriate, data was analysed for statistical significance using 
Student's t-test for unpaired data.
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Fig. 2.1 Elution profiles of ra-32P1-ATP and
T8-3Hl-cAMP from dowex and alumina 
columns.
[8-3H]-cAMP (34 000 cpm in 0.5ml) (open circles) and [a-32P] (19 
OOOcpm in 0.5ml) (closed circles) were added to a dowex column then eluted 
from the column by repeated additions of 1ml volumes of H20  (Fig. 2.1a) and 
counted as described in section 2.13b. [8-3H]-cAMP (34 OOOcpm in 1ml) was 
added to a dowex column and eluted onto alumina by the addition of 5ml H20 . 
Counts were then eluted from the alumina column by repeated addition of 1ml 
volumes of imidazole, pH7.5 (Fig. 1.1b). Fractions were collected and counted 
as above.
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Fig,.2,2 Standard curve for cAMP determination.
Standard solutions of cAMP (from 0-320pmoles/ml) were set up and 
assayed as described in section 2.14c. Counts from non-specifically bound 
[3H]-cAMP have been subtracted from each value (350cpm). Data are mean+/-SD 
for one standard curve performed in duplicate. Significant displacement of 
labelled cAMP from specific binding sites was obtained from upwards of 
lOpmols/ml (p < 0.05). Similar results were obtained in all successful cAMP 
assays.
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Fig. 2.3 Standard curve for phosphate determination.
A standard curve was prepared in which phosphate solutions containing 
phosphate (O-lOOpg) were assayed and absorbance measured 
spectophotometrically as described in section 2.15.
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Chapter. 3
The P9 cell line as a model system for studying  
adenvlvl cvclase signalling
3.1 Introduction
The P9 cell line was generated by transfection of native rat hepatocytes with 
DNA from the S V40 virus and expresses the large T antigen, evidence that DNA has 
entered the ceil genome resulting in immortalisation of the cells. Cell lines, whether 
tumour-derived or virally-transformed show considerable phenotypic differences when 
compared to their native, differentiated counterparts. Before carrying out extensive 
work on the cell line, it was judged important to examine basic characteristics and 
agonist responses in the cells in order to compare them to rat hepatocytes. Rat 
hepatocytes transfected in the same manner by other workers have yielded stable cell 
lines which, despite their fibroblast-like morphology express albumin, tyrosine 
aminotransferase (Isom et al., 1980) and transferrin, haemopexin and 
glucose-6-phosphatase (Woodworth et al., 1986) all of which are specific to 
hepatocytes as opposed to the non-parenchymal cells present in liver. However, the 
quantity of markers expressed was variable, indicative of phenotypic differences 
between cell lines generated.
Previous work done on the P9 hepatocyte-derived cell line (MacDonald, C., 
unpublished work) has demonstrated that whilst the cells are de-differentiated, having a 
fibroblast-like morphology in culture, they possess bilirubin glucuronyl transferase 
activity, a hepatocyte-specific enzyme involved in conjugation of bilirubin, convincing 
evidence that the cells were indeed derived from hepatocytes and retain at least one 
differentiated characteristic. They can be passaged up to 20 times without any change in 
morphology. No previous study however, has been made of adenylyl cyclase 
signalling or insulin action in the P9 cell line. The purpose of this chapter then, was 
firstly to study basic adenylyl cyclase responses in P9 cells, viz. agonist-stimulated 
plasma membrane adenylyl cyclase activity and agonist-elevated intracellular cAMP, to 
examine how comparable they were to those of rat hepatocytes and to consider the
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usefulness of the cell line as a model system for studying adenylyl cyclase signalling.
Secondly, G-protein subtypes expressed by the cells were identified 
immunologically and quantitatively compared to those of rat hepatocytes. Finally, 
attempts at promoting differentiation of the cells are briefly discussed.
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3.2 Results
The P9 cell line in monolayer culture is fibroblast-like in morphology and 
rapidly growing as a uniform monolayer, reaching confluence 3-4 days after subculture 
and showing no morphological change at confluence (Fig. 3.1). Cells retained the same 
morphology with repeated subculture. Glucose-6-phosphatase activity was found to be 
present in a crude homogenate from the cells at about a fifth of the level found in native 
rat hepatocytes (Table 3.1).
As shown in Table 3.2, P9 cell plasma membranes possess adenylyl cyclase 
activity which can be potently stimulated by the diterpene forskolin in the same manner 
as that of rat hepatocyte adenylyl cyclase. Maximum stimulation in membranes and 
maximal cAMP accumulation in whole cells in response to forskolin was at 1(HM, 
resembling other mammalian adenylyl cyclase systems. The small stimulation by GTP 
and the receptor-mediated stimulatory response to PGEi in the presence of GTP 
demonstrates that the cells possess functional Gs coupled to adenylyl cyclase 
stimulation (GTP must be present at saturating concentrations in order to obtain optimal 
receptor mediated responses). The response to the prostanoid was slightly smaller in P9 
cells than in rat hepatocytes. PGEi potently elevated intracellular cAMP when intact P9 
cells were challenged with the hormone (Table 3.3 and Fig. 3.2). Dose response curves 
for agonist-stimulated adenylyl cyclase activity in P9 cell plasma membranes are given 
in Chapter 4.
There was no stimulatory response to the hormone glucagon in P9 cells, which 
gave potent stimulation of adenylyl cyclase activity in rat hepatocyte plasma membranes 
(Table 3.2). Similarly, glucagon over a range of concentrations (10‘9-10'6M) did not 
elevate intracellular cAMP above basal levels in the cells when intact cells were
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challenged with the hormone (not shown), whilst rat hepatocytes showed a 
considerable elevation over basal levels when challenged with glucagon (10_8M) (Fig. 
3.3). These data were in line with glucagon binding data from the two cell types, where 
plasma membranes from P9 cells showed specific glucagon binding at 3.7% of the 
level observed in rat hepatocyte plasma membranes.
Forskolin in combination with glucagon showed considerable synergism in its 
action in intact rat hepatocytes. After two hours in culture however, the response had 
fallen in proportion to the response to glucagon alone. This synergism between the two 
agonists was also observed in P9 cells. Glucagon, when incubated with P9 cell plasma 
membranes, in the presence of GTP (lCMM), enhanced in a dose-dependent manner, 
the ability of forskolin to stimulate adenylyl cyclase activity (Fig. 3.4). Dose 
dependence on glucagon for enhancement of the response was of the same order as that 
in rat hepatocytes where 1.4 x 108M yields a half maximal response and approximately 
10'7M yields a maximal response (Gawler et al, 1987). Glucagon and forskolin also 
showed synergism in their ability to elevate intracellular cAMP in intact P9 cells (Fig. 
3.5). The potency of the synergism was greater in intact cells, an effect generally 
observed with forskolin's synergistic responses. Similarly, PGEi showed marked 
synergism with forskolin in elevating intracellular cAMP, but more potent than in the 
case of glucagon given its ability alone to elevate intracellular cAMP above basal levels 
in the cells (Table 3.3).
The ability of forskolin to elevate intracellular cAMP was considerably greater 
in P9 cells than in rat hepatocytes (Fig. 3.6). As forskolin similarly stimulated plasma 
membrane adenylyl cyclase activity in both cell types in the presence of the 
phosphodiesterase inhibitor IBMX, this finding suggests that the P9 cells possess 
lower phosphodiesterase activity than rat hepatocytes. In further support of this, was 
the finding that in P9 cells IBMX pre-incubation did not generally cause much
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enhancement of intact cell cAMP accumulation in response to agonist. In one 
experiment, challenge of intact P9 cells with 5 x 105M PGEi elevated intracellular 
cAMP to 24+/-3 pmols/50pl extract (SEM for triplicate observations), whilst in cells 
pre-incubated with ImM IBMX, the level was 28+/-2 pmols/50|il extract.
On examination of the time course for agonist elevation of intracellular cAMP, 
forskolin caused a rapid and potent elevation of intracellular c AMP reaching a plateau 
and not returning to basal levels during the time period of the experiment (Fig. 3.7). 
The response to glucagon and forskolin combined yielded a time course entirely parallel 
to that of forskolin. Like forskolin, PGEi caused a rapid elevation in intracellular 
cAMP again reaching a plateau (Fig. 3.8). When the time course here was repeated in 
the presence of IBMX, a similar shape of curve was obtained. As both agonists at 
10'5M over a period of two minutes gave readily measurable and submaximal 
responses, this concentration and time period were used in later studies of intracellular 
cAMP elevation by these agonists.
P9 cell plasma membranes were immunoblotted using specific antisera in order 
to identify G-proteins expressed by the cells. P9 cells were shown to express Gi-2a 
(40kDa) (Fig. 3.9), Gi-3a (41kDa) (Fig. 3.10), Gs-a (45kDa and 42kDa forms) (Fig. 
3.11) and G-protein 6 subunit (35kDa) (Fig. 3.12). The immunological data showed 
that these antisera were selective and could be used as probes for examining expression 
of specific G-proteins. Signals obtained from all polypeptides on loading increasing 
amounts of P9 cell membrane protein were found to be linear up to about lOOjig of 
protein. Thereafter, this amount of membrane protein was loaded in order to maximise 
the signals obtained and ease quantification.
G-protein levels in P9 cell plasma membranes were quantitatively compared to 
those in rat hepatocytes. The signals obtained from Gi-2a and Gi-3a co-migrated with
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signals from rat cerebral cortex, a tissue in which both these G-proteins are expressed 
(Fig. 3.13). The gel system used in Fig. 3.13a. provides greater resolution in the 
35-45kDa region and is adequate for resolving G i-la and Gi-2a, but no signal was 
obtained from P9 cells or rat hepatocytes corresponding to Gi-la, expressed by rat 
cerebral cortex. The higher molecular weight band observed using the I3C antiserum 
may represent a cross reaction with another G-protein a  subunit, possibly the 45kDa 
form of Gs-a, as this antiserum is already known to recognise other a  subunits at high 
titres. The signal obtained from each Gi subtype was greater in P9 cells than in rat 
hepatocytes.
On probing with the CS1 antiserum, signals were obtained at 45kDa and 42kDa 
(Fig. 3.14) representing Gs-a subunits. The 45kDa form reacted more strongly with 
the antiserum, presumably being the more prevalent of the two. The signal obtained 
from the 45kDa subunit was greater in the case of P9 cells than for rat hepatocytes, 
whilst the 42kDa a  subunit in P9 cells reacted more weakly with the antiserum than in 
rat hepatocytes.
The BN3 antiserum reacted strongly with a 35kDa polypeptide from P9 cell 
plasma membranes, which co-migrated with a signal from rat cerebral cortex, 
demonstrating that the cells express at least one form of the G-protein 6 subunit (Fig. 
3.14). The electrophoresis system used here is inadequate for resolving the different 
GB subtypes. Again the signal obtained from P9 cells was much larger than that from 
rat hepatocytes.
Toxin-catalysed ADP-ribosylation of P9 cell plasma membranes was carried out 
in order to confirm that the bands observed on immunoblotting co-migrated with toxin 
substrates and therefore represented G-protein a  subunits. Cholera toxin-catalysed 
ADP-ribosylation of P9 cell plasma membranes yielded labelled bands at approximately
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45kDa and 42kDa representing the two Gs-a forms (Fig. 3.15). These bands 
co-migrated with signals obtained when membrane proteins were blotted and probed 
using an antiserum to Gs-a (Fig. 3.14). As in immunoblotting experiments, the 45kDa 
form appeared the more prevalent in the cells. Radioactivity was incorporated into other 
bands, but in none was the incorporation as great as in the Gs-a forms. Pertussis toxin 
catalysed ADP-ribosylation yielded a broad band at approximately 40kDa (Fig. 3.15). 
As the gel system used here is not adequate to resolve toxin-labelled Gi-2a and Gi-3a, 
this band must represent a combination of at least these two a  subunits, expressed by 
the cells. There was very little labelling of other polypeptides present in the membranes.
A range of GppNHp concentrations^to influence forskolin-stimulated adenylyl 
cyclase activity in P9 cell plasma membranes but no inhibitory phase was obtained, 
although there was a marked low affinity, stimulatory phase (Fig. 3.16). Using a range 
of GTP concentrations to influence basal adenylyl cyclase activity in P9 cell plasma 
membranes, it was possible to demonstrate a consistent impairment of the optimal 
response by 10*3M GTP (Fig. 3.17). Pertussis toxin pre-treatment of P9 cells, at a 
concentration adequate to ADP-ribosylate 92% of the Gi present in P9 cell plasma 
membranes, had no influence on the response to glucagon (Fig. 3.18).
Experiments to measure phosphate incorporation into Gi-2a upon agonist 
challenge of P9 cells showed no uptake of labelled phosphate over basal on challenge 
with TPA or 8-bromo-cAMP even in the presence of the phosphatase inhibitor okadaic 
acid (Fig. 3.19). Experiments done in parallel on rat hepatocytes showed considerable 
labelling of the immunoprecipitated Gi-2a on agonist challenge (not shown).
Elevation of intracellular cAMP levels and plasma membrane adenylyl cyclase 
responses to agonist stimulation showed considerable variation in magnitude between 
experiments. Possible reasons for this are integrity of the agonist itself (concentration
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and activity) and cell factors, for example the precise degree of cell confluence at 
stimulation and actual differences in receptor expression between batches of cells. It 
was noted that at passage 13, the cells lost the stimulatory response to PGEi, 
presumably due to loss of receptor expression and thereafter, cells were not used for 
experiment after passage 12. However, there was no obvious relationship between 
passage number and response to agonist to suggest a gradual reduction in receptor 
number.Variation between batches of serum used in the growth medium could be 
responsible for variation between cells. In addition, other authors have reported that rat 
hepatocytes transformed in a chemically-defined medium show a greater tendency to 
retain differentiated functions than those transformed in serum-supplemented medium 
(Woodworth et a l , 1986). These factors emphasise the desirability of using defined 
media where possible for cell culture work. Whatever the cause of this variation in 
responsiveness, it limits to some extent, the usefulness of the cells as a model system.
On calculating values for fold stimulation by agonist over basal intracellular 
cAMP levels it is important to remember that basal intracellular cAMP levels are within 
the range in which cAMP cannot measurably displace labelled cAMP from the binding 
protein, ie below 0.5pmols/50jil, as discussed in section 2.14c. The assay can only 
reliably detect cAMP at levels greater than this. This suggests that basal cAMP levels 
are likely to be inaccurately measured by the binding protein assay. Evidence that these 
values are indeed inaccurate is provided by their large percentage errors, in comparison 
to the errors on stimulated cAMP level measurements. For example, in the dose 
response curve for forskolin given in Fig. 3.5, basal cAMP was measured as 
0.50+/-0.20 (Mean+/-SEM for triplicate observations), a 40% error and maximal 
forskolin stimulation gave 105+/-6pmols/50jil extract, a 6% error. Values for fold 
stimulation over basal are therefore also likely to be inaccurate. Likewise, basal values 
for plasma membrane adenylyl cyclase activity were also generally less accurate than 
those for stimulated activity, as indicated by the errors. Less weight then, should be
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given to values for fold stimulation than to absolute values for agonist stimulation.
All attempts to promote differentiation of the cells failed. Growing the cells on 
collagen-coated plates had no effect on cell morphology or glucagon responsiveness. 
Nor did exposure of cells to dexamethasone (0.25p.M, 16 hours) or insulin (0.5p.M, 16 
hours) affect morphology or restore glucagon responsiveness. However, insulin at this 
concentration did stimulate cell growth and had marked effects on adenylyl cyclase 
signalling which are discussed in Chapter 4.
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3.3 Discussion
Previous studies have shown that rat hepatocytes, although immortalised or 
transformed by S V40, retain a variety of differentiated cell characteristics. The P9 cell 
line expresses glucose-6-phosphatase and bilirubin glucuronyl transferase. These 
findings are consistent with those of other authors who have examined 
SV40-immortalised, rat hepatocyte-derived cell lines (Isom et al., 1980, Woodworth et 
al., 1986). This, along with the high degree of cell purity in the preparations from 
which they were derived, makes it hard to imagine how the cell line could have arisen 
from any cell type other than hepatocytes, present during the transfection procedure. 
The situation in these fibroblast-like cells however, is clearly very different from that in 
3T3 LI fibroblasts. Whilst the latter can be encouraged to differentiate in response to 
various agents (Watkins et al., 1987), P9 cells appear irreversibly fixed in their 
relatively de-differentiated, rapidly proliferating form. In this way P9 cells more closely 
resemble established hepatoma cell lines than other fibroblast cell lines.
Despite the presence of these two hepatocyte-specific marker proteins the 
adenylyl cyclase signalling system in the cells, on close examination, showed 
considerable divergence from that of rat hepatocytes. There are clear functional 
alterations in signalling at the level of the receptor and G-protein in the P9 line as 
compared to rat hepatocytes. Firstly, the cells have lost elevation of intracellular cAMP 
in response to glucagon, a highly specialised cellular response, implying that their 
cyclase functioning, in addition to their morphology, has moved in the direction of a 
non-differentiated state. This loss of responsiveness appears to be due to the low level 
of glucagon receptors in the plasma membrane, though we cannot say whether it 
reflects an actual reduction in receptor expression or simply receptor sequestration at a 
subcellular site. This is in line with the findings of Houslay et al. (1980) who showed 
that lost responsiveness would require at least 75% of the receptor to be absent from the 
plasma membrane. Changes in receptor expression are a major factor in control of
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responses and cells undergoing transformation, are commonly known to lose 
receptor-mediated responses. However, down-regulation of the glucagon response 
observed on culture of rat hepatocytes suggests that the low responsiveness of P9 cells 
may also be a consequence of their removal from the original tissue and adherence to 
plates rather than as a result of transfection alone. In this respect, the absent glucagon 
response may reflect the artificial environment of the cultured cells, rather than their 
state of differentiation. In addition, receptor phosphorylation, a form of modification 
known to be involved in desensitisation of receptor-mediated responses may be 
contributing to the loss of glucagon responsiveness (Houslay, 1991b).
There are several factors that may contribute to the plateau observed on 
examining the time courses for intracellular cAMP elevation in response to agonist.
This levelling-off of the response may be achieved at the level of cAMP generation, 
hydrolysis or by its extrusion from the cell. Phosphodiesterase activation can be 
excluded as a cause, as the phosphodiesterase inhibitor IBMX had no influence on the 
plateau. Both PGEi (Brunton and Mayer, 1979) and phenol red (King and Mayer, 
1974) present in the serum-free medium surrounding the cells, have been reported to 
inhibit cAMP extrusion. Indeed, Brunton et al reported in their system a Ko.5 of 10|iM 
PGEi for the effect. This suggests that cAMP extrusion is unlikely to be responsible for 
the plateau. More likely it may reflect desensitisation to or metabolism of the agonist, or 
feedback by high levels of cAMP on the cAMP generating system. Similar causes may 
be proposed for the plateau observed on the time course for forskolin-elevated 
intracellular cAMP, except for desensitisation as forskolin is not known to elicit 
desensitisation in any cell type. That the time course with glucagon and forskolin in 
combination was entirely parallel, suggests that the glucagon response too showed no 
ability to desensitise, unlike that in rat hepatocytes (Muiphy et al., 1989).
The synergism observed between forskolin and glucagon action in P9 cells is 
further evidence that the cells retain at least small numbers of functional glucagon
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receptors (with apparently normal kinetics for cAMP generation). As synergism is 
indicative of forskolin's high affinity action on the adenylyl cyclase system, this finding 
also suggests that, like rat hepatocytes, they possess both high and low affinity sites for 
forskolin action. In common with diverse cell types, P9 cells retain a stimulatory 
reponse to PGEi, though the ability of this agonist to stimulate plasma membrane 
adenylyl cyclase activity was smaller in P9 cells than in rat hepatocytes.
P9 cells like rat hepatocytes express at least two out of a possible four Gs-a 
variants (Bray et al., 1986) and two Gi forms, but the polypeptides were expressed in 
different relative amounts between the two cell types. There are a number of possible 
reasons for the change in G-protein levels observed in the immortalised cells. Although 
a change in expression could potentially occur due to the differences in hormonal or 
physical environment between rat liver and cell culture plate, it is much more likely that 
the changes are indicative of a change in cell phenotype as observed in other cells on 
differentiation or de-differentiation (Uhing et al., 1987), except that the changes in P9 
cells, like their fibroblast-like morphology, are not subject to change on challenge with 
differentiation agents. Furthermore, if for example the level of glucocorticoid hormones 
in the cell culture serum as opposed to the animal were responsible for the differences, 
one might expect to see inconsistencies in the pattern of expression between different 
batches of cells, which was not the case. Similarly, the changes are unlikely to be in 
response to a chronic elevation in basal cAMP as basal cAMP levels in both P9 cells 
and rat hepatocytes were barely detectable. The greater expression of Gi-a and the B 
subunit suggests that these polypeptides may have specific functions in the 
immortalised cell that require their presence in larger amounts, relative to other plasma 
membrane proteins. Mobilisation of G-proteins to the plasma membrane has been 
proposed as a mechanism by which cells can regulate the activity of receptors which 
signal through these G-proteins. Indeed these changes may confer specificity for 
responses which have not been examined in the P9 cells. The changes in G-protein 
expression may be driven by the cell in an attempt to compensate for the loss of
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stimulatory receptor or Gi input into adenylyl cyclase. Alternatively, the increase in 
plasma membrane Gi levels in P9 cells may, like the level of glucagon responsiveness, 
be a consequence of primary culturing the cells rather than a result of immortalisation 
alone. Fujinaga et al. (1989), on studying of cultured rat hepatocytes, noted that a 
sustained increase in pertussis toxin substrate occurred early during their primary 
culture. In addition they found that pertussis toxin preincubation could abolish DNA 
synthesis in response to insulin only at an early stage after plating the cultures, but not 
after 24 hours. The authors concluded that a pertussis toxin sensitive G-protein may 
play a role in cell cycle control in the transition from the resting (Go) state to the state in 
which DNA synthesis occurs (Gi). The mechanism of the increased level of Gi-a in P9 
cells could be increased expression, decreased degradation or greater message stability 
and may be involved in the high growth rate of P9 cells as compared to rat hepatocytes.
It is particularly difficult to speculate about the reasons for co-ordinate 
regulation of the two Gs-a forms as nothing is known with certainty about the specific 
activities and functions of these splice variants. However, the increase in one form 
without the other shows that they are differentially regulated, presumably with 
consequences for adenylyl cyclase signalling in the cells. This finding raises the 
question of the site of the regulation. Granneman et al. (1990) in studies on Gs 
expression in various rat tissues showed that the levels of individual splice variants in 
tissues correlated well with the levels of their respective mRNAs. In liver the level of 
mRNA for the higher molecular weight form of Gs was marginally more abundant than 
the mRNA encoding the lower molecular weight splice variant. It would be interesting 
to measure the levels of mRNAs for the Gs forms in P 9 cells in order to find whether 
there is a similar correlation with protein levels and therefore to provide evidence for the 
site of control of their levels being at transcription.
In rat hepatocyte plasma membranes there is a characteristic dual regulation 
of adenylyl cyclase by GppNHp. Low concentrations inhibit the response which has
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been stimulated by forskolin, an effect half maximal at 0.1 nM and high concentrations 
further stimulate the response (Gawler and Houslay, 1987). This is thought to be due 
to Gi and Gs having respectively high and low affinities for this non-hydrolysable 
GTP analogue. Using this method there was however, no evidence of Gi function in 
P9 cell plasma membranes, though there was ample Gs function as evidenced by the 
low affinity, stimulatory phase. In addition to the lack of GppNHp-mediated inhibition 
of adenylyl cyclase we have no evidence of receptor-mediated Gi function in the cells. 
However, an inhibitory phase was observed in the GTP dose response curve. This has 
been proposed to represent Gi function in other systems studied for example rat 
adipocytes (Strassheim et al., 1990), mouse adipocytes (Palmer et al., 1992) and rat 
hepatocytes (Hey worth et al., 1984) as Gi has a low affinity for the nucleotide as 
opposed to Gs, so that the inhibitory phase follows the stimulatory phase. This 
inhibitory phase as a measure of Gi function in P9 cells however, took place at much 
higher concentrations and was of much smaller magnitude than in rat hepatocytes, 
where the authors noted half maximal inhibition at I jiM  GTP.
It is particularly intriguing that some measure of Gi function could be 
demonstrated by one method but not the other. Presumably this reflects a difference in 
the mechanics of guanine nucleotide binding to Gi in the two cell types. That adenylyl 
cyclase inhibition by these two guanine nucleotides can be differentially influenced by 
circumstances is a phenomenon which has been previously observed. Palmer et al. 
(1992) noted on studying mouse adipocytes, that maximal inhibition of 
agonist-stimulated adenylyl cyclase was achieved at much higher concentrations of 
GppNHp (10*6M) than in hepatocyte plasma membranes. The authors also found that 
inhibition of agonist-stimulated adenylyl cyclase by GppNHp was similar in control 
and diabetic animals, whilst the inhibitory phase on employing GTP was considerably 
reduced in diabetic animals. Gi function, as measured by the ability of low 
concentrations of GppNHp to inhibit forskolin-stimulated adenylyl cyclase activity, has 
been noted to be abolished in both adipocyte (Strassheim et al., 1990) and hepatocyte
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(Gawler et al., 1987) plasma membranes from streptozotocin-induced diabetic rats. A 
similar influence to that present in diabetes which brings about these functional 
changes, may be at work in P9 cells. There appears then to be considerable scope for 
variation in Gi functional measurements between systems and their alteration in disease 
states.
In addition to disease states, changes in the physical environment of the 
signalling system are known to influence Gi function. High sodium chloride 
concentrations for example, are known to decrease agonist affinity of 
G-protein-coupled receptors and to affect the interaction of G-proteins with GTP, 
thereby modulating G-protein function (Gierschik et al., 1988). However, it seems 
unlikely that such a major alteration in the internal environment could be responsible for 
the change observed in P9 cells and one would expect such an influence, if present in 
the cells, to be removed on preparing and assaying membranes.
Another possibility for the lack of functional cyclase inhibition is that Gi-2 has 
been largely inactivated by a covalent modification in the cells. Gi-2a phosphorylation 
has been shown to occur in response to a number of stimuli (Pyne et al., 1989a) and 
has been proposed as the mechanism of Gi-2 inactivation in diabetes (Bushfield et al., 
1990b). Again, one might expect such a modification to be reversible on making 
membranes, as the cells were harvested and membranes prepared for these experiments 
in the absence of phosphatase inhibitors. The inability to show agonist-induced 
phosphorylation of Gi-2a in P9 cells distinguishes them from rat hepatocytes, where 
agonists resulting in PK-A or PK-C activation stimulate incorporation of labelled 
phosphate into the a  subunit of Gi-2 (Bushfield et al., 1990a). The failure to 
incorporate phosphate into P9 cell Gi-2a in response to agonists could be as a result of 
the G-protein being already phosphorylated in the basal state, possibly due to 
overactivity of one of these kinases. Another possible mechanism of Gi-2 
phosphorylation that could be envisaged in P9 cells, is as a result of the activity of the
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large T antigen which is known to activate a kinase capable of phosphorylating and 
potentiating the activity of the protein p53 involved in cell transformation 
(Scheidtmann, 1989). It is possible that this kinase may have other, as yet unidentified 
substrates, including signal transduction components. Alternatively, rather than 
reflecting phosphorylation in vivo, the failure to incorporate phosphate into P9 cell 
Gi-2a may be due to the G-protein being a poorer kinase substrate as a result of its 
conformation or, may result from kinases responsible for G-protein phosphorylation 
being less abundant in P9 cells than in rat hepatocytes. In order to further investigate 
these possibilities, we would need to examine Gi function in P9 cell plasma membranes 
after phosphatase treatment and study expression of the above kinases by the cell line.
Whatever the cause of reduced cyclase inhibition it does suggest that the Gi-a 
subtypes may subserve other functions in the cells, as both Gi-2a and Gi-3a are 
expressed in abundance. Possibly the coupling of Gi to other effectors is of greater 
priority to the immortalised phenotype than cyclase inhibition. Indeed, we have not 
been able to demonstrate any receptor-mediated inhibitory responses in P9 cells 
presumably due to lack of expression of the appropriate receptors, which would mean 
that Gi was in any case redundant in this regard. Further evidence that there is little or 
no Gi input into adenylyl cyclase signalling in P9 cells came from the finding that 
pertussis toxin pre-treatment had no effect on the response to glucagon or PGEi (see 
Chapter 5). The low stimulatory response to glucagon in P9 cells is probably entirely 
due to reduced receptor expression rather than any change in Gi or Gs input.
Indirect evidence has been provided for differences in cAMP phosphodiesterase 
activity between P9 cells and their native rat hepatocyte counterparts. The nature of the 
cAMP degradation pathway depends on the cell phenotype and evidence has previously 
been presented that the complexity of this process may be greater in differentiated cells 
(Conti et al., 1991). As P9 cells are rapidly dividing and cAMP is inextricably involved 
in growth control (Roesler et al., 1988), there is good reason to expect differences in
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its regulation between the two cell types. The phosphodiesterases expressed in P9 cells 
would merit formal investigation.
The adenylyl cyclase catalytic subunit is ubiquitous in mammalian cells so it is 
not surprising to find that the cells have this enzyme activity. However, given the 
differences in receptor and G-protein expression in P9 cells as compared to native 
hepatocytes, it is also possible that the cells express a different array of catalyst 
subtypes and that this may account in part for the differences in stimulatory and 
inhibitory cyclase regulation between the two cell types. This would be interesting to 
investigate when antisera to the various subtypes are more readily available.
Various cell lines have been studied extensively and are currently in use as 
model systems. The P9 cell line does not possess the normal responses of the cell type 
from which it was derived and shows marked phenotypic differences from rat liver, 
both functional and morphological. As the most useful model systems express a wide 
variety of receptors and responses comparable to their native tissues, this mitigates 
against use of the P9 cell line as a hepatocyte model system. The main problems with 
the cell line which limit its usefulness are a poor variety of responses and loss of 
responsiveness after a finite number of passages. It is clearly not possible by using the 
cell line to gain further insight into some of the most interesting aspects of hepatocyte 
adenylyl cyclase signalling such as glucagon desensitisation and the influence Gi on 
responses. Its advantages are ease of growth thus obtaining substantial amounts of 
material for experiment. Studying the cell line may give us more information about 
signalling and change in expression of markers as a result of the viral transfection. 
Presumably, some of the features noted will apply to virally-immortalised cells in 
general and whilst we cannot hope to compare the cells more than superficially to 
hepatocytes, we can certainly use them to examine features of adenylyl cyclase 
signalling, some of which are common to all mammalian cells.
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Table 3.1 GIucose-6-phosphatase activity in P9 cells and
rat hepatocytes.
Confluent P9 cells were harvested and stored at -80°C as described in 
section 2.6d. Freshly isolated rat hepatocytes were stored at -80°C until use. 
Cells were thawed, homogenised in ImM EDTA, lOmM Tris HC1, pH 7.4 and 
glucose-6-phosphatase activity assayed as described in section 2.15. Samples of 
homogenate were retained for protein assay. Data are mean+/-SEM for triplicate 
observations obtained in three experiments.
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Table 3.1
Cell type
P9 cells 
Rat hepatocytes
Glucose-6-phosphatase activity 
(jig Pi/mg protein /  minute)
1.9+/-0.2
9.2+/-0.2
Table 3.2 Agonist-stimulated adenvlvl cvclase activity in 
P9 cell and rat henatocvte plasma membranes.
Plasma membrane preparations from P9 cells and rat hepatocytes were 
assayed for adenylyl cyclase activity in response to agonists as described in 
section 2.13. Agonists were used alone or in combination at the following 
concentrations GTP (1(MM), glucagon (10~5M), PGEi (lCHM), GppNHp 
(KHM), forskolin (1(MM) and NaF (1.5 x 10'2M). Data are mean+/-SEM for 
triplicate observations obtained in one experiment. Figures in brackets are values 
for fold stimulation over the respective basal values. Similar results were obtained 
in another experiment.
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Table 3.2
Agonist
GTP
Glucagon + GTP 
PGEi + GTP 
GppNHp 
Forskolin 
NaF
Adenylyl cyclase activity 
(pmols/mg protein/min)
P9 cells
19+/-1 
40+/-6 (2) 
41+/-4 (2) 
95+/-4 (5) 
130+/-7 (7)
611+/-26 (32) 
653+/-24 (27)
Rat hepatocytes 
38+/-3 
105+/-3 (3) 
367+/-26 (10) 
341+/-14 (9) 
330+/-3 (9) 
870+/-8 (23) 
620+/-8 (16)
lafrlg 3,2 Elevation of P9 cell intracellular cAMP in
response to forskolin and PGEi. alone and 
combined.
Confluent P9 cells were incubated for 16 hours in serum-free medium 
then challenged for 2 minutes with forskolin (10_5M), PGEi (10_5M) and 
forskolin and PGEi combined at the same concentrations. Cyclic AMP was 
extracted and assayed as described in section 2.14. Results are mean+/-SEM for 
triplicate observations in one experiment. Values in brackets are fold stimulation 
over basal cAMP. Similar results were obtained in another experiment
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Table 3.3
Agonist
PGEi
Forskolin
PGEi + Forskolin
Intracellular cAMP 
(pmols/50p.l extract)
0.1+/-0.04
25.1+/-0.7 (224)
15.4+/-1.4 (137)
49.4+/-1.6 (442)
Table 3.4 Quantitative comparison o f G-protein levels in
P9 cell and rat hepatocyte plasma membranes.
G-proteins expressed in P9 cells and rat hepatocytes were identified by an 
immunoblotting procedure using specific antisera as described in the legend to 
Figure 3.10. Membrane protein, 100}ig was blotted in every case. Blots were 
scanned densitometrically as described in section 2.1 Of. and the density of the 
band obtained from P9 cells given as a percentage band density of the signals 
obtained from rat hepatocytes for each polypeptide. Similar results were obtained 
in two other experiments. The blots from one experiment are shown in Figs. 3.14 
and 3.15.
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Table 3.4
Polypeptide 
Gs-a (45kDa)
Gs-a (42kDa)
GB
Gi-2a
Gi-3a
P9 cell s/Rat hepatocytes (%) 
377
50
258
210
543
Fig» 3»1 P9 cells and rat hepatocytes in culture.
P9 cells in culture (Magnification x 90), a. one day after subculture and b. 
at confluence, c. rat hepatocytes in primary culture (Magnification x 90) two 
hours after isolation.
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Figure 3.1 (a)
F igu re 3.1 (b)
Figure 3.1 (c)
Fig> 3.2 Effect of increasing concentrations of PGEi on
P9 cell intracellular cAMP.
P9 cells were challenged for 2 minutes with increasing concentrations of 
PGEi (KHM-KHM) then cAMP extracted and assayed as described in section
2.14. Fold stimulation over basal was 48+/-2). Ko.5 for PGEi was 1.35 x 
10-5M. Basal cAMP was 0.43+/-0.06 pmols cAMP /50fil extract. All data are 
mean+/-SEM for triplicate observations obtained in one experiment Similar 
results were obtained in another experiment.
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Fig,.3.3 Elevation o f rat heoatocvte intracellular cAM P
in response to forskolin and glucagon, alone 
and combined.
Freshly isolated rat hepatocytes were kept in primary culture as described 
in section 2.5a. and after 40 minutes (column 1) and 2 hours (column 2) were 
challenged with forskolin (10"5M) alone (white bars), glucagon (10_8M) alone 
(black bars), or forskolin and glucagon combined at the same concentrations 
(grey bars). After 2 minutes buffer was aspirated and cAMP extracted and 
assayed as described in section 2.14. Basal cAMP levels were 0.17+/-0.06 
pmols/50|il extract (40 minutes) and 0.07+/-0.02 pmols/50|il extract (2 hours). 
Data are mean+/-SEM for triplicate observations obtained in two experiments. 
Glucagon response was enhanced significantly by forskolin (p < 0.001) at both 
time points and both glucagon and glucagon/forskolin responses were 
significandy reduced (p < 0.01) after 2 hours.
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Figure 3.3
Fig. 3.4 Effect of increasing concentrations of glucagon
on forskolin-stimulated adenvlvl cvclase 
activity in P9 cell plasma memhranes.
P9 cell plasma membranes incubated with forskolin (10'5M), GTP 
(10^M) and glucagon (0-10_6M) were assayed for adenylyl cyclase activity, as 
described in section 2.13. The maximum response to glucagon (at 10'6M) was 
123+/-4% of that to forskolin alone (p < 0.01). The Ko.5 for glucagon's effect 
was 2.9 x 10*9M. Data are mean+/-SEM for triplicate observations obtained in 
one experiment. Similar results were obtained in another experiment.
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Fig, 3i5 Elevation of P9 cell intracellular cAMP in
response to forskolin combined with increasing 
concentrations o f glucagon.
P9 cells grown to confluence in 24 well plates and exposed to serum 
free medium for 16 hours were challenged for 2 minutes with forskolin (10~5M) 
and increasing concentrations of glucagon (0 to 2 x 10'7M). Cyclic AMP was 
extracted and assayed as described in section 2.14. The maximum response to 
glucagon (at 5 x 10_8M) was 151+/-7% of the response to forskolin alone (p < 
0.001) The Ko.5 for glucagon's action in enhancing the response to forskolin was 
3 x 10-10M. Data are mean+/-SEM for triplicate observations obtained in one 
experiment. Similar results were obtained in two other experiments.
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Fig. 3.6 Effect of increasing concentrations of forskolin
on P9 cell intracellular cAMP.
P9 cells were challenged for 2 minutes with increasing concentrations of 
forskolin (10-6M to 4.0 x 10^M) then cAMP was extracted and assayed as 
described in section 2.14. Fold stimulation over basal was 186+/-6. Ko.5 for 
forskolin was 7.2 x 10 5M. Basal cAMP was 0.50+/-0.35 pmols/50|il extract. 
Results are mean+/-SEM for triplicate observations obtained in one experiment 
Similar results were obtained in another experiment.
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Fig. 3.7 Time course for elevation of P9 cell
intracellular cAMP in response to forskolin. 
alone and combined with glucagon.
P9 cells were challenged with forskolin (10 5M) alone (open circles) or in 
combination with glucagon (10_8M) (closed circles) for 2 minutes and cAMP 
extracted at intervals. Samples were neutralised and assayed for cAMP content as 
described in section 2.14. Data are mean+/-SEM for triplicate observations 
obtained in one experiment Similar results were obtained in three other 
experiments.
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Fig* .3,8 Time course for elevation of P9 cell
intracellular cAMP in response to PGEi.
P9 cells were challenged with PGEi (10-5M) and cAMP extracted at 
intervals then samples neutralised and assayed for cAMP as described in section
2.14. Data are mean+/-SEM for triplicate observations obtained in one 
experiment. Similar results were obtained in three other experiments.
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Fig.3.9 Immunological identification of Gi-2a in P9
cell plasma membranes.
Samples of P9 cell plasma membrane protein (20jxg to 150jig) were TCA 
precipitated and resolved using SDS PAGE as described in section 2.10 then 
transferred onto nitrocellulose membrane as described in section 2.11. 
Immunoblotting was performed using a 1: 200 dilution of antiserum 1432. 
Detection of the primary antiserum was achieved using anti-rabbit IgG at 1:500 
dilution which was coupled to horseradish peroxidase (Fig. 3.9a). The substrate 
for the peroxidase was o-dianisidine. Bands were scanned densitometrically and 
results plotted graphically (Fig. 3.9b), using arbritary units for band density. Data 
shown are from one experiment Similar results were obtained in another 
experiment.
119
Gi
-2 
ba
nd
 
de
ns
ity
 
(a
rb
itr
ar
y 
un
its
)
Figure 3.9 (al
Mr x 10"3
200
98
6 8
43
25
18
14
--------------G,
2 0  3 0  4 0  5 0  6 0  8 0  10O 1 5 0
pg protein
F ig u re  3 .9  (b )
500
400
300
200
100
200150100
-2 06
protein (fig)
Fig. 3.10 Immunological identification of Gi-3a in P9_
cell plasma membranes.
Samples of P9 cell plasma membrane protein (20fig to 150|ig) were TCA 
precipitated, resolved and transblotted as described in the legend to Figure 3.9 
then Gi-3a detected using a 1: 1000 dilution of the antiserum I3C and horseradish 
peroxidase-linked IgG as second antibody (Fig. 3.10a). Bands were scanned 
densitometrically and results plotted graphically (Fig. 3.10b). Data shown are 
from one experiment Similar results were obtained in another experiment
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Eigi.3,11 Immunological identification of Gs-a in P9 cell
plasma membranes.
Samples of P9 cell plasma membrane protein (20p.g to 200|ig) were TCA 
precipitated, resolved and transblotted as described in the legend to Figure 3.9 
then Gs-a detected using a 1:200 dilution of the antiserum CS1 and horseradish 
peroxidase-linked IgG as second antibody (Fig. 3.11a). Bands were scanned 
densitometrically and results plotted graphically (Fig 3.1 lb). Data shown are 
from one experiment Similar results were obtained in another experiment
121
Figure 3.11 (a)
Mr x 10-3
200
98
6 8
43
25
18
14
2 0  3 0  4 0  5 0  6 0  8 0  100 1 5 0  2 0 0
|jg protein
Figure 3.11 (bl
.ti
7 3a a<u p
c ec3 C
5/5 V-J
O w
600
500
400
300
200
100
0 o-o
250200100 150500
q
q
protein (jig)
Gs- a 4 5
G S-<X 42
Fig. 3.12 Immunological identification of G-protein ft
subunit in P9 cell plasma membranes.
Samples of P9 cell plasma membrane protein (20|ig to 200|ig) were TCA 
precipitated, resolved and transblotted as described in the legend to Fig. 3.9 then 
G-protein 6 subunit detected using a 1: 200 dilution of the antiserum BN3 and 
horseradish peroxidase-linked IgG as second antibody (Fig. 3.12a). Bands were 
scanned densitometrically and results plotted graphically (Fig. 3.12b). Data 
shown are from one experiment Similar results were obtained in another 
experiment.
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Fig. 3.13 Expression of Gi-q subtypes in P9 cells and 
rat tissues*
Samples of membrane protein (100{ig) from P9 cells (lane 1) , rat hepatocytes 
(lane 2) and rat brain (lane 3) were resolved using SDS PAGE and immunoblotted to 
compare quantitatively G-protein levels in plasma membranes from the respective 
tissues. In panel A, samples were resolved using a 12.5% acrylamide/0.0625% 
bisacrylamide resolving gel as described in section 2.10a. In panel B samples were 
resolved using a 10% acrylamide, 0.27% bisacrylamide resolving gel. Thereafter, 
samples were immunoblotted and proteins detected using the antisera: 1432 (panel A) 
and I3C (panel B) at the same dilutions as given in Figs. 3.9 and 3.10. The primary 
antisera were detected and bands scanned densitometrically as in Fig. 3.10. 
Densitometric data are presented in Table 3.4. Data shown are from one experiment. 
Similar results were obtained in two other experiments.
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JFigt 3,14 Expression of Gs-a forms and G-protein fi 
subunit in P9 ceils and rat tissues.
Samples of membrane protein (100|ig) from P9 cells (lane 1), rat 
hepatocytes (lane 2) and rat brain (lane 3) were resolved using SDS PAGE and 
immunoblotted in order to quantitatively compare levels of Gs-a and GB in the 
respective tissues. In both panels samples were resolved using a 10% 
acrylamide/0.27% bisacrylamide resolving gel. Thereafter proteins were detected 
using the antisera CS1 (panel A) and BN3 (panel B) at the same dilutions as in 
Figures 3.11 and 3.12. The primary antisera were detected and bands scanned 
densitometrically as in Fig. 3.9. and data presented in Table 3.4. Data shown are 
from one experiment Similar results were obtained in two other experiments.
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Fie. 3.15 Toxin catalysed ADP-ribosvlation of P9 cell
plasma membranes.
Toxin substrates expressed by P9 cells were examined. Plasma 
membranes from P9 cells (lane 2) were ADP-ribosylated using thiol pre-activated 
pertussis toxin (panel A) and cholera toxin (panel B) and [32P]-NAD+ as 
described in section 2.12. P9 cell plasma membranes were also subjected to the 
same treatment in the absence of toxin (lane 1). Samples were resolved using 
SDS PAGE (10% acrylamide/0.27% bisacrylamide) as detailed in section 2.10. 
Data shown are from one experiment Similar results were obtained in two other 
experiments.
125
Figure 3.15
M r x  1 0 ' 3
A
200—
9 8
68—
4 3
•  — G r o6 2 5 —
200—
s s -
e s —
4 3 —
2 5 — 18
Figi 3,16 Effect o f increasing concentrations o f G p p N H p 
on forskolin-stimulated adenvlvl cvclase 
activity in P9 cell plasma membranes.
P9 cell plasma membranes incubated with forskolin (1(HM) and 
increasing concentrations of GppNHp (1010M to 10_3M) were assayed for 
adenylyl cyclase activity as described in section 2.13. The maximum response to 
GppNHp ( at 10'5M) was 231+/-10% of that to forskolin alone. There was no 
significant inhibition of the response to forskolin by 10*10M GppNHp. The Ko.5 
of GppNHp for enhancement of the forskolin response by GppNHp was 6.2 x 
10-7M. Data are mean+/-SEM for triplicate observations obtained in one 
experiment. Similar results were obtained in two other experiments.
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Fig. 3,17 Effect of increasing concentrations o f GTP on 
adenvlvl cvclase activity in P9 cell plasma 
membranes.
P9 cell plasma membranes incubated with increasing concentrations of 
GTP (10'7M-10*3M) were assayed for adenylyl cyclase activity as described in 
section 2.13. The maximum response to GTP (at 10-5M) was 253+/-22% of the 
basal adenylyl cyclase activity. The Ko.5 for GTP for stimulation of adenylyl 
cyclase was 2.7 x 10 7M. Inhibition of the optimal response by 10_3M GTP was 
38+/-6% (CV) Data are mean+/-SEM for triplicate observations obtained in one 
experiment Similar results were obtained in two other experiments.
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Fig» 3,18 Effect o f pertussis toxin oretreatm ent on
glucagon response and toxin labelling in P9  
cells.
In Fig. 3.18a. confluent P9 cells were exposed to serum-free medium for 
16 hours alone, (black bars) or with pertussis toxin (lOOng/ml) present during the 
final 2 hours of the incubation (hatched bars). Cells were then challenged with 
forskolin (105M) (column 1) or forskolin (105M) combined with glucagon 
(108M) (column 2), for 2 minutes in each case. Cyclic AMP was then extracted 
and assayed in section 2.14. Glucagon responses were significant in each case, 
but there was no significant difference in the presence of pertussis toxin. Data are 
mean +/-SEM for triplicate observations obtained in four experiments.
In Fig. 3.18b. P9 cells exposed to serum-free medium alone, (lane 1) or 
containing pertussis toxin as in (A) during the final 2 hours of exposure, ( la n e  2) 
were harvested, membranes prepared and ADP-ribosylated using pertussis toxin 
and p 2P]-NAD+ as described in section 2.12. Pertussis toxin treatment in this 
manner ADP-ribosylated 92% of the substrate available. Data shown are from one 
experiment Similar results were obtained in two other experiments.
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Fig. 3.19 Phosphorylation of Gi-2a in intact P9 cells.
Confluent P9 cells were pre-incubated with [32P]Pi for 3 hours then 
challenged for 15 minutes with no agonist (lane 1), TPA, lOng/ml (lane 2), 
TPA, lOng/ml and okadaic acid, 10 6M (lane 3), 8-bromo-cAMP, 300(iM (lane 
4), 8-bromo-cAMP, 300|iM and okadaic acid, 10_6M (lane 5) and okadaic acid, 
10-6M alone (lane 6). Gi-2a was immunoprecipitated from the solubilised cell 
extract using the 1432 antiserum, as described in section 2.17. Samples were 
resolved by SDS PAGE and autoradiography performed as described in section 
2.10. Results shown are from one experiment. Similar results were obtained in 
another experiment using 8-bromo-cAMP and TPA alone.
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Chapter 4
Low affinity effects o f insulin on adenvlvl cvclase
signalling in P9 cells
4.1 Introduction
As discussed in Chapter 3, the initial aim of exposing confluent P9 cells to a 
high concentration of insulin (0.5JJ.M for 16 hours) was to observe whether it could 
promote any morphological differentiation of the cells or restore glucagon 
responsiveness. Whilst it had neither of these effects, insulin was found to have 
low affinity effects on cyclase signalling. The aim of this chapter then was to 
characterise these effects and to observe whether changes in signalling in P9 cells 
on insulin exposure resemble those in other systems.
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4,2 Results
Exposure of P9 cells to a high concentration of insulin (0.5p.M) for 16 hours 
was found to have pronounced effects on the responses to stimulatory agonists in 
plasma membranes derived from these cells (Table 4.1 and Figs. 4.1-4.3). The 
responses to PGEi and GppNHp were markedly enhanced as was the response to 
forskolin, although there was no significant increase in basal adenylyl cyclase activity. 
For PGEi and GppNHp there was a slight reduction in the concentration of agonist 
required to give a half maximal response but with forskolin there was no left shift of the 
dose response curve. An examination of the time course for the effect on the forskolin 
response, showed that increased cyclase activity was visible two hours and maximal 16 
hours after insulin exposure, typical for a growth related effect of insulin (Fig. 4.4).
Insulin and IGF-1 both caused a small stimulation of [3H]-Thymidine uptake 
into P9 cells at concentrations at which these agonists would be expected to act as 
growth factors (Fig. 4.5). In addition, 0.5fiM insulin markedly enhanced the ability of 
stimulatory agonists to elevate intracellular cAMP as shown for PGEi in Fig. 4.6. The 
basal cAMP level was not significantly altered. Dose dependence for insulin of this 
increased intact cell responsiveness is shown for PGEi (Fig. 4.7) and forskolin (Fig.
4.8). The low affinity stimulatory effect of insulin on both responses paralleled dose 
dependence on insulin for stimulation of pH]-Thymidine uptake and both were blocked 
by concurrent exposure to the protein synthesis inhibitor cycloheximide (lp.M) (Fig.
4.9). The fold enhancement by 0.5}iM insulin of stimulatory agonist responses was 
considerably larger than the stimulation of [3H]-Thymidine uptake by the same insulin 
concentration. This experiment showed that approximately 18% of the enhanced cAMP 
accumulation was due to increased cell number and the remainder to increased cAMP 
generation by plasma membrane adenylyl cyclase. On examining dose dependence for 
insulin it was noted that insulin at low concentrations impaired cAMP accumulation in
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response to PGEi and enhanced cAMP accumulation in response to forskolin. These 
high affinity effects are discussed in Chapter 5.
Membranes from insulin-exposed P9 cells were subjected to toxin labelling with 
pertussis toxin and cholera toxin (Fig. 4.10 and Table 4.2) and G-proteins quantitated 
by immunoblotting using specific antisera (Fig. 4.11 and Table 4.2). After insulin 
exposure there was a considerable reduction in labelling of toxin substrates. Labelling 
with cholera toxin of both 45kDa and 42kDa Gs-a splice variants was reduced and a 
reduction in labelling of the 'Gi' band with pertussis toxin. This change in labelling 
was not the result of a reduction in G-protein levels, as no changes in G-protein a  or B 
subunit levels were observed on immunoblotting.
The low affinity effect of insulin on adenylyl cyclase functioning was 
considerably variable in magnitude. Presumably this reflects differences in expression 
of IGF-1/insulin receptors or other proteins required for insulin responsiveness 
between batches of cells. There was no obvious relationship between insulin 
responsiveness in this manner and passage number. Again the possibility is raised of 
variability between cells as a result of the growth factor content and age of the serum 
which will not be the same on every occasion. Receptor number has been shown to 
vary widely in cells, depending on the batch of foetal calf serum used (Devedjian et al., 
1991). Alternatively, the variability may arise from the state of the cells at the time of 
insulin exposure. Nakamura et al. (1983) showed in studies on cultured hepatocytes 
that induction of DNA synthesis by insulin took place after a time lag, the duration of 
which was dependent on cell density. At a high cell density near confluence, induction 
of DNA synthesis required a longer exposure time. The situation may be similar in P9 
cells where the precise cell density could influence insulin's effect on cell growth and 
plasma membrane adenylyl cyclase activity.
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4.3 Discussion
In this section, the ability of insulin (at a high concentration over a long time 
period) to modulate P9 cell adenylyl cyclase signalling was investigated. Increased 
intracellular cAMP accumulation in response to PGEi was shown to be associated with 
increased stimulatory responses of plasma membrane adenylyl cyclase. The long time 
course for the effect and its abolition by cycloheximide in intact cells suggest that 
protein synthesis underlies the effect. An influence on cAMP phosphodiesterase 
activity is not implicated in this action of insulin, as the non-specific phosphodiesterase 
inhibitor EBMX was present routinely in the adenylyl cyclase assay buffer.
As forskolin at high concentrations is thought to act directly on the adenylyl 
cyclase catalytic subunit, (ie. more distally in the signalling system than PGEi and 
GppNHp), this suggests that insulin was having a positive effect at the catalytic subunit 
of adenylyl cyclase, possibly by increasing its quantity in the membranes, 
disproportionately over other membrane proteins. This could be further investigated by 
immunological quantitation of the catalytic subunit when antisera become available, or 
by measuring binding of radiolabelled forskolin to the membranes.
Apart from increasing the quantity of effector in plasma membranes, there are 
other possible ways in which insulin might bring about functional cyclase activation 
which should be considered. Firstly, sensitisation of adenylyl cyclase to stimulatory 
agonists has been noted under conditions where PK-C is active. Phorbol esters, which 
activate PK-C, sensitised intact human astrocytoma cells to cAMP-elevating agonists 
(Johnson and Toews, 1990) and Summers and Cronin (1986) found that phorbol ester 
treatment of a pituitary cell line enhanced forskolin- and PGEi-stimulated cAMP 
accumulation and adenylyl cyclase activity. Simmoteit et al. (1991) attributed the 
increase in adenylyl cyclase activity in the presence of phorbol esters to
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phosphorylation of the adenylyl cyclase catalytic subunit. In a recent report Jacobowitz 
et al. (1993) showed that specific adenylyl cyclase subtypes viz. AC-I, -II and -III are 
targets for PK-C activation. Insulin itself has been suggested to activate PK-C in some 
cell types (Houslay, 1991b) and, if doing so in P9 cells, could potentially account for 
the cyclase sensitisation observed here. However, if a phosphorylation event were 
responsible for the sensitisation, we would have expected a shorter time course for the 
effect, unless expression of the kinase itself was induced by insulin.
Insulin sensitisation to adenylyl cyclase-activating hormones has also been 
observed in a rat sarcoma cell line (Hickman and McElduff, 1990). These authors 
proposed that a lessening of Gi input was responsible in their system. It seems unlikely 
that this could apply to P9 cells, as we have little evidence of Gi input into cyclase 
activity in P9 cells.
It has recently become clear that certain adenylyl cyclase subtypes are subject to 
activation following receptor-mediated By release from G-proteins. AC-II and -IV are 
known to be regulated in this manner (Gao and Gilman, 1991) and AC-IV is expressed 
in liver (Kelley Bentley and Beavo, 1992). Such a mechanism has been proposed to 
explain why hormones not signalling directly through adenylyl cyclase can potentiate 
those that do. We would expect such an effect to be most prominent at high 
concentrations of stimulatory agonist and not observable in absence of agonist, ie. on 
basal cyclase activity or intracellular cAMP concentrations which was the result 
observed. Insulin, if it were acting in the cells to promote G-protein dissociation, could 
potentiate cyclase activation in this manner. Evidence that insulin exposure of P9 cells 
may indeed promote dissociation of Gi, with release of By components, was provided 
by the reduction in pertussis-toxin labelling of Gi observed after insulin exposure, 
implying a reduction in proportion of the undissociated holomer. The released By 
components would presumably be available to interact with effectors such as adenylyl
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cyclase. However, without more detailed investigation we cannot conclude to what 
extent, if any, these various mechanisms contribute to insulin's sensitising effect.
In addition to its positive effect on maximal stimulatory responses observed for 
all three agonists the increased activation of adenylyl cyclase by lower concentrations of 
PGEi and GppNHp after insulin exposure suggested an additional action of insulin at a 
more proximal site in the system. An alteration in the number or affinity of prostanoid 
receptors could explain the change in PGEi response. Indeed it would be reasonable to 
suggest that insulin might positively affect receptor expression given its effects on 
differentiation noted in other cell types and sensitisation to PGEi action in platelets 
(Kahn and Sinha, 1990). An increase in PGEi binding affinity however, would not 
explain the higher affinity response to GppNHp whose activation of cyclase is 
independent of the receptor. This response suggested a positive effect of insulin at the 
level of the G-protein. This possibility is considered below.
The reduction in cholera toxin-labelling of Gs-a after insulin exposure may 
suggest a decrease in the proportion of dissociated, GTP-bound Gs-a as this is the 
form which is the substrate for cholera toxin (Northup et al., 1980). As discussed in 
section 1.4.2 insulin has been proposed to influence guanine nucleotide binding by a 
functional interaction with the G-protein system. Whilst insulin by means of such an 
interaction with Gs could potentially influence the amount of GTP binding and thence 
the dissociation equilibrium of Gs, we would have expected to observe a decrease 
rather than an increase in adenylyl cyclase activity, as dissociated Gs-a is the active 
form. If insulin is indeed having a negative effect at this proximal site, its influence 
must be outweighed by the considerable stimulatory effect of the hormone at the 
catalytic subunit of adenylyl cyclase. This explanation for the reduction in cholera toxin 
labelling of Gs-a does not however explain the observed decrease in Ko.5 for GppNHp 
which implies a positive rather than a negative effect of insulin on agonist activation of
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cyclase. An alternative explanation to accommodate this finding is that the reduction in 
cholera toxin labelling may not reflect any influence of insulin on the Gs dissociation 
equilibrium, but rather a covalent modification or conformational change in Gs in such a 
manner as to enhance the activity of the protein favouring GppNHp stimulation of the 
system and additionally rendering it less susceptible to toxin action.
Gi-a was also a poorer substrate for pertussis toxin after insulin exposure 
though we cannot say to what extent the reduced labelling was due to functional 
changes in specific polypeptides as Gi-2a and Gi-3a, the two Gi subtypes expressed 
in P9 cells are not resolved by the gel system used. If the dissociation state of the 
G-protein is responsible for the change in labelling (Rothenberg and Kahn, 1988) this 
implies, as mentioned above, that there is less Gi in the trimeric (inactive) form, as the 
holomer is the toxin substrate. This is certainly consistent with the higher adenylyl 
cyclase activity after insulin exposure though it appears from the data presented in 
Chapter 3, that a reduction in Gi input would have little consequence for stimulatory 
cyclase functioning in P9 cells. Sensitisation to stimulatory agonists after insulin 
exposure of P9 cells cannot then, as has been proposed for hepatocytes from diabetic 
animals (Bushfield et al., 1990b), be due to removal of tonic Gi input into the catalytic 
subunit of adenylyl cyclase. As discussed above for Gs, the reduction in toxin labelling 
of Gi may be caused by mechanisms other than an alteration in the dissociation 
equilibrium of the G-protein.
Whatever the mechanism of insulin's action in influencing toxin labelling, it 
speaks for a functional interaction between insulin signalling and the G-protein system 
either directly, as discussed in section 1.5 through interaction with the insulin or IGF-1 
receptor, or indirectly, as a consequence of increased cell growth. One could speculate 
that a similar mechanism may underlie the impairment of toxin labelling observed in 
diabetic states (section 1.5.2.1). This could be further investigated by carrying out
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studies like those of Rothenberg and Kahn (1988), to determine whether insulin can 
directly effect toxin labelling in isolated P9 cell plasma membranes. It seems likely that 
this reduction in toxin labelling might have consequences for cyclase functioning and be 
at least partly responsible for the functional changes observed here in plasma membrane 
adenylyl cyclase activity.
From the measurement of pH]-Thymidine uptake it is clear that both insulin 
and IGF-1 are at best poor mitogens in P9 cells. This means that that increased plasma 
membrane adenylyl cyclase activity rather than cell growth must be responsible for 
most of insulin's low affinity effect in enhancing whole cell cAMP responses to 
stimulatory agonists. P9 cells must express at least the IGF-1 receptor, as IGF-1 has 
less than 1% of the potency of insulin at the insulin receptor (Baxter and Williams, 
1983) but gives a similar response to insulin here. Insulin is recognised to exert low 
affinity effects on cell growth through the IGF-1 receptor (Florini et al., 1991) and this 
is in line with its ability to cause maximal growth stimulation at supraphysiological 
concentrations, between 20nM and l|iM. Insulin then may be acting here at low affinity 
through the IGF-1 receptor but could in addition be acting through its own receptor. In 
a few cases insulin has been reported to increase pH]-Thymidine incorporation into 
DNA by acting through the high affinity insulin receptor (Koontz and Iwahashi, 1981, 
Massague et al., 1982, Taub et al., 1987). However, this was clearly not the case in P9 
cells where supraphysiological concentrations were required for even a small 
stimulation of pH]-Thymidine incorporation. The situation in P9 cells then, resembles 
that in fibroblasts, where insulin under normal conditions is a weak mitogen (Burgering 
etal., 1991), as fibroblasts contain a relatively small number of insulin receptors as 
compared to receptors for IGF-1 (Rechler and Nissley, 1985). Evidence of higher 
affinity insulin responsiveness and therefore expression of insulin receptors in P9 cells 
is given in Chapter 5.
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Given the low affinity nature of this insulin response, it may represent a 
response signalling growth through the IGF-1 receptor. An important factor to bear in 
mind here is that all the cells used for experiment were serum-starved in order to 
remove the influence of other growth factors and quiesce the cells prior to agonist 
stimulation. Control cells exposed to serum-free medium alone would already be 
suffering from an absence of growth factors for 16 hours at the time of experiment 
whilst the insulin-exposed cells would be facing a more normal situation, viz. the 
presence of a growth factor. It might be more appropriate then to consider these data in 
terms of response down-regulation on serum deprivation, rather than up-regulation on 
growth factor exposure. Adenylyl cyclase and receptor expression may depend on the 
presence of serum. Indeed, serum growth factors are probably required for maintaining 
second messenger system integrity and integrity of the cells in general as the cells fail to 
adhere or grow if subcultured into serum-free medium. Insulin then, may exert a tonic 
control on cyclase expression (whose effect is noted only by its absence) rather than a 
positive effect in its own right. One could speculate that the removal of this tonic 
control, whether artificially as here or in disease states, may cause defects to arise in the 
second messenger system. From this arguement it is clear that it is difficult to decide in 
what state, with respect to serum exposure, the cells are best studied.
This suggestion is in line with the findings of Johnson et al. (1990), who noted 
that exposuring human astrocytoma (132INI) cells to serum caused sensitisation of 
cAMP accumulation in response to the agonists forskolin, isoproterenol and PGEi. The 
sensitisation was dose-dependent, reversible on serum removal and resulted from an 
increase in the maximum, rather than from a change in potency in the agonists. The 
authors were able to demonstrate the effect on membranes derived from the cells and 
concluded that it was due to an increase in the activity of the adenylyl cyclase catalytic 
subunit. Interestingly, the PK-C inhibitor staurosporine inhibited this serum-induced 
sensitisation and down-regulation of PK-C abolished the ability of serum to
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subsequently induce sensitisation. The authors were however, unable to identify the 
serum component reponsible for sensitisation. Serum-induced sensitisation of adenylyl 
cyclase has been noted in a number of other cell types including human lymphoma 
cells, rat osteosarcoma cells and rat glioma cells (Toews and Ameson-Rotert, 1990). A 
component of blood plasma increased hormone stimulated adenylyl cyclase activity in 
human mononuclear leucocytes (Motulsky et al., 1987). This phenomenon may 
therefore be widespread and it will be interesting to discover whether, in line with the 
work done here on P9 cells, insulin turns out to be a factor responsible for 
sensitisation.
From this work it is clear that large changes in adenylyl cyclase signalling can 
occur after insulin exposure and in the absence of any change in G-protein expression. 
This is interesting in view of the many G-protein defects observed in animal models of 
diabetes where there is either a lack of insulin or insulin resistance and insulin itself 
presumably has some influence on G-protein expression and function. It is likely that 
insulin itself cannot influence genes for these proteins in P9 cells. Presumably their 
levels are inextricably linked to the level of cell differentiation which is uninfluenced by 
insulin, as discussed in Chapter 3.
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Table 4.1 Agonist-stimulated adenvlvl cvclase activity in 
plasma membranes from P9 cells exposed to 
insulin C0.5uM. 16hours).
Confluent P9 cells were exposed to serum-free medium alone (-ins) or 
containing insulin, 0.5|iM (+ins). After 16 hours medium was removed and cells 
harvested as described in section 2.6. Plasma membranes were prepared and 
assayed for agonist-stimulated adenylyl cyclase activity in order to determine 
maximum responses and Ko.5 values. Stimulation parameters for the agonists 
were obtained from the dose response curves shown in Figs. 4.1 to 4.3. In each 
case results are mean+/-SEM for triplicate observations obtained in one 
experiment Similar results were obtained in another experiment in each case.
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Table 4.1
Agonist
PGEi
GppNHp
Forskolin
-ins
Maximum
stimulation
(pmols/mg/min)
129+/-29 
97+/-4 
153+/-29
K0.5
(M)
9.4 x 10-6
2.2 x 10-6
2.4 x 10-5
+ins
Maximum
stimulation
(pmols/mg/min)
276+/-44 
143+/-7.2 
375+/-11
K0.5
(M)
5.4 x 10-6
1.2 x 10-6
2.4 x 10-5
Table 4,2 Quantitative comparison o f toxin labelling and 
G-protein levels in plasma membranes from P9 
cells exposed to insulin (0.5iiM. 16 hours)
P9 cells were exposed to serum-freee medium alone or containing insulin, 
0.5|iM for 16 hours, harvested and membranes prepared. Membranes were then 
ADP-ribosylated as described in section 2.12., using pertussis toxin and cholera 
toxin. Proteins were resolved using SDS PAGE and gels autoradiographed as 
described in section 2.10. G-protein levels were compared in these membranes as 
described in the legend to Fig. 4.11. All blots and autoradiographs were scanned 
densitometrically as described in section 2.10 and results from Figs 4.10 and 
4.11 presented as the percentage alteration in level of the signal after insulin 
exposure. Data are mean+/-SEM for three separate experiments.
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Table 4.2
Insulin-induced change in 
toxin labelling (%)
Gi-a
G s-a  (45kDa) 
G s-a  (42kDa)
Gi-2a
Gi-3a
G s-a  (45kDa) 
G s-a  (42kDa) 
GB
-73+/-14
-56+/-9
-58+/-7
Insulin-induced change in 
G-protein level (%)
+ 18+ / - 15 
+29+/-26 
+10+/-1 
-6+1- 29 
- 6+ 1-6
Fig, 4,1 Effect of increasing concentrations of PGEi on 
adenylyl cvclase activity in plasma membranes
from control P9 cells and cells exposed to 
insulin (0.5uM. 16 hours).
Confluent P9 cells were exposed to serum-free medium alone (open 
circles) or containing insulin, 0.5pM (closed circles). After 16 hours, medium 
was removed,the monolayer washed with buffer and cells harvested as described 
in section 2.6. Plasma membranes were prepared and assayed for agonist 
stimulated adenylyl cyclase activity in the presence of increasing concentrations of 
PGEi as detailed in section 2.13. Stimulation parameters are given in Table 4.1. 
Results are mean+/-SEM for triplicate observations obtained in one experiment 
Similar results were obtained in another experiment.
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Fig. 4.2 Effect of increasing concentrations of GppNHp
on adenvlvl cvclase activity in plasma 
membranes from control P9 cells and cells 
exposed to insulin f0.5uM . 16 hours).
Plasma membranes from control P9 cells (open circles) and P9 cells 
exposed to insulin (0.5jiM, 16 hours) (closed circles) as in the legend to Fig. 4.1 
were assayed for adenylyl cyclase activity in the presence of increasing 
concentrations of GppNHp. Stimulation parameters are given in Table 4.1. 
Results are mean+/-SEM for triplicate observations obtained in one experiment 
Similar results were obtained in another experiment.
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Fig, 4,3 Effect of increasing concentrations of forskolin
on adenvlvl cvclase activity in plasma 
membranes f rom control P9 cells and cells 
exposed to insulin (0.5uM . 16 hours).
Plasma membranes from control P9 cells (open circles) and cells exposed 
to insulin (0.5pM, 16 hours) (closed circles) as in the legend to Fig. 4.1 were 
assayed for adenylyl cyclase activity in the presence of increasing concentrations 
of forskolin. Stimulation parameters are given in Table 4.1. Results are mean +/- 
SEM for triplicate observations obtained in one experiment Similar results were 
obtained in another experiment
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Fig, 4.4 l im e  course for change in forsKolin-stimulated
plasma membrane adenvlvl cvciase activity  
after addition o f insulin (0.5uM) to P9 cells.
Confluent P9 cells were exposed to insulin, 0.5|iM as described in the 
legend to Fig. 4.3. and harvested at intervals. Membranes were then prepared 
and assayed for adenylyl cyclase activity in the presence of forskolin (1(HM) as 
described in section 2.13. Results are mean+/-SEM for triplicate observations 
obtained in one experiment Similar results were obtained in another experiment
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Figure 4.4
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Figt 4,5 Uptake o f r^Hl-Thvmidine bv P9 cells in
response to insulin and IGF-1.
Confluent P9 cells were exposed to serum-free medium containing 
pH]-Thymidine and increasing concentrations of insulin (open circles) or IGF-1 
(closed circles) as described in section 2.16. Results are mean+/-SEM for 
triplicate observations obtained in one experiment. Insulin, at 0.5|iM caused a 
maximum increase in uptake of 18+/-1% (CV) with a Koj value of 2.3 x 10-8M. 
IGF-1, at 10_7M gave a maximum increase in uptake of 15+/-1% (CV) with a 
Ko.5 value of 2.0 x 10_8M.
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Fig.4-6 Effect o f increasing concentrations o f PG Ei on
P9 cell intracellular cAM P after exposure to 
insulin (Q,5uMi 16 lwurs)>
P9 cells were exposed to serum-free medium alone (open circles) or 
containing insulin 0.5pM (closed circles). After 16 hours, cells were challenged 
for 2 minutes with increasing concentrations of PGEi and cAMP extracted and 
assayed as described in section 2.14. Maximum control response (at 5 x 10~5M) 
was 21+/-1 pmols/50|il extract with a Ko.5 for PGEi of 1.35 x 10_5M. Maximum 
response in insulin exposed cells (at 2 x 10_5M) was 25+/-3 with a Ko.5 for PGEi 
of 8.2 x 10'6M. Results are mean+/-SEM for triplicate observations obtained in 
one experiment. Similar results were obtained in another experiment
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Figure 4.6
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Fig. 4.7 Effect of increasing concentrations of insulin
(16 hours exposure) on PGEi-elevated  
intracellular cAMP in P9 cells.
Confluent P9 cells were incubated with serum-free medium containing 
increasing concentrations of insulin (0-10*6M). After 16 hours, cells were 
challenged for 2 minutes with PGEi (10'5M) and cAMP extracted and assayed as 
described in section 2.14. Enhancement of the PGEi response by 0.5pM insulin 
was 1.95+/-0.15 fold, with a Ko.5 value for insulin of 1.35 x 10*8M. Results are 
mean+/-SEM for triplicate observations performed in one experiment Similar 
results were obtained in three other experiments.
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Fig. 4.8 Effect of increasing concentrations of insulin
(16 hours exposure) on forskolin-elevated 
intracellular cAMP in P9 cells.
Confluent P9 cells were incubated with serum-free medium containing 
increasing concentrations of insulin (0-10*6M). After 16 hours, cells were 
challenged for 2 minutes with forskolin (10'5M) and cAMP extracted and assayed 
as described in section 2.14. Enhancement of the forskolin response by 0.5jiM 
insulin was 1.70+/-0.13 fold, with a Ko.5 value for insulin of 9.2 x 10'8M. 
Results are mean+/-SEM for triplicate observations obtained in one experiment. 
Similar results were obtained three other experiments.
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Fit?. 4.9 Effect of cvcloheximide pre-treatm ent on
insulin’s modulation o f PG E i- and forskolin- 
elevated intracellular cAM P in P9 cells.
P9 cells were incubated with serum-free medium alone (column 1) or
out"
containing cycloheximide, l}iM (column 2). Cells were incubated with (hatched 
bars) or with (black bars) insulin, 0.5}iM. After 16 hours, cells were 
challenged with PGEi (105M for 2 minutes) in Fig. 4.9a and forskolin (10-5M 
for 2 minutes) in Fig. 4.9b. Cyclic AMP was extracted and assayed as described 
in section 2.14. Data are expressed in each case as a percentage of the value 
without insulin present. Results are mean+/-SEM for triplicate observations 
obtained in one experiment in each case. Similar results were obtained in two 
other experiments in the case of PGEi, and one other experiment in the case of 
forskolin.
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Fig. 4.10 Toxin-catalysed ADP-ribosvlation o f
G-proteins in plasma membranes from P9 cells 
exposed to insulin (0.5uM. 16 hours).
P9 cells were exposed to serum-free medium alone (lane 2), or containing 
insulin, 0.5pM (lane 3) for 16 hours, harvested and plasma membranes prepared 
as in Figs. 4.1 to 4.3. Membranes were then ADP-ribosylated as described in 
section 2.12 using pertussis toxin (panel A) and cholera toxin (panel B). 
Membranes were also subjected to the same treatment in the absence of toxins 
(lane 1). Proteins were resolved and gels stained, dried, autoradiographed and 
scanned as described in section 2.10. Densitometric data are shown in Table 4.2. 
Results shown are from one experiment Similar results were obtained in two 
other experiments.
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Fig. 4.11 G-protein levels in plasma membranes from P9
cells exposed to insulin (0.5uM. 16 hours),
Control P9 cells (lane 1) and cells exposed to insulin, 0.5|iM for 16 hours 
(lane 2) were harvested and membranes prepared as described in Figure 4.1. 
Samples of membrane protein (lOOpg) were resolved, transferred to 
nitrocellulose paper and probed with antisera as described in section 2.11. The 
antisera used were 1432 (panel A), I3C (panel B), CS1 (panel C) and BN3 (panel 
D). Blots were scanned densitometrically and and results presented in Table 4.2. 
Data shown are from one experiment Similar results were obtained in two other 
experiments.
152
Figure 4.11
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.ChaptenS
High affinity effects o f insulin on adenvlvl cvclase 
signalling in P9. cells
5.1 Introduction
In the previous chapter we investigated low affinity effects of insulin on 
adenylyl cyclase signalling in P9 cells. These effects, because of the high 
concentrations of hormone required to achieve them, are probably more relevant to 
growth factor action on the cells than events taking place through insulin receptor 
activation. If the P9 line is to be used as a model system for studying insulin action we 
need evidence of higher affinity insulin responsiveness. Such information may provide 
insight into the role of the high affinity insulin receptor in cyclase regulation. 
Furthermore, with regard to the data presented in Chapter 3 it would be interesting to 
know to what extent, if any, insulin responsiveness in the cells is comparable with that 
in rat hepatocytes. Here we investigated the effect of insulin (InM) on agonist-elevated 
intact cell cAMP, plasma membrane adenylyl cyclase activity and G-protein levels in P9
|
i cells.
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5.2 Results
On examinining the effects of insulin exposure on agonist-elevated intracellular 
cAMP, it was noted that exposure of cells to lower concentrations of insulin for 16 
hours resulted in an impairment of the response to PGEi (Fig. 5.1) and elevated the 
response to forskolin (Fig. 5.2). Both effects of insulin on these responses were still 
observed in the presence of IB MX and with cycloheximide pre-treatment. The 
remaining experiments in this chapter were devoted to investigating these high affinity 
actions of insulin.
Incubation of P9 cells with insulin (InM) in the same manner as before, caused 
a shift to the right of the PGEi dose response curve and, in addition, reduced the 
maximum agonist response (Fig. 5.3). No such shift in dose-dependence was observed 
when the agonist forskolin was used to elevate intracellular cAMP (Fig. 5.4). 
Pre-treatment of P9 cells with pertussis toxin had no effect on insulin's ability to impair 
the PGEi response (Fig. 5.5).
An investigation of the time course for the effect revealed that in insulin-treated 
cells, as opposed to cells treated with serum-free medium alone, there was a biphasic 
time course for insulin's action on the PGEi response. Insulin acutely enhanced the 
response which reached a maximum after 22 minutes and thereafter declined reaching a 
minimum after 10 hours (Fig. 5.6). The acute effect of insulin on the PGEI response in 
P9 cells is discussed later in this section.
In order to further examine insulin's action on the PGEi response, it was 
decided to observe whether the effect could be demonstrated on plasma membranes 
from insulin-exposed cells, as the stability or otherwise of the effect could provide 
clues as to its cause (Fig. 5.7 and Table 5.1). At high GTP concentrations, the PGEi
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response was on average smaller in plasma membranes from insulin-exposed cells. 
There was no difference in the magnitude of the inhibitory phase, whether or not cells 
had been exposed to insulin. (PGEi was used here in addition to GTP in order to 
maximise the responses and give smaller percentage errors, so that the respective 
adenylyl cyclase activities could be compared more reliably). Inhibition by GppNHp 
however, was not observed in plasma membranes from insulin-exposed cells. For 
example, in a typical experiment, stimulation of adenylyl cyclase by GppNHp (1(HM) 
in membranes from insulin-exposed cells gave an activity of 381+/-7 pmols/mg 
protein/min (mean+/-SEM for triplicate observations) and an activity of 346+/-34 
pmols/mg protein/min in control membranes. We must exercise caution in comparing 
adenylyl activities between different membrane preparations, especially when seeking a 
relatively small impairment of the response, as we are here. Nevertheless, it does 
appear that that in the presence of high GTP concentrations insulin's inhibition is stable 
and can be demonsted in plasma membranes from treated cells.
The ability of a glucagon/forskolin combination to elevate P9 cell intracellular 
cAMP over the level achieved by forskolin alone was slightly by exposure of cells to 
insulin (InM), but this reduction in response was not statistically significant (Fig. 
5.12a).
Insulin's acute enhancement of the PGEi response was found to be 
dose-dependent for insulin (Fig. 5.8) and observed both in the presence and absence of 
IB MX. In contrast to the inhibition produced by the 16 hour insulin exposure, this 
acute effect was not seen on plasma membranes made from insulin-treated cells (Fig. 
5.9 and Table 5.1), nor was there any enhancement of PGEi-stimulated plasma 
membrane adenylyl cyclase activity observed when membranes were challenged 
directly with PGEi together with insulin. (Fig. 5.10 and Table 5.1). Membranes were 
prepared in the presence of phosphatase inhibitors.
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Experiments designed to examine whether insulin was also able to affect acutely 
intracellular cAMP elevated by forskolin, yielded at best a response which was small 
compared to the effect of insulin on the PGEi response and dose dependence could not 
be established (Fig. 5.11).
Whilst insulin (InM) acutely and significantly enhanced the response to PGEi 
in intact P9 cells, it had no effect on the glucagon response (Fig. 5.12b). Insulin, at a 
concentration of l|iM, slightly enhanced the response to forskolin alone and abolished 
any further response on addition of glucagon to the cells (Fig. 5.12c).
On exposure of P9 cells to insulin (InM), there was no significant change in 
toxin labelling of Gs-a or Gi-a to suggest any functional change in G-proteins as 
observed when using high concentrations of insulin (Fig. 5.13 and Table 5.2). Nor 
was there any alteration in plasma membrane levels of any of the G-protein a  subunits 
or G-protein 6 subunit to account for insulin's action on the response (Fig. 5.14 and 
Table 5.2).
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5.3 Discussion
In this chapter the action of insulin to modulate agonist-stimulated adenylyl 
cyclase activity in P9 cells was examined. The data indicated that insulin, at a 
concentration of InM, impaired the ability of PGEi to elevate acutely intracellular 
c AMP over a period of hours. This effect is unlikely to be due to activation of cAMP 
phosphodiesterase activity as pre-treatment of cells with IBMX failed to block insulin’s 
action. Given that inhibition was only observed on the response to PGEi and not to 
forskolin this action of insulin was clearly exerted at a site in the signalling system 
proximal to the catalytic subunit of adenylyl cyclase and occurred at sufficiently low 
concentrations to suggest that it was mediated through high affinity insulin receptors.
Protein synthesis was not involved in this action as the effect was not blocked 
by cycloheximide pre-treatment. Indeed, the percentage inhibition was larger in the 
presence of cycloheximide. This is possibly because in the absence of cycloheximide 
insulin was having a small stimulatory effect on cell growth and adenylyl cyclase 
expression which was partially masking its functional impairment of the response to 
PGEi. On removing any effect of the hormone on protein synthesis, only its functional 
influence on the system remains intact.
The inhibition, although occurring at the level of the membrane was not brought 
about by any change in G-protein levels. Nor did it appear to be mediated by Gi on 
adenylyl cyclase as pre-incubation of cells with pertussis toxin at a concentration 
adequate to ADP-ribosylate most of the Gi present in the cells, had no effect on 
insulin's impairment of the PGEi response. The inability of insulin’s effect to be 
abolished by pertussis toxin pre-treatment in P9 cells distinguishes it from insulin's 
effect in hepatocytes (Heyworth et al., 1986) and excludes the involvement of an 
established or insulin-specific toxin substrate in insulin's action. That the magnitude
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of the inhibitory phase of the GTP dose response curve was unaltered in membranes 
from insulin-exposed cells or in the acute presence of insulin, is further evidence that 
insulin’s effect was unrelated to Gi function. The situation in P9 cells is different from 
that in rat hepatocyte plasma membranes where a dose-dependent inhibition of adenylyl 
cyclase activity by insulin was demonstrated in the presence of GTP (Heyworth and 
Houslay, 1983).
The site of insulin's action was at the level of the membrane and independent of 
protein synthesis, G-protein levels, Gi or cAMP phosphodiesterase activation. How 
then, did insulin bring about this effect ? The dependence of the effect on PGEi 
concentration and its inability to be overcome by high concentrations of the agonist 
strongly suggest that the site of insulin's action was at the prostanoid receptor, either by 
a change in receptor affinity or by down-regulating the number of cell surface 
receptors. This explanation is compatible with the long time course observed for the 
effect which implies an adaptive change of the cells such as a change in protein 
distribution rather than a functional effect such as phosphorylation which we would 
expect to be rapid.
It was possible to demonstrate that insulin's inhibition of the PGEi response 
was retained in membranes from insulin-exposed cells, providing evidence in favour of 
a stable reduction in receptor number or affinity. The attenuation of PGEi response was 
observed on membranes and was apparently GTP dependent. In rat hepatocytes, GTP 
dependence for insulin's inhibition of cyclase was proposed to suggest the existence of 
an insulin-specific G-protein (Heyworth and Houslay, 1983). However, the authors 
quoted a Ko.5 for the effect of 3|iM GTP, whereas here a significant inhibition in the 
presence of GTP was observed only at 1(HM with no effect at low concentrations such 
that a Ki value could not be calculated accurately. A possible explanation here is that 
saturating GTP is required to achieve an optimal agonist response thereby making
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apparent the inhibition, itself exerted at a more proximal site in the signalling system.
An action of insulin to reduce the number of cell surface prostanoid receptors 
could be achieved either by reduced synthesis or accelerated degradation of the receptor 
in response to insulin or sequestration of the receptor at a subcellular site. Certainly 
there is extensive literature on insulin's ability to affect expression of G-protein-coupled 
receptors in cells. An impairment of o^-adrenergic receptor number for example, in 
response to insulin in the nM range has been observed in the HT29 (human 
adenocarcinoma) cell line (Devedjian et al., 1991). As cycloheximide treament had no 
influence on insulin's action, the authors proposed a decrease in transcription of the 
receptor as underlying this particular effect.
Interestingly, exposure to InM insulin, as with exposure to the high 
concentration, caused no change in G-protein levels in P9 cells. Agonist-induced 
changes in G-protein expression are largely restricted to heterologous desensitisation of 
agonists acting directly through G-protein linked receptors. In studies on receptor 
down-regulation, after prolonged exposure to PGEi in NG 108-15 cells, the prostanoid 
receptor was shown to co-downregulate with Gs-a, indicating that the two processes 
were co-ordinated (Adie et al.t 1992). Clearly insulin, if acting in P9 cells by 
down-regulating the prostanoid receptor, is capable of doing so independently of any 
action on Gs, as G-protein levels in P9 cells were not altered by any form of insulin 
exposure.
No evidence was provided for any change in G-protein function as contributing 
to insulin's high affinity effect on the PGEi response. GppNHp stimulation of adenylyl 
cyclase unlike the receptor-mediated response was not observed in membranes, 
demonstrating that insulin's effect on the PGEi response occurred proximal to coupling 
with Gs. However, we have only examined Gs function in membranes and not in the
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intact cell. Although it remains possible that prolonged insulin exposure could influence 
the degree of GTP binding to G-proteins and thereby influence coupling, such an 
influence would not necessarily survive the process of membrane preparation, in which 
the hormone and endogenous GTP are removed. Thus, we cannot exclude an additional 
influence by insulin on coupling between the receptor and Gs, as contributing to 
insulin's effect.
That insulin, over the same time period as the experiments with PGEi, appears 
to have little effect if any on glucagon responsiveness, suggests that this action is 
receptor-specific for the PGEi receptor in P9 cells. We must be cautious in our 
interpretation however, given the small size of the glucagon response in P9 cells and 
that its demonstration requires the presence of the exogenous agonist forskolin. The 
small size of the glucagon response over that of forskolin, means that a reduction in its 
magnitude, in order to be considered statistically significant, would require abolition of 
the entire response (given the size of the experimental errors arising from the cAMP 
assay and elsewhere in the experiment). Clearly, if the situation with the glucagon 
receptor parallels that of the PGEi receptor, abolition of the response would not occur, 
as the latter response was only impaired by some 25% under the same conditions. It 
may well be that insulin is having a similar effect on both stimulatory responses but that 
the limitations of the methodology make it impossible to conclude this with certainty.
Another modulating influence of insulin to consider is the possibility of the 
insulin receptor phosphorylating and thereby reducing the affinity of the prostanoid 
receptor. Phosphorylation of the receptor or any other component of the adenylyl 
cyclase signalling system could potentially occur either directly, as a result of tyrosine 
kinase activation, or indirectly following PK-C activation serving either to uncouple it 
from Gs or as a signal for its internalisation. PK-C is known to be activated in certain 
cell types in response to insulin which can generate diacylglycerol by hydrolysis of
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inositol glycolipids (Saltiel and Cuatrecasas, 1986) and there is evidence for activated 
PK-C influencing adenylyl cyclase activity at all levels of the second messenger system 
(Houslay, 1991b). However, phosphorylation events in response to insulin are 
generally rapid ie. within minutes (Knutson, 1991), whereas this effect of insulin in P9 
cells was only apparent after hours. Furthermore, lipid signalling has not been 
examined in P9 cells so it is not known whether insulin is capable of generating such a 
second messenger and thereby activating PK-C. Gi phosphorylation cannot be 
implicated as Gi appears to have little if any input into cyclase functioning in P9 cells 
and its inactivation has no influence on insulin's action. The only other site proximal to 
the adenylyl cyclase catalytic subunit which is a potential site of regulation is Gs. 
However, Gs-a is not known to be phosphorylated in response to insulin, either by the 
purified receptor tyrosine kinase (Krupinski et a i, 1988) or by insulin exposure of 
intact hepatocytes (Houslay, 1991b).
The absence of any impairment of the forskolin response by 10'9M insulin was 
shown not to be a consequence of the concentration of forskolin used and suggested 
insulin's site of action on the PGEi response to be proximal to the adenylyl cyclase 
catalytic subunit. The ability of lower concentrations of insulin, after a 16 hour period, 
to enhance the response to forskolin, suggested an insulin receptor-mediated effect on 
the catalytic subunit of adenylyl cyclase. It is more difficult to explain the mechanism of 
this high affinity effect of insulin on forskolin responsiveness in the cells, as we have 
less information regarding the effect. Like insulin's effect on the response to PGEi it 
was not dependent on protein synthesis or phosphodiesterase activity. However, the 
lower concentrations of insulin required for the effect on the forskolin response suggest 
a different mode of action from that on the PGEi response. A physical effect such as 
insulin's high affinity action on membrane fluidity could be implicated here, enhancing 
the enzymic activity of adenylyl cyclase. The functioning of adenylyl cyclase signalling 
system has been shown elsewhere to be influenced by membrane fluidity, for example
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the 6-adrenergic signalling system (Salesse et al., 1982) and glucagon-stimulated 
adenylyl cyclase in rat liver (Dipple and Houslay, 1978).
Unlike exposure to 0.5|iM insulin, exposure to InM insulin had little effect on 
toxin labelling of G-protein a  subunits. Furthermore, if insulin’s impairment of the 
PGEi response were mediated through an alteration in G-protein activity ie. a change in 
the subunit dissociation equilibrium, we might have expected to find an alteration in 
labelling for the reasons discussed in Chapter 4. That there is no change in labelling 
lends further credence to the view that insulin's high affinity action is at a site distinct 
from Gs.
Insulin’s effect of acutely enhancing the ability of PGEi to elevate intracellular 
P9 cell cAMP levels was clearly also exerted at the level of the membrane. Various 
mechanisms can be proposed for this action. These include recruitment of PGEi 
receptors from a subcellular site, a change in physical properties of the plasma 
membrane, production of an intracellular second messenger or interaction with a 
G-protein in a manner enhancing coupling. The rapidity of insulin's acute effect on the 
PGEi response favours a functional interaction exerted by insulin at the level of the 
plasma membrane and makes receptor synthesis or synthesis of an associated protein 
unlikely causes of the enhanced response. That the effect is not stable on membrane 
preparation, nor repeated by challenging isolated membranes with the two agonists 
makes receptor recruitment unlikely, since insulin's ability to enhance acutely platelet 
PGEi-stimulated adenylyl cyclase activity by this mechanism was still observed on 
membranes from insulin challenged platelets (Kahn and Sinha, 1990). However, one 
could still propose that receptor recruitment occurs but that the time period after insulin 
removal and before membrane preparation (ie. during harvesting and washing of the 
cells) is adequate to allow reversal of the effect by receptor internalisation. This theory 
is appealing, as it means that insulin would be having both its high affinity effects at the
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same site ie. an initial acute enhancement by increasing plasma membrane receptor 
number and an ensuing desensitisation of the response by reduction in receptor 
number.
The acute action of insulin on the glucagon response was different from its 
action on the response to PGEi. This response specificity for the effect of l|iM insulin 
implies different effects on the prostanoid and glucagon receptors, stimulatory and 
inhibitory respectively in which intact cell integrity is required either to provide a 
soluble protein substrate or components needed for mediator generation.
Although there was no change in plasma membrane GTP-stimulated adenylyl 
cyclase after insulin exposure suggesting no influence of insulin on coupling to Gs, we 
would as above, not necessarily expect enhanced coupling to be a stable phenomenon. 
Similarly, when isolated membranes were challenged with both PGEi and GTP, no 
enhancement by insulin was observed, regardless of the GTP concentration. Clearly, 
isolated membranes do not possess all the components required for this effect of 
insulin. The possibility of a soluble mediator being involved in this action of insulin 
should be considered as such a mediator could easily be removed during the process of 
membrane preparation. Such a mediator may either not be generated by isolated 
membranes or be unable to exert its effects in this situation because of removal of for 
example, a soluble protein kinase required for its action.
On speculating why insulin could not produce any effect in isolated membranes 
in the adenylyl cyclase assay it should also be noted that a high concentration of cAMP 
was present in the assay to act as a p 2P]-cAMP ’trap'. It has been suggested that 
cAMP acting via PK-A can cause phosphorylation and inactivation of the insulin 
receptor (Tanti et al., 1987). This could potentially account for our inability to observe 
any effect of insulin when assaying cyclase activity in isolated membranes.
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Any effect of insulin on signalling is likely to be produced downstream of 
receptor tyrosine kinase activation. Phoshorylation responses to insulin are generally 
stable to cell extraction in the presence of phosphatase inhibitors (Sale and Smith, 
1989). As phosphatase inhibitors were present during cell breakage, phosphorylation 
of a protein dephosphorylated during the membrane preparation can be excluded as the 
mechanism of insulin's action. However, soluble protein substrates would clearly be 
lost during membrane preparation and clearly be unable to exert any effect on adenylyl 
cyclase during the assay. This seems the most likely explanation for the inability of 
insulin to directly affect membrane responses. In addition, phosphorylation in response 
to insulin is rapid and would precede any effect of insulin on mediator generation or 
receptor distribution. Whatever the mechanism of insulin's action here the integrity of 
the intact cell is clearly required.
Table 5.1 Parameters for GTP/PGEi-stimulated adenvlvl 
cvclase activity in P9 cell plasma membranes.
P9 cells were exposed to serum-free medium alone (-ins) or containing 
insulin (+ins) InM for 16 hours (a) or InM for 10 minutes (b), then membranes 
prepared and assayed for adenylyl cyclase activity in the presence of increasing 
concentrations of GTP (0-10-3M) and a constant concentration of PGEi (10-5M). 
Dose response curves are shown in Figs. 5.7 and 5.9 respectively. In (c) plasma 
membranes from untreated cells were assayed similarly but in the absence (-ins) 
and presence (+ins) of insulin, ljxM. The dose response curve is shown in Fig. 
5.10. Maximal stimulation (mean+/-SEM for triplicate observations in one 
experiment) and Ko.5 values were obtained. Percentage inhibition by 10 3M GTP 
was calculated and given as mean+/-%CV for triplicate observations in one 
experiment. Similar results were obtained in two other experiments.
Table 5.1
(a) -ins
+ins (InM, 16h)
(b) -ins
-i-ins (InM, 10')
(c) -ins
+ins (lfiM, 10')
Maximum
stimulation
(pmols/mg/min)
759+/-29 
632+/-18
596+/-4 
575+/-16
621+/-4 
569+/-10
K0.5
(M)
3.5 x 10-7
7.0 x 10-8
2.2 x 10-7 
2.9 x 10-7
6.6 x 10-7
4.0 x 10-7
% inhibition 
by 103M GTP
46+/-3.1 
47+/-5.0
36+/-4.2
36+/-4.0
30+/-2.0
38+/-2.2
Table 5.2 Quantitative comparison of toxin labelling and
G-protein levels in plasma membranes after 
exposure of P9 cells to insulin (InM . 16hours)
P9 cells were exposed for 16 hours to serum-free medium alone or 
containing insulin, InM, harvested and membranes subjected to toxin labelling 
and immunoblotting as described in the legends to Figs. 5.12 and 5.13 
respectively. Bands from three experiments in each case were scanned and the 
insulin-induced alteration given as a percentage. All data are mean+/-SEM.
Table 5.2
Polypeptide
Gi-OC
Gs-a (45kDa) 
Gs-a (42kDa)
Gi-2ot
G i-3a
Gs-a (45kDa) 
Gs-a (42kDa) 
GB
Insulin-induced change in 
toxin labelling
+13+/-2.6
-19+/-11
-13+/-13
Insulin-induced change in 
G-protein level
+12+/-9.5
+13+/-28
+ 11+ /-8.0
-10+/-4.1
+6.9+/-2.4
Fig. 5.1 Effect of IBMX and cycloheximide pre-treatment
on insulin's modulation of PGEi-elevated
intracellular cAMP in P9 cells.
P9 cells were incubated with serum-free medium containing insulin (from 
0 to 10’9M) alone (open circles), with IBMX (ImM, 15 minute pre-incubation) 
(closed circles) and with cycloheximide (ljiM, during the entire period of insulin 
exposure) (closed squares). After 16 hours cells were challenged with PGEi 
(10"5M for 2 minutes) and cAMP extracted and assayed as described in section
2.14. In the absence of insulin, cAMP level was 9.7+/-1.3 (control), 20+/-1.3 
(IBMX) and 16+/-0.2 pmols/50|il extract (cycloheximide). Ki values for insulin 
were 1.7 x 10 n M (control), 1.7 x 10-n M (IBMX) and 5.3 x 1012M 
(cycloheximide). Data are mean+/-SEM for triplicate observations in one 
experiment Similar results were obtained in two other experiments.
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Fig. 5.2 Effect of IBMX and cycloheximide pre-treatment 
on insulin's modulation of forskolin elevated 
intracellular cAMP in P9 cells.
P9 cells were incubated with serum-free medium containing insulin (from 
0 to 10'9M) alone (open circles), with IBMX (ImM, 15 minute pre-incubation) 
(closed circles) and with cycloheximide (l|iM during the entire period of insulin 
exposure) (closed squares). After 16 hours cells were challenged with forskolin 
(10-5 for 2 minutes) and cAMP extracted and assayed as described in section
2.14. In the absence of insulin, cAMP level was 9.8+/-0.1 pmols/50p,l extract 
(control), 16.6+/-0.6 (IBMX) and 2.8+/-0.5 (cycloheximide). Koj values for 
insulin were 2.2 x 10 n M (control), 3.2 x 10'12M (IBMX) and 7.0 x 10-12M 
(cycloheximide). Data are mean+/-SEM for triplicate observations in one 
experiment. Similar results were obtained in another experiment.
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Fig, 5.3 Elevation of P9 cell in tracellular cAMP bv
increasing concentrations of PGEi after
exposure to insulin (InM . 16 hours).
P9 cells were exposed to serum-free medium alone (open circles) or 
containing insulin, InM (closed circles). After 16 hours, cells were challenged 
with PGEi (0-5 x 10_5M for 2 minutes) and cAMP extracted and assayed as 
described in section 2.14. Maximal control response was 36+/-3 pmols/50|il 
extract with a Ko.5 for PGEi of 1.5 x 10'6M. Maximal response after insulin 
exposure was 25+/-2 pmols/50|il extract with a Ko.5 value for PGEi of 2.0 x 
10 6M. Data are mean +/-SEM for triplicate observations in one experiment. 
Similar results were obtained in two other experiments and in one experiment in 
which cells were preincubated with IBMX (ImM, 15minutes).
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Fig. 5.4 Elevation of P9 cell intracellular cAMP bv
increasing concentrations o f forskolin after 
exposure to insulin fln M . 16 hours!
P9 cells were exposed to serum-free medium alone, (open circles) or 
containing insulin, InM (closed circles). After 16 hours, cells were challenged 
with forskolin (0-4 x lO^M for 2 minutes) and cAMP extracted and assayed as 
described in section 2.14. Maximal control response was 95+/-1 (SEM) 
pmols/50pl extract with a Ko.5 value for forskolin of 4.2 x 10-5M. Maximal 
response after insulin exposure 102+/-2 (SEM) pmols/50jil extract with a Ko.5 
value for forskolin of 4.1 x 10-5M. Data are mean+/-SEM for triplicate 
observations in one experiment Similar results were obtained in another 
experiment.
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Fig. 5.5 Effect o f pertussis toxin pre-treatment on 
impairment o f PG E i-elevated P9 cell 
intracellular cAM P bv insulin (InM. 16 hours).
In column 1, P9 cells were exposed for 16 hours to serum-free medium 
alone (black bars), or containing insulin, InM (grey bars). In column 2, cells 
were similarly treated except that pertussis toxin, lOOng/ml was included during 
the last 2 hours of exposure to serum free medium. Cells were then challenged 
with PGEi (10-5M) for 2 minutes and cAMP extracted and assayed as described 
in section 2.14. Data are mean+/-SEM for triplicate observations in one 
experiment Similar results were obtained in two other experiments.
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Fig, 5,6 Time course for insulin’s (InM) modulation of
PGEi elevated intracellular cAMP in P9 cells.
P9 cells were incubated with serum-free medium alone (control) or 
containing insulin (InM). At intervals cells were challenged with PGEi (10"5M 
for 2 minutes) and cAMP extracted and assayed as described in section 2.14. 
Results are plotted as the the response with insulin present as a percentage of the 
control response, in order to allow for any change in response over time, on 
exposure to serum-free medium alone. In Fig 5.6a. data are given for time points 
between zero and 22 minutes and in Fig. 5.6b. data for time points between 22 
minutes and 16 hours. Enhancement of the response by insulin was 1.72+/-0.01 
fold at 22 minutes (p < 0.001). The response at 10 hours was 45.5+/-0.8% of the 
control response (p < 0.05). Data are mean+/-SEM for triplicate observations in 
one experiment. Similar results were obtained in another experiment
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Fig. 5.7 Effect of increasing concentrations of GTP on
PGEi-stimulated adenvlvl cvclase activity, after
exposure of P9 cells to insulin (InM . 16 hours).
P9 cells were exposed for 16 hours to serum-free medium, alone (open 
circles) or containing insulin (InM) (closed circles), harvested, membranes 
prepared and assayed for adenylyl cyclase activity in the presence of increasing 
concentrations of GTP (0-10-3M) and a constant concentration of PGEi (10'5M) 
as described in section 2.13. Adenylyl cyclase activity in the absence of insulin 
exposure was 162+/-9 and with insulin exposure was 198+/-13 pmols/mg protein 
/min. Stimulation parameters are given in Table 5.2. Data are mean+/-SEM for 
triplicate observations in one experiment. Similar results were obtained in two 
other experiments.
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Fig. 5.8 Effect of increasing concentrations of insulin
(10 minutes exposure) on PGEi-elevated
intracellular cAMP in P9 cells.
P9 cells were washed with serum-free medium and exposed to insulin 
(0-10_6M) for 10 minutes before challenge with PGEi (10*5M for 2 minutes) and 
cAMP extracted and assayed as described in section 2.14. Maximal enhancement 
of the response by insulin was 2.08+/-0.10 (fold value without insulin present). 
The Ko.5 value for insulin was 5.0 x 10_10M. Data are mean+/-SEM for triplicate 
obtained in one experiment. Similar results were obtained in two other 
experiments and in one experiment in which cells were pre-incubated with IBMX 
(ImM, 15 minutes).
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Fig. 5.2 Effect of increasing concentrations o f  G TP on  
PGEl-stim ulated adenvlvl cvclase activity, after 
exposure o f P9 cells to insulin (InM . 10 
minutes).
P9 cells were exposed for 10 minutes to serum-free medium, alone (open 
circles) or containing insulin (InM) (closed circles), harvested, membranes 
prepared and assayed for adenylyl cyclase activity in the presence of increasing 
concentrations of GTP (0-10*3M) and a constant concentration of PGEi (10"5M) 
as described in section 2.13. Adenylyl cyclase activity in the absence of insulin 
exposure was 115+/-3 and with insulin exposure was 168+/-6 pmols/mg 
protein/min. Stimulation parameters are given in Table 5.2. Data are mean+/-SEM 
for triplicate observations in one experiment. Similar results were obtained in two 
other experiments.
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Fig. 5.1Q Effect o f Increasing concentrations o f GTP on 
PG Ei-stim ulated adenvlvl cvclase activity in the 
presence o f insulin.
P9 cells were harvested, membranes prepared and assayed for adenylyl 
cyclase activity in the presence of increasing concentrations of GTP (from 0 to 
10-3M) and a constant concentration of PGEi with (closed circles) or without 
(open circles) insulin (10-6M) present in the assay. Adenylyl cyclase activity 
without insulin present was 177+/-33 and with insulin was 212+/-12 pmols/mg 
protein /min. Stimulation parameters are given in Table 5.2. Data are 
mean+/-SEM for triplicate observations in one experiment. Similar results were 
obtained in two other experiments.
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Fig. 5.11 Effect of increasing concentrations of insulin
(10 minutes exposure) on forskolin-elevated
intracellular cAMP in P9 cells.
P9 cells were washed with serum-free medium, exposed to insulin at 
increasing concentrations for 10 minutes in each case then challenged with 
forskolin (10 5M for 2 minutes). Cyclic AMP was extracted and assayed as 
described in section 2.14. Data are mean+ASEM for triplicate observations in one 
experiment. Similar results were obtained in another experiment.
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Figure 5.11
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E ig i5 il2  Effect o f insulin exposure on glucagon- and 
forskolin-elevated intracellular cAM P in P9 
cells.
P9 cells were exposed to serum-free medium alone (column 1) or 
containing insulin (column 2), InM for 16 hours (Fig 5.12a.), InM for 10 
minutes (Fig 5.12b.) or ljiM for 10 minutes (Fig 5.12c.) then challenged with 
forskolin (10_5M) for 2 minutes (black bars) or with forskolin (10_5M) and 
glucagon (10 8M) combined for 2 minutes (grey bars). Cyclic AMP was extracted 
and assayed as described in section 2.14. Data are mean+/-SEM for triplicate 
observations in one experiment Similar results were obtained in two other 
experiments and one experiment in which cells were pre-incubated with IB MX 
(ImM, 15 minutes).
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Fig. 5 .U  Effect o f insulin exposure (InM. 16 hours) on  
toxin labelling of  G-proteins in P9 cell plasma 
membranes.
P9 cells were exposed for 16 hours to serum-free medium alone (lane 1) 
or containing insulin, InM (lane 2) then harvested and plasma membranes 
prepared and subjected to toxin labelling in the presence of pertussis toxin (panel 
A) and cholera toxin (panel B) as described in. section 2.12. Samples were 
resolved and gels dried, autoradiographed and scanned as described in section 
2.10. There was no labelling in the absence of toxins. Densitometric data are 
presented in Table 5.1. Data shown are from one experiment Similar results were 
obtained in two other experiments.
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Fig- 5-14 Effect of insulin exposure (InM . 16 hours) on
G-protein levels in P9 cell plasma membranes.
P9 cells were exposed for 16 hours to serum-free medium alone (lane 1) 
or containing insulin, InM (lane 2) then harvested and plasma membranes 
prepared. Samples of membrane protein (lOOpg) were resolved using SDS 
PAGE, transferred onto nitrocellulose paper and probed with antisera as 
described in section 2.11. The antisera used were 1432 (panel A), I3C (panel B), 
CS1 (panel C) and BN3 (panel D). Blots were scanned densitometrically and 
results presented in 5.1. Data shown are from one experiment. Similar results 
were obtained in two other experiments.
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Chapter 6
G-nrotein expression and adenvlvl cvclase activity in 
mononuclear leucocytes from type 2 diabetic subjects
6.1 Introduction
As discussed in section 1.5.2, various studies have shown alterations in 
G-protein expression and function in animal models of type 1 and type 2 diabetes. This 
is a phenomenon which has been relatively poorly studied in humans mainly because of 
the difficulty in obtaining adequate amounts of insulin-sensitive tissues (viz. liver, 
adipose tissue and muscle) for study. In addition, the findings from studies carried out 
in small samples particularly of type 2 diabetic patients can be difficult to interpret 
because of the heterogeneous nature of the disorder itself and other factors which may 
contribute to the changes observed eg. the effects of any therapy (medication or other) 
and the presence of co-existing disorders which must be taken into account. Insulin's 
target tissues are the most useful for studies of signal transduction in diabetes as it is in 
these tissues that insulin's regulation of metabolism is best understood and any defects 
found will presumably have important consequences for the metabolic status of these 
tissues. However, only small amounts can be obtained by sampling under local 
anaestheic, which limits the number of measurements that can be made. Larger amounts 
can be obtained at time of elective surgery although any diabetic undergoing elective 
surgery is likely to have their condition well controlled by anti-diabetic therapy. 
Consequently, many studies have used blood cells from diabetic subjects to examine 
signalling and other aspects of cell function rather than using insulin-sensitive tissues, 
as these samples are readily obtained in sufficient quantities for analysis.
Leucocyte function is of particular relevance to diabetes, as both type 1 and type 
2 diabetics are known to have a predisposition to infection which accounts for a 
considerable amount of morbitity and mortality associated with the disease (Ganda, 
1983) although the reasons for this reduction in immune function are still unclear.
There are various reports from animal models of diabetes of abnormalities in both 
humoral (Fletcher-McGruder et al., 1984) and cell-mediated (Pasko et al., 1981)
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immunity. As there is evidence for activation of both lymphocytes (Roper et al., 1990) 
and neutrophils (Reibman et al., 1990) involving G-protein-mediated signal 
transduction, it is possible that defective cyclase regulation may contribute to the 
impairment of immune function in diabetes. Since defects noted in cyclase signalling in 
insulin sensitive tissues from animal models go some way to explaining the 
pathophysiology of the condition, leucocytes certainly merit examination to consider 
whether cyclase signalling may play a role in their altered physiology.
This study had initially aimed to examine G-protein expression and adenylyl 
cyclase activity in neutrophil plasma membranes to examine whether any change in the 
function in this signalling system might be contributing to the altered physiology of 
these cells in diabetic patients. Neutrophils have the advantage that assays of their 
function are readily available (Shah et al., 1983) and neutrophils from diabetic subjects 
are known to have defective functioning (Ganda, 1983). However, despite the liberal 
use of protease inhibitors during membrane preparaton, a problem with proteolysis of 
Gi was encountered, to a degree which would have prevented reliable quantification of 
this protein. This section of work was therefore abandoned. Consequently, the study 
was limited to examination of G-protein expression and adenylyl cyclase activity in 
mononuclear leucocyte plasma membranes the results of which are presented here.
Leucocytes for study were separated only into two main fractions, that 
containing granulocytes (about 66% of leucocytes in whole blood) viz. neutrophils 
(neutrophil polymoiphonuclear leucocytes), basophils and eosinophils and a fraction 
containing mononuclear leucocytes viz. lymphocytes (30%), monocytes (1-3%) (Hunt, 
1987). Further separation of leucocytes for specific functional studies can be achieved 
by density gradient centrifugation to remove monocytes and cell sorting to separate T 
(-70%) and B (-30%) lymphocytes but these techniques were not employed in this 
study. Whilst lymphocytes are predominant in the fraction studied, monocytes are also
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present and contribute to the data obtained.
Type 2 diabetic patients were chosen for study as it is relatively easy to recruit 
either newly diagnosed patients, before commencement of treatment or previously 
diagnosed patients who are receiving no treatment (other than dietary) at the time of 
sampling. It was particularly important that the patients should be free from infection at 
the time of sampling, as T lymphocyte activation is known to be accompanied by 
increases in Gs and Gi expression and enhanced cAMP responsiveness to E series 
prostaglandins (Holter et al., 1991). The investigation was designed as a pilot study to 
screen type 2 diabetics for gross changes in functioning of the second messenger 
system which could later be followed up if desired. In order to have adequate plasma 
membrane protein to carry out more detailed studies would have meant taking 
unreasonably large blood samples and unreasonable expense in terms of cyclase assay 
materials. Therefore due to the small amount of membrane protein available from each 
subject the study did not examine closely the effect on Gi function or responses to a 
large range of agonists but rather, by examining a reasonably large number of patients, 
aimed to observe whether there were any marked changes in G-protein expression or 
agonist-stimulated adenylyl cyclase activity which could later be pursued.
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6.2 Results
As shown in Table 6.1. all type 2 diabetic patients had plasma glucose levels 
diagnostic of diabetes (The hospital quote a reference range for plasma glucose of 
2.8-6.0mmols/l). In addition, the 10 male diabetics had a mean HbAic (glycosylated 
haemoglobin) of 9.4+/-2.8% (SEM) and the 10 female diabetics had a mean HbAic of 
10.8+/-4.2%. This measurement is indicative of persistently elevated blood glucose 
levels during a period of about three months before sampling. (Normally about 6% of 
the total haemoglobin is glycosylated). From these measurements it was clear that the 
subjects selected were indeed diabetic and suitable for study.
Experiments were initially carried out to find the range of leucocyte plasma 
membrane protein over which increasing protein concentration yielded increasing band 
density on immunoblotting (Figs. 6.1-6.3). Using the three antisera, 1432 for Gi-2a, 
CS2 for Gs-a and BN1 for G-protein 6 subunit, signals were obtained which increased 
up to 200jig of membrane protein. The 1432 antiserum is specific for Gi-2a in 
mononuclear leucocytes as they, in common with neutrophils and platelets, do not 
express Gi-1 (Holter et al., 1991). Probing blots with the CS2 antiserum yielded a 
band at 42kDa corresponding to the Gs-a form expressed by leucocytes. Probing blots 
with the BN1 antiserum yielded a band at 35kDa corresponding to the G-protein B 
subunit.
Leucocyte plasma membranes from 20 control and 20 diabetic patients were 
then subjected to immunoblotting using these specific antisera (Figs. 6.4 and 6.5). In 
view of the limited membrane protein available, the amount of protein chosen for 
blotting was lOOpg. No significant differences were observed in G-protein levels 
between leucocyte plasma membranes obtained from control and diabetic subjects in 
either the male or female groups. However, in the case of Gi-2a alone, larger signals
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on average were obtained from female than from male subjects by a factor of 1.7 in the 
control group and 1.4 in the diabetic group. This difference was only statistically 
significant (p < 0.05) in the control group. There was no significant correlation 
between G-protein levels observed and the subjects age, except in the case of the female 
diabetics where there was a weak positive correlation between Gs-a expression and age 
(r = 0.70, p<  0.05).
Adenylyl cyclase activities were compared in leucocyte plasma membranes from 
all control an diabetic subjects (Fig. 6.6). There was a reduction in the ability of PGEi 
to stimulate adenylyl cyclase in leucocyte plasma membranes from male (p < 0.05) but 
not female diabetic subjects. There was however no significant difference in the fold 
stimulation of adenylyl cyclase activity over the activity observed with GTP alone by 
PGEi or forskolin. No differences were observed between control and diabetic groups 
for any of the other agonists used viz. GTP (lO^M), forskolin (10^M) and forskolin 
and GTP combined at the same concentrations. However, considerable sex differences 
were noted in adenylyl cyclase activity. Lower cyclase activity was observed in 
leucocyte plasma membranes from female subjects, both control and diabetic, for all 
agonists used (p < 0.001). On examining values for fold stimulation over the cyclase 
activity with GTP present, this sex difference was retained only in the case of the 
diabetic patients. No correlation was observed between age and adenylyl cyclase 
activity for any agonist used, in any of the subject groups.
6.3 Discussion
Plasma membranes from leucocytes were shown to contain Gi-2a, Gs-a 
(42kDa form) and G-protein B subunit. Holter et al. (1991) showed using their 
antiserum to Gs-a that resting lymphocytes (the predominant cell type examined here) 
expressed a 42kDa form of Gs-a and also gave a very faint signal at 47kDa, both of 
which increased upon cell activation. Our failure to detect this higher molecular weight 
form in plasma membranes from any of the subjects may reflect a lower sensitivity of 
our detection system or a difference in the specificity of our antiserum.
In the study comparing control and diabetic subjects yielded we found that there 
was a significant reduction in PGEi-stimulated adenylyl cyclase in leucocyte plasma 
membranes from male diabetics. In considering this finding we must bear in mind the 
reservations discussed in Chapter 5 when comparing cyclase activities between 
different membrane preparations. Indeed less difference was observed between the 
groups on comparing fold stimulation by the agonist which implies that the effect is less 
significant than the statistics on the raw data would suggest. However, a large number 
of membrane preparations were examined here which would tend to reduce the 
influence of such errors. The change can be proposed to be either at the level of the 
prostanoid receptor or at the level of coupling to Gs. It was clearly not due to any 
change in G-protein expression as has been suggested as the cause of alteration in 
cyclase signalling in some animal models of diabetes. The absence of any difference 
between control and diabetic groups on measuring the response to GTP alone would 
suggest that the difference is at the level of the prostanoid receptor rather than at a more 
distal point in the system though the smaller responses in the presence of GTP alone 
may not have been large enough to make any change in Gs function apparent. There 
was no evidence for a change in forskolin responsiveness to suggest an additional 
effect of the diabetic state at the adenylyl cyclase catalytic subunit.
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As discussed in section 1.4.1.2, there is extensive evidence that E series 
prostaglandins have a role in regulation of immune responsiveness. Thus there is 
certainly reason to believe that the reduction in PGEi-stimulated adenylyl cyclase 
observed in the male subjects might have consequences for the immune functioning of 
these leucocytes. However, the absence of any similar change in female patients makes 
one cautious in interpreting this result as male type 2 diabetics are no more or less prone 
to infection than female diabetics. This finding is particularly interesting in light of the 
work of Kahn and Sinha (1990) which suggested that at least in platelets, PGEi and 
insulin may modulate each others function by influencing binding of these agonists to 
their respective receptors. Perhaps a similar mechanism is at work in leucocytes where 
a reduction of insulin’s influence in diabetes manifests itself in the adenylyl cyclase 
signalling system as a reduction in PGEi responsiveness. Unlike the findings in 
platelets however, this change presumably has no important consequences for cell 
physiology and simply represents an epiphenomenon associated with the diabetic state, 
although it would be interesting to substantiate this by measurements of lymphocyte 
immune functioning.
As a similar reduction in PGEi responsiveness has been observed in platelets 
from male type 2 diabetics (Livingstone et al.> 1991) it is interesting to speculate that 
males may have a genetic predisposition to this effect of diabetes on cyclase signalling. 
Perhaps the reduction in PGEi responsiveness represents a widespread phenomenon 
associated with insulin resistance. If this is the case, then in adipose tissue where the 
prostanoid receptor couples to Gi. a reduction in PGEi responsiveness would tend to 
enhance intracellular cAMP accumulation in response to stimulatory agonists and 
therefore promote lipolysis. Indeed, a decreased antilipolytic response to PGEi noted in 
adipocytes from diabetic rats has been proposed to result from a decrease in Gi function 
(Green and Johnson, 1991). This would be worthwhile to consider in any subsequent 
study undertaken on human adipose tissue or any other tissues from diabetic subjects.
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One study carried out on adipocytes from type 1 diabetic subjects showed no 
change in G-protein expression (Ohisalo et al., 1989). However, the study was carried 
out on only a small number of patients and did not examine adenylyl cyclase activity in 
the membrane preparations. Until extensive studies have been done on insulin sensitive 
tissues from both type 1 and type 2 diabetic subjects, it is not possible to say how 
closely the situation in humans resembles that in animal models.
In view of the size of the sex differences observed in both control and diabetic 
groups and that they were observed both on cyclase activity and Gi-2a levels, it seems 
unlikely that the changes were artifacts. The spread of ages between the two groups 
selected was reasonably similar so we cannot suggest that the sex differences are 
accounted for by an uneven comparison of age groups. In addition, all samples were 
processed in an identical manner. A study by Bouvier et al. (1991) on pituitary 
G-protein expression in rats noted that oestrogen treatment caused a significant 
reduction in G-protein levels with the exception of G i-la and the 42kDa form of Gs-a. 
Levels of these polypeptides varied during phases of the oestrous cycle and levels of 
Go-a, Gi-3a, GB and the 47kDa form of Gs-a were significantly lower in female than 
in male rats. These changes were not observed in corpus striatum showing that they 
were tissue specific. It is clear that ovarian hormones can influence G-protein levels and 
may account for sex differences in expression observed in animals. Here however, the 
majority of the female subjects were post-menopausal, implicating genetic factors rather 
than ovarian hormones in the aetiology of the sex differences in G-protein expression.
It is interesting to speculate that the higher level of Gi-2a expression in cells from 
female subjects may be responsible for the lower adenylyl cyclase activity observed 
with all agonists as this is the Gi-a subtype thought to be responsible for adenylyl 
cyclase inhibition. Presumably these sex differences in the second messenger system 
have no effect on physiological functioning of the cells. In this regard it would be 
interesting to know in detail the roles of particular G-protein subtypes in leucocyte
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function and the precise levels required for normal functioning: In addition it would be 
interesting to follow up this finding by studying G-protein expression in other tissues 
from both sexes.
Age differences in adenylyl cyclase functioning have been reported. Krall et al 
(1981) noted an increase in plasma catecholamine levels in elderly subjects and a 
reduction in lymphocyte adenylyl cyclase responsiveness. Abrass and Scarpace (1982) 
obtained similar results and concluded that the reduction in activity was at the catalytic 
subunit and that there was no change in G-protein function. However, their study only 
examined male subjects. Here we have observed no such correlation with age, although 
the study was not designed primarily to address this question and because of the nature 
of type 2 diabetes, the majority of subjects were elderly. In addition to the subjects sex, 
it may be that there is another factor which we have not taken into account, common to 
many of the subjects of one sex and responsible for the difference in cyclase regulation. 
Possibilities include body weight, dietary habits and self medication.
It is worthwhile to consider other follow-up clinical studies which could be 
done in the light of the findings obtained here from diabetic subjects. Firstly, in 
leucocytes it would be interesting to obtain adequate samples to examine the level of 
prostanoid receptor binding to see whether the impaired response to this agonist in male 
subjects represents a reduction in the level of prostanoid receptor or whether there is 
abnormal coupling between components of the signalling system. It would be 
interesting to follow up some of these patients after treatment, particularly if their 
clinical condition had improved and a normal blood glucose had been achieved for a 
prolonged period. All these studies would again require to be done on a reasonably 
large number of patients for the reasons discussed above.
189
Type 2 diabetes is associated with insulin resistance in peripheral tissues as a 
result of these subjects having supraphysiological levels of glucose despite normal or 
elevated insulin levels. In view of this it would be worthwhile, by measuring the 
plasma insulin level and pancreatic beta cell reserve, to observe whether the reduced 
PGEi stimulation of cyclase correlates with the degree of insulin resistance. The study 
on neutrophils could be repeated using an alternative form of membrane preparation and 
studies of whole cell cAMP elevation in response to agonist could be carried out on 
freshly isolated cells. In order to assess G-protein levels a chosen number of 
neutrophils from each patient coud be solubilised directly in SDS to denature the 
proteases and samples subjected directly to immunoblotting.
The study could be extended to include type 1 diabetics, ideally patients who 
have been newly diagnosed and before the commencement of insulin treatment These 
subjects have the advantage that they are of a younger age group and have fewer 
coincidental medical conditions although, for practical reasons, samples from these 
patients are more difficult to obtain for study. Thus there are many ways in which the 
work could be extended in order to clarify the effects of diabetes on cyclase signalling 
and the role of such defects in the pathology of the condition.
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Table 6.1 Plasma glucose measurements from control and 
type 2 diabetic subjects.
Fasting plasma glucose was estimated in 20 control (10 male and 10 
female) and 20 type 2 diabetic (10 male and 10 female) subjects. Age ranges of 
the subjects in each group are given in brackets. Data shown are mean+/-SEM for 
the 10 subjects in each group.
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Tabk 6,1
Subject group
Male controls (35-74) 
Male diabetics (30-73) 
Female controls (38-72) 
Female diabetics (40-77)
Plasma glucose level 
(mmols/1)
5.5+/-0.8
12.3+/-4.8
5.2+/-0.5
10.9+/-4.2
Fig. 6.1 Immunological identification of G \-2 a  in
m ononuclear leucocyte plasma m em branes.
Samples of leucocyte plasma membrane protein (40-200|ig) were TCA 
precipitated and resolved using SDS PAGE on a 10% acrylamide/0.27% 
bisacrylamide gel as described in section 2.10 then transferred onto nitrocellulose 
membrane as described in section 2.11. Immunoblotting was performed using a 
1: 200 dilution of antiserum 1432. Detection of the primary antiserum was 
achieved using 125I-labelled anti-rabbit IgG (2jiCi/50ml) (Fig.6.la). Bands were 
scanned densitometrically and results plotted graphically (Fig. 6.1b) using 
arbritary units for band density. Data shown are from one experiment
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Fig. 6.2 Immunological identification of Gs-a in
mononuclear leucocyte plasma membranes.
Samples of leucocyte plasma membrane protein (40-200|ig) were TCA 
precipitated, resolved and transblotted as described in the legend to Fig. 6.1, then 
Gs-a detected using a 1:200 dilution of the antiserum CS2 and 125I-labelled 
anti-rabbit IgG (2p.Ci/ml) as second antibody (Fig. 6.2a). Bands were scanned 
densitometrically and results plotted graphically using arbritary units for band 
density (Fig. 6.2b). Data shown are from one experiment.
193
Gs
 b
and
 
de
ns
ity
 
(ar
br
ita
ry
 
un
its
)
Figure 6.2 (a)
Mr x 1Cf3
200—
98
68
25
18—
4 0  5 0  6 0  8 0  100  1 5 0  2 0 0
|jg protein
Figure 6.2 (b.)
400
300
200
100
2500 50 100 150 200
protein (|Xg)
Fig. 6.3 Immunological identification of G-nrotein B
subunit in mononuclear leucocyte plasma 
membranes.
Samples of leucocyte plasma membrane protein (40-200|ig) were TCA 
precipitated, resolved and transblotted as described in the legend to Fig. 6.1, then 
G-protein 6 subunit detected using a 1:200 dilution of the antiserum BN1 and 
125I-labelled anti-rabbit IgG (2pCi/ml) as second antibody (Fig. 6.3a). Bands 
were scanned densitometrically and results plotted graphically using arbritary 
units for band density (Fig. 6.3b). Data shown are from one experiment.
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Fig. 6.4 G-protein levels in mononuclear leucocyte
plasma membranes from control and type 2 
diabetic subjects*
Samples of leucocyte plasma membrane protein (lOOpg) from control 
(lane 1) and diabetic (lane 2) subjects were TCA precipitated, resolved and 
transblotted as described in the legend to Fig. 6.1. Polypeptides were detected 
using the antisera 1432 (panel A), CS2 (panel B) and BN1 (panel C) and 
125I-labelled anti-rabbit IgG (2|iCi/ml) as second antibody. All SDS gels were 
stained for protein to confirm equal protein loading in all lanes (panel D). Samples 
from a total of 20 control and 20 type 2 diabetic subjects were run in a similar 
manner. Autoradiographs were scanned densitometrically, band densities 
compared to an internal standard included on every blot and the results presented 
in Fig. 6.5.
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Fig. 6.5 Comparison o f G-protein levels in
mononuclear leucocyte plasma membranes from  
control and type 2 diabetic subjects.
G-protein levels were examined in leucocyte plasma membranes from 10 
control (black bars) and 10 type 2 diabetic subjects (hatched bars) of each sex, 
male (column 1) and female (column 2). Polypeptides were detected by 
immunoblotting using specific antisera as described in the legend to Fig. 6.4. 
Antisera used were 1432 to detect Gi-2a (Fig. 6.5a), CS2 to detect Gs-a (Fig. 
6.5b) and BN1 to detect G-protein B subunit (Fig. 6.5c). The second antiserum 
was 125I-labelled anti-rabbit IgG. Autoradiographs were scanned 
densitometrically and all densities given relative to an internal standard included 
on every blot. Data are mean+/-SEM for 10 subjects in each case. There were no 
significant differences between control or diabetic groups for any of the 
polypeptides detected, but control males showed significantly lower Gi-2a levels 
than control females (p < 0.05).
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Fig, 6,5 Comparison o f G-protein levels in
mononuclear leucocyte plasma membranes from  
control and type 2 diabetic subjects.
G-protein levels were examined in leucocyte plasma membranes from 10 
control (black bars) and 10 type 2 diabetic subjects (hatched bars) of each sex, 
male (column 1) and female (column 2). Polypeptides were detected by 
immunoblotting using specific antisera as described in the legend to Fig. 6.4. 
Antisera used were 1432 to detect Gi-2a (Fig. 6.5a), CS2 to detect Gs-a (Fig. 
6.5b) and BN1 to detect G-protein 6 subunit (Fig. 6.5c). The second antiserum 
was 125I-labelled anti-rabbit IgG. Autoradiographs were scanned 
densitometrically and all densities given relative to an internal standard included 
on every blot. Data are mean+/-SEM for 10 subjects in each case. There were no 
significant differences between control or diabetic groups for any of the 
polypeptides detected, but control males showed significantly lower Gi-2a levels; 
than control females (p < 0.05).
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EigJLS Comparison o f adenvlvl cvclase activities in
m ononuclear leucocyte plasma membranes from  
control and type 2 diabetic subjects.
Adenylyl cyclase activity was measured in leucocyte plasma membranes 
from control (black bars) and type 2 diabetic subjects (hatched bars) of each sex, 
male (column 1) and female (column 2). Activities given are those stimulated with 
GTP (lO^M) (Fig. 6.6a), PGEi (lCHM) and GTP (10^M) (Fig. 6.1b), 
forskolin (10^M) alone (Fig. 6.1c) and forskolin and GTP combined at the same 
concentrations (Fig,6. Id).
Fold values for PGEi/GTP stimulation over the level of adenylyl cyclase 
activity with GTP alone in Fig. 6.1b were: control males, 2.81+/-1.57; diabetic 
males, 2.15+/-0.51; control females 2.91+/-2.35; diabetic females, 3.18+/-1.47. 
Fold values for forskolin/GTP stimulation over the level of adenylyl cyclase 
activity with GTP alone were: control males, 2.80+/-1.08; diabetic males, 
2.61+/-0.75; control females, 3.08+/-1.66; diabetic females, 4.22+/-1.87.
All data are mean+/-SEM for assays performed in triplicate, for 10 
patients in each group. There was a significant reduction in PGEi-stimulated 
adenylyl cyclase activity in leucocyte plasma membranes from male diabetic 
subjects as compared to their controls (p < 0.05). No other significant differences 
were observed between control and diabetic data. Significantly lower 
agonist-stimulated adenylyl cyclase activity was observed in leucocyte plasma 
membranes from female subjects, in both control and diabetic groups, for all 
agonists employed (p < 0.001).
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General discussion
It has been suggested from work on marker protein expression, that 
S V40-transfected hepatocytes, at least at low passage number, bear greater similarity to 
rat hepatocytes than to established hepatoma cell lines (Naim et al., 1990). 
SV40-transfected cells have also been shown to be genotypically more similar to native 
cells than other cell lines having a smaller degree of chromosomal damage than tumour 
cell lines (MacDonald et al., 1991). The work presented here attempted to examine how 
closely one such line P9, resembled native hepatocytes in its adenylyl cyclase signalling 
and thereby to extend this comparison with native cells, in order to consider the merits 
of this potentially very useful cell line. Two main findings have arisen from the work. 
Firstly, that adenylyl cyclase signalling in the P9 cell line has probably diverged further 
from that of native hepatocytes than the soluble enzyme systems examined by other 
authors. Secondly, insulin's influence on the cells, both as a growth factor and in its 
acute modulation of cyclase activity is very different from its established actions on 
cyclase in hepatocytes. This means that as regards cyclase signalling, SV40-transfected 
cell lines are probably no more useful than the established hepatoma cell lines. Indeed 
the P9 line has the disadvantage that it cannot be passaged indefinitely, without 
phenotypic change in its signalling, unlike tumour cell lines. This finding was in 
agreement with those of Woodworth et al. (1988) who noted expression of 
hepatocyte-specific genes to change with time in culture. Some of the other implications 
of the work carried out here and possibilities for future study are discussed below.
Artificiality in cell culture systems is the price paid for being able to examine 
responses in isolated, proliferating cells. This work has centred on the response to 
PGEi, an agonist little used in hepatocytes. It would be interesting therefore to know 
more about insulin's effect on PGEi responsiveness in rat hepatocytes and find 
whether there is any further similarity between the two cell types. However, as 
discussed in sections 1.5.1 and 1.5.2 insulin's modulation of cyclase signalling
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appears highly system-specific and it seems likely that P9 cells would be as divergent in 
this as in other aspects of their signalling. Speculation is difficult firstly as we are 
studying a facet of insulin's action which is far from understood in native hepatocytes 
and even less in artificial systems such as this. Secondly, in considering the relevance 
of these effects to in vivo hormone action, we must bear in mind that PGEi was used 
here in a highly artificial manner. It is normally present in vivo in the ciculation at 
about 10*9M (Norman and Litwack, 1987) and is active locally at about 10_8M. 
Systemically it never reaches the high concentrations used here and would be toxic if it 
did so; whether insulin could influence the action of the low concentrations of PGEi 
present in vivo is more doubtful. It is possible that insulin's impairment of the ability 
of PGEi to elevate intracellular cAMP may, like agonist-induced receptor 
down-regulation, represent a form of cell memory to a stimulus, depending upon both 
the magnitude of the stimulus and duration of exposure. The lower agonist-stimulated 
cAMP levels after prolonged insulin exposure could, as in hepatocytes, influence the 
level of phosphorylation and activity of key enzymes or modulate the effects of these 
agonists on gene expression. An investigation into these factors in the cell line would 
put us in a better position to speculate on the role of insulin action in functioning of the 
cells. Whether or not the effects observed here are entirely artificial, they demonstrate 
that insulin can markedly modulate adenylyl cyclase signalling in the cell line, 
suggesting that crosstalk between the two signalling systems is present as a form of 
control. Mechanisms of crosstalk, like the structure of signalling components 
themselves, are likely to be similar in many cell types and therefore worthwhile 
investigating in artificial systems.
A full assessment of glucagon and PGEi binding in P9 cells as compared to rat 
hepatocytes would provide further information regarding the phenotypic similarities or 
otherwise between the two cell types. Indeed it would be revealing to carry out such 
studies and work similar to that done here on hepatoma cell lines. It is possible that
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many of the findings would prove common to transformed and artificially immortalised 
cells. Although preliminary evidence has been presented here for the presence of insulin 
and IGF-1 receptors in the cells, the P9 line would in addition merit an examination of 
its insulin-binding characteristics. As both native hepatocytes and hepatoma cells are 
known to show insulin receptor down-regulation in response to insulin exposure, 
presumably the same would be true for SV40-transfected cells. If so, the cells could be 
used for studies on receptor expression, trafficking and signal generation by the insulin 
receptor. Furthermore, it would be interesting to know in this regard whether, like rat 
hepatocytes and hepatoma cell lines, the P9 line is truly insulin resistant after insulin 
exposure.
At the level of the G-protein, a study of G-protein phosphorylation in the cells 
could be rewarding, with respect to understanding more about Gi function in the cells 
and why inhibitory regulation of adenylyl cyclase should be different from that in native 
cells. The effect of phosphatase treatment of cell membranes on subsequent phosphate 
incorporation in response to agonist could be investigated. Removal of endogenously 
incorporated phosphate by phosphatase treatment might provide a means of 
demonstrating that Gi-2a is already phosphorylated in vivo in P9 cells. Furthermore, 
the factors influencing expression of G-proteins and other signalling components merit 
investigation since the cells clearly show priority for alteration in expression of these 
components over other highly hepatocyte-specific proteins. This would tell us more 
about how the immortalisation process affects gene expression and thereby cell 
signalling.
The expression of PK-C isoforms would merit investigation, firstly as the 
kinase may have a role in insulin's low affinity sensitisation of cyclase responses, as 
discussed in Chapter 4 and secondly, as this kinase is thought to be involved in 
glucagon desensitisation and Gi-2 phosphorylation in rat hepatocytes, both of which 
are profoundly altered in P9 cells, suggesting a lesion of PK-C. ~
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It would be interesting finally, to know more about metabolic responses of the 
cells. If, like other SV40-immortalised hepatocytes, the cells contain a good 
complement of hepatocyte-specific proteins (including the complete pathway required 
for glutathione synthesis in one such cell line), then their metabolism and its regulation 
by insulin may yet prove fairly similar to that of hepatocytes, as may the expression 
and function of the soluble kinases acting as intermediates in insulin signalling. If so, 
the cell line would prove a useful asset to workers in this field. Furthermore, the 
variability in marker protein expression between cell lines, noted by the first workers to 
generate immortalised hepatocytes (Isom ex al., 1980) suggests that some may more 
closely resemble native hepatocytes than others and therefore demand closer scrutiny 
with a view to there use as model systems.
The heterogeneity noted between different cell lines derived in the same manner 
also suggests that the alterations in cyclase signalling in the P9 line will not necessarily 
apply to all cell lines and any prospective model system would clearly require to 
undergo thorough characterisation before use. The cells may yet also prove suitable as a 
model system for studying other second messenger systems or other cellular processes.
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